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The most beautiful thing we can experience is the mysterious. 
It is the source of all true art and science. 
- Albert Einstein - 
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1  Hyperhomocysteinemia 
 
 
1.1  Homocysteine metabolism  
  
Homocysteine is a sulphur-containing branch point metabolite of the 
methionine metabolism and is formed by the demethylation of methionine, an 
essential amino acid (figure 1.1).  Methionine is converted by methionine S-
adenosyltransferase (MAT) into S-adenosylmethionine (AdoMet) using 
adenosine-5-triphosphate (ATP). AdoMet is the methyl donor for methylation 
of e.g. DNA, RNA and proteins. By donating its methylgroup to 
methyltransferases S-adenosylhomocysteine (AdoHcy) is formed, which is an 
inhibitor of most AdoMet-dependent methyltransferases. AdoHcy is hydrolyzed 
to homocysteine and adenosine by a reversible reaction involving S-
adenosylhomocysteine hydrolase (AHCY). Homocysteine can then be 
metabolized via two metabolic pathways; it can be degraded by the irreversible 
transsulfuration pathway or it can be remethylated to methionine1. 
Transsulfuration occurs mainly in liver and kidney and involves the 
condensation of homocysteine and serine to cystathionine by the pyridoxine-
dependent enzyme cystathionine β-synthase (CBS). Cystathionine is further 
metabolized to cysteine and α-ketobutyrate by the pyridoxine-dependent 
enzyme cystathionine γ-lyase (CTH). Remethylation of homocysteine occurs by 
receiving a methyl group of the active folate derivative: 5-
methyltetrahydrofolate (MeTHF) and is catalyzed by methionine synthase 
(MTR). Folate is obtained via the diet and is in the cell reduced via several steps 
involving serine hydroxymethyltransferase (SHMT), methylenetetrahydrofolate 
dehydrogenase (MTHFD) and 5,10-methylene tetrahydrofolatereductase 
(MTHFR) into 5-methyltetrahydrofolate (5-MeTHF), which is the circulating 
form of folate in plasma. In the liver and kidney, methyl groups for the 
remethylation of homocysteine can also be donated by betaine and requires 
the action of betaine-homocysteine methyltransferase (BHMT). 
In case of higher intracellular production of homocysteine than the elimination 
by remethylation or transsulfuration, homocysteine will be exported from the 
tissues to the plasma. In plasma, homocysteine is mainly present in its protein 
bound form (e.g. bound to albumin). Most of the non-protein bound 
homocysteine exists as circulating disulfides (oxidized), and only a very small 
proportion of the non-protein bound homocysteine remains in the reduced 
form2. Generally, total homocysteine is measured, which refers to the sum of 
all forms of homocysteine in plasma, i.e. both protein and non-protein bound 
homocysteine moieties. 
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1.2   Hyperhomocysteinemia and vascular disease  
 
Cardiovascular diseases are one of the most common causes of death in the 
Western industrialized world. In addition to traditional risk factors as 
hypertension, smoking and hypercholesterolemia, hyperhomocysteinemia is 
also associated with increased risk of vascular disease.  
Hyperhomocysteinemia can be classified into moderate (15-30 µmol/L), 
intermediate (30-50 µmol/L) and severe hyperhomocysteinemia (>50 µmol/L).  
The finding that patients with severe hyperhomocysteinemia due to different 
inborn errors of enzymes of the homocysteine pathway had arterial damage, 
led to the hypothesis that elevated homocysteine is a risk factor for the clinical 
manifestation of vascular disease3.  
Early epidemiological data obtained from retroprospective studies showed a 
strong association between plasma homocysteine levels and atherosclerosis4,5 
as well as thrombosis6,7. However, these studies cannot exclude the possibility 
that elevated homocysteine levels may be associated with some other factor, 
rather then being causally related to vascular disease. Prospective studies 
showed a much less strong association as it was demonstrated that a 25% 
lower usual homocysteine level was associated with a 11% lower risk of 
Figure 1.1: Folate-dependent homocysteine metabolism. Main regulating enzymes with corresponding cofactors are
depicted. AHCY, S-adenosylhomocysteine hydrolase; MAT, methionine adenosyltransferase; BHMT, betaine-homocysteine
methyltransferase; MTHFR, methylenetetrahydrofolate reductase; MTR, methionine synthase; MTRR, methionine synthase
reductase; SHMT, serine-hydroxymethyltransferase; MTHFD, methylenetetrahydrofolate dehydrogenase; FS, 10-formyl
tetrahydrofolatesynthetase; CH, 5,10-methenyltetrahydrofolatecyclohydrolase; CBS, cystathionine beta-synthase; CTH,
cystathionine gamma-lyase.  
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ischemic heart disease5. Randomized clinical trials will help to determine 
whether elevated homocysteine levels are causally related to vascular disease. 
The results of the first randomised clinical trial of B vitamins for secondary 
prevention of stroke were neutral8,9. However, this study had several 
limitations, and, therefore, more studies are needed before a final conclusion 
can be reached about the validity of the homocysteine hypothesis and B 
vitamin supplementation in relation to vascular diseases including stroke. 
 
 
1.3  Genetic and environmental determinants of homocysteine  
 
Hyperhomocysteinemia is associated with increased risk of cardiovascular 
diseases, congenital abnormalities like neural tube defects, impaired cognitive 
function and obstetric complications, and has both environmental as well as 
genetic origins (table 1.1). Environmental risk factors involve dietary factors 
such as low intake of B vitamins (B12 or folate)10,11 or life-style factors like 
coffee consumption and smoking12,13. Homocysteine levels are also often 
elevated due to impaired renal function, probably as a result of decreased renal 
clearance of homocysteine14,15.  
 
Table 1.1: Determinants of hyperhomocysteinemia 
Genetic factors 
Variants in genes  
Gene-nutrient interaction 
Male sex 
Dietary factors 
Low folate status 
Low vitamin B12 status 
Lifestyle 
Smoking 
Coffee consumption 
Lack of physical activity 
Low alcohol intake 
Other 
Drugs 
Renal dysfunction 
Increasing age 
 
Folate administration strongly reduces plasma total homocysteine levels. 
Therefore, genetic determinants of hyperhomocysteinemia may involve 
variants in genes coding for enzymes of the homocysteine and/or folate 
metabolism. At the time we initiated the project described in this thesis, 
genetic variants in genes coding for MTHFR, MTR, MTHFD, and CBS had been 
described. In the MTHFR gene our group had identified two SNPs: the 677 C>T 
and the 1298 A>C16,17, of which only the 677 C>T SNP has been demonstrated 
to increase homocysteine levels18. Recently, results from a meta-analysis 
showed that the MTHFR 677 TT genotype is a risk factor for deep-vein 
thrombosis and coronary artery disease (CAD), which supports the hypothesis 
Chapter 1 
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that impaired folate metabolism, resulting in high homocysteine levels, is 
causally related to increased risk of CAD and thrombosis19. In the MTR gene, 
the 2756 A>G SNP was found, which has been described to be associated with 
hyperhomocysteinemia, although data are conflicting20,21,22. In the gene coding 
for the trifunctional enzyme MTHFD the 1958 G>A SNP has been found by our 
group, which is not associated with elevated homocysteine levels23. In the CBS 
gene, we identified a 31-bp variable number of tandem repeats, which is 
associated with reduced CBS enzyme activity and elevated homocysteine levels, 
in particular after methionine loading24.  
Results from family studies showed that the heritability of 
hyperhomocysteinemia is about 50%, of which about 10% can be explained by 
the variants identified so far, indicating that a significant proportion of the 
heritability of hyperhomocysteinemia still needs to be resolved25. Genetic 
variants in other genes of the homocysteine/folate metabolism seem therefore 
good candidates. 
 
 
2  Pathophysiology of hyperhomocysteinemia 
 
Moderate hyperhomocysteinemia has been shown to be an independent risk 
factor for vascular disease. Several mechanisms have been proposed by which 
homocysteine exerts its adverse effects on the vascular wall (table 1.2)26,27,28, 
of which endothelial dysfunction, oxidative stress and methylation will be 
further discussed.  
 
Table 1.2: Pathophysiological mechanisms involved in hyperhomocysteinemia 
Endothelial dysfunction 
Impaired bioavailability of nitric oxide 
Proliferation of smooth muscle cells 
Impairment of platelet function 
Atherosclerosis 
Inflammation 
Oxidative stress 
Increased production of ROS 
Lipid peroxidation 
Reduced expression of glutathione-peroxidase 
Endoplasmatic reticulum stress 
Decreased methylation 
DNA metylation 
Protein methylation 
 
 
2.1  Endothelial function  
 
The endothelium is an important locus of control of vascular functions; it 
regulates the balance between coagulation and fibrinolysis, the composition of 
the subendothelial matrix, the adhesion of leucocytes, inflammatory activity 
and the functioning of vascular smooth muscle cells (table 1.3)29. To carry out 
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these functions, the endothelium produces several regulatory mediators, such 
as nitric oxide (NO), prostacyclins, endothelin, angiotensin-II, tissue-type 
plasminogen activator, plasminogen-inhibitor-1, von Willebrand factor, 
adhesion molecules and cytokines. 
Endothelial dysfunction is defined as the impairment of normal homeostatic 
properties of the vascular endothelium, and appears to be an early event in the 
promotion of atherogenesis. 
 
Table 1.3: Functions of the endothelium 
Decreasing vascular tone 
Limiting leucocyte adhesion and inflammatory activity 
Maintaining vascular permeability 
Inhibition of platelet adhesion and aggregation 
Limiting the activation of the coagulation cascade 
Regulating fibrinolysis 
 
Several studies in humans as well as in animal models have demonstrated that 
elevated homocysteine levels are associated with impaired endothelium-
dependent vasodilatation30,31,32,33. Over the past few years, studies examining 
differential gene expression to explore the molecular mechanism of 
hyperhomocysteinemia were performed. Most of these studies have been 
performed on cultured human umbilical vein endothelial cells (HUVEC), in 
which genes involved in endoplasmatic reticulum-stress response34,35, 
inflammatory response36,37, and oxidative stress response have been 
identified38. However, in the majority of these studies physiologically irrelevant 
concentrations or forms of homocysteine were applied to analyze gene-
expression differences. Therefore, the analysis of gene expression differences 
in physiologically relevant tissues like coronary arteries or aorta of an in vivo 
model of hyperhomocysteinemia is of great interest.  
 
2.1.1  NO-mediated vasodilatation 
Nitric oxide (NO) is the most common vasodilator and is produced by the 
endothelial isoform of NO synthase (eNOS). Several studies have demonstrated 
that not the production but rather the bioavailability of NO is decreased in 
hyperhomocysteinemia39,40. It is, therefore, likely that the bioavailability of NO 
is decreased in hyperhomocysteinemia due to alternative mechanisms like 
oxidative stress or nitrosylation41,40,39,42. NO can react with thiols like 
homocysteine to form S-nitrosothiols41. S-nitrosothiols have vasodilatory 
properties, and it is suggested that when less NO is available, decreased 
amounts of S-nitrosothiols will be formed, resulting in impaired vasodilatation. 
There is also growing evidence that homocysteine exerts its effect on the 
progression of vascular disease by promoting oxidative damage43,44. The main 
source of endothelial superoxide is NAD(P)H oxidase45. However, eNOS itself 
can also produce superoxide in presence of low concentrations of the cofactor 
tetrahydrobiopterin (BH4)46. Due to reduced availability of BH4, eNOS switches 
Chapter 1 
           18 
from a coupled state (directed to NO synthesis) to an uncoupled state (directed 
to superoxide synthesis), which results in oxidative stress and decreased 
endothelium dependent vasodilatation46. Folate has been shown to restore 
endothelium-dependent vasodilatation possibly via regeneration of BH4 from 
BH247,48, which suggests that folate not only improves endothelium-dependent 
vasodilatation by lowering total homocysteine levels but also by increasing the 
bioavailability of BH4.  
 
2.1.2  EDHF-mediated vasodilatation 
The best-characterized vasodilating agents are nitric oxide (NO) and 
prostacyclins (PGl2)(figure 1.2). Several studies have shown that a third not yet 
identified factor exists that elicits vasodilatation49. The existence of a third 
pathway was discovered because after inhibition of NO and PGl2 with specific 
inhibitors, the endothelium-dependent relaxation followed by smooth-muscle 
cell hyperpolarization was still observed50. This third factor, therefore, was 
called endothelium-derived hyperpolarizing factor (EDHF), and contributes to 
endothelium-dependent vasodilatation in many arteries, in particular in 
resistance arteries51. 
 
 
It is likely that several EDHFs exist, which are specific to different species and 
vascular beds52. Several candidates for EDHF or factors that are involved in the 
EDHF-mediated vasodilatation have been postulated, including cytochrome 
P450 metabolites, K+ ions, H2O2, and gap junctions50.  
There is convincing evidence that EDHF-mediated responses are initiated by an 
increase in endothelial calcium, which activates the Ca2+ channels leading to 
hyperpolarization of the endothelial cell50. In some tissues, cytochrome P450 
metabolites might be involved in the hyperpolarization of the endothelial cell 
(figure 1.3). The endothelial hyperpolarization is subsequently transmitted to 
the smooth muscle cells, which most likely involves gap-junctions50.  
Our group suggested a role for EDHF in relation to hyperhomocysteinemia as it 
was shown that EDHF-mediated vasodilatation was restored by folate53, which 
is often used as a therapeutic agent to lower homocysteine levels. It that study 
it was shown that the L-NAME and indomethacin-resistant vasodilatation (i.e. 
Figure 1.2: Endothelium-dependent vasodila-
tation. In response to different stimuli (e.g. shear
stress, acetylcholine, thrombin or homocysteine),
endothelial cells produce vasodilating as well as
vasoconstricting agents to maintain vascular
tone. Three main vasodilating factors can be
discriminated: nitric oxide (NO), prostaglandins
(PGl2) and endothelium-derived hyperpolarizing
factor (EDHF). 
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EDHF-mediated vasodilatation) to intrarenal acetylcholine was significantly 
reduced in streptozotocin-induced diabetic rats. Interestingly, infusion of 5- 
 
 
MeTHF resulted in an acute normalization of the impaired EDHF-mediated 
vasodilatation53.  This led to the hypothesis that a disturbed homocysteine 
metabolism hampers the EDHF-mediated vasodilatation. 
 
2.1.2.1  Gap-junctions / Connexins 
Gap junctions are intercellular channels, which connect the cytoplasm of 
adjacent cells allowing passage of ions and small molecules54. Each gap 
junction is composed of 12 subunits, so-called connexins (Cx), assembled 
from two hemichannels54. Endothelial cells express connexin37 (Cx37), 
connexin40 (Cx40) and connexin43 (Cx43), which are named according to 
their molecular mass in kDa55,56,57. Three types of gap-junctions are possible: i) 
a homotypic/homomeric gap junction channel composed of 12 identical 
connexin subunits, ii) a heterotypic gap junction channel that consists of two 
types of connexins, six of one type in a hemichannel and six of the other type 
in the other hemichannel, and iii) a heteromeric gap junction channel where 
different connexins are present within one hemichannel58.  
Previously, others and we demonstrated that the inhibition of gap junctional 
communication with connexin-mimetic peptides against Cx37, Cx40 and Cx43 
blocked the EDHF-mediated signal transmission in vivo59,60,61, which supports 
the involvement of gap-junctions in the transfer of EDHF-mediated 
vasodilatation. 
 
2.1.2.2  Cytochrome P450-metabolites 
Cytochrome P450 (CYP) enzymes are membrane-bound, heme-containing 
enzymes, which are involved in the detoxification of drugs, chemicals, and 
carcinogens62. More than 500 CYP genes have been identified, which are 
catagorized according to their sequence homology63.  Most of these genes are 
expressed in human liver, but many are also expressed in extrahepatic 
tissues62.  Human CYP enzymes of the 1A, 2B, 2C, 2D, 2E, 2J, and 4A families 
are, besides the process listed above, also involved in the production of 
epoxyeicosatrienoic acids (EETs) from arachidonic acid. EETs have vasodilating 
properties, and especially, CYP2C8 and 9 are considered to play a role in 
Figure 1.3: Relaxation is initiated by the influx of
calcium (Ca2+) via Ca2+-activated K+ channels.
Endothelial cell (EC) hyperpolarization is
conducted via gap junctions to the smooth muscle
cells (SMC), in which the hyperpolarization is
spread via gap junctions. In some cells,
metabolites of arachidonic acid (AA), which most
likely involves the cytochrome P450 2C subfamily
(CYP2C), may contribute to the release of EDHF. 
 
EC
SMC
AA
Ca2+Ca2+
CYP2C
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vasodilatation and are postulated as EDHF synthases, although data remain 
conflicting.  Several reports have provided evidence for the involvement of EETs 
in EDHF-mediated vasodilatation in coronary arteries of human, porcine, 
bovine, canine and rat64,65,66. Recently, an alternative hypothesis was proposed 
that EETs are not involved in the synthesis of EDHF but might play a role in the 
pathway resulting in the release of EDHF67.  Disturbances in gene and protein 
expression of in particular the CYP2C family might therefore lead to impaired 
EDHF-mediated vasodilatation. 
 
 
2.2  Oxidative stress 
 
The hypothesis that increased production of ROS is involved in impairment of 
endothelium-dependent vasodilatation was based on the initial finding that 
antioxidants prevented the impairment in endothelium-dependent 
vasodilatation68,69,70,71.  It has been suggested that the highly reactive thiol 
group of homocysteine undergoes auto-oxidation in plasma to generate ROS, 
leading to endothelial dysfunction72. It has also been shown that homocysteine 
can enhance the intracellular production of superoxide anions by inhibition of 
detoxifying enzymes73,42. Superoxide can react with nitric oxide to decrease 
the availability of nitric oxide, which yields peroxinitrite46. Furthermore, the 
involvement of glutathione peroxidase activity in relation to homocysteine was 
demonstrated74. It was demonstrated that in presence of elevated 
homocysteine levels, the activity of glutathione peroxidase was inhibited. 
Glutathione peroxidase is involved in the detoxification of ROS, and therefore 
decreased activity of this enzyme will lead to oxidative stress75. 
 
 
2.3  DNA methylation 
 
Under normal physiological conditions, AdoHcy is hydrolyzed to adenosine and 
homocysteine by AHCY in a reversible reaction (figure 1.1). Because the 
equilibrium of this reaction favors AdoHcy formation, its levels will increase 
when homocysteine levels are increased. AdoHcy is a potent inhibitor of most 
AdoMet-dependent methyltransferases by binding to the active site with higher 
affinity than AdoMet, and several studies have demonstrated that increased 
AdoHcy levels lead to decreased DNA methylation in presence of 
hyperhomocysteinemia76,77,78,79. Thus, methylation of DNA and proteins might 
be disturbed due to elevated homocysteine levels. 
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3.  Objectives and outline of this thesis 
 
 
3.1  Objectives 
 
The aims of the present thesis were to explore the molecular genetics and 
pathophysiology of hyperhomocysteinemia. These objectives will be addressed 
by the following two research questions: 
 
1. Which genetic variants contribute to hyperhomocysteinemia? 
 
2. What is the pathophysiology of homocysteine in relation to the 
endothelium-dependent vasodilatation? 
 
 
3.2  Outline 
 
This thesis is divided into two parts. Part I includes studies in which we 
investigated whether genetic variation in genes coding for two major 
regulating enzymes of the homocysteine metabolism (e.g. BHMT and SHMT) is 
associated with elevated homocysteine levels (chapters 2-3). In part II we have 
i) investigated the role of EDHF-mediated vasodilatation, connexins and 
cytochrome P450 in small renal arterioles of hyperhomocysteinemic rats 
(chapters 4-6) and, ii) examined the pathophysiology of 
hyperhomocysteinemia in aorta by microarray analysis (chapters 7-8) and 
studied the role of a common polymorphism in the eNOS gene in relation to 
hyperhomocysteinemia (chapter 9). 
 
 
PART I 
 
In chapter 2 the genetic analysis of the coding region of betaine-homocysteine 
methyltransferase (BHMT) is described in relation to hyperhomocysteinemia 
and vascular disease. Chapter 3 describes the identification of genetic variation 
in genes coding for the cytosolic and mitochondrial isoforms of serine-
hydroxymethyltransferase (SHMT) in relation to hyperhomocysteinemia and 
neural tube defects risk. 
 
 
PART II 
 
In this part we investigated the pathophysiology of hyperhomocysteinemia in 
relation to endothelium-dependent vasodilatation of small and large arteries.  
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In chapter 4 we tested our hypothesis that EDHF-mediated vasodilatation is 
disturbed in hyperhomocysteinemic rats, and in chapter 5 we examined 
whether the mRNA expression of Connexin 40 and Connexin 43 is disturbed in 
hyperhomocysteinemic rats by the application of lasermicrodissection and 
real-time quantitative PCR. In chapter 6 we investigated the role of the 
cytochrome P450-2C isoform in relation to EDHF-mediated vasodilatation by 
studying its mRNA expression in lasermicrodissected endothelial cells from 
renal arterioles. 
Concerning the large arteries, we performed microarray analysis on RNA 
isolated from rat aorta. First, we examined the reproducibility of the RNA 
amplification method, which was performed prior to micro-array analysis, by 
the application of real-time quantitative PCR (chapter 7). In chapter 8 we 
applied micro array analysis on RNA isolated from rat aorta to investigate 
which genes are involved in the pathophysiology of hyperhomocysteinemia. In 
Chapter 9 we investigated the role of a common polymorphism in the gene 
coding for endothelial nitric oxide synthase (eNOS) in relation to 
hyperhomocysteinemia and thrombosis risk. 
 
Finally, in chapter 10 the studies presented in this thesis are discussed and 
several new challenges for the future are proposed. 
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Abstract  
 
 
Elevated homocysteine levels have been associated with arteriosclerosis and 
thrombosis. Hyperhomocysteinemia is caused by altered functioning of 
enzymes of its metabolism due to either inherited or acquired factors. Betaine-
homocysteine methyltransferase (BHMT) serves, next to methionine synthase, 
as a facilitator of methyl group donation for remethylation of homocysteine 
into methionine, and reduced functioning of BHMT could theoretically result in 
elevated homocysteine levels. Recently, the genomic sequence of the BHMT 
gene was published. Mutation analysis may reveal mutations of the BHMT gene 
that could lead to hyperhomocysteinemia. In the present study we performed 
genomic sequencing of the BHMT gene of 16 vascular patients with 
hyperhomocysteinemia and detected three mutations in the coding region of 
this gene. The first was an amino acid substitution of glycine to serine (G199S), 
which was only found in the heterozygous state. The second mutation was a 
substitution of glutamine to arginine (R239Q), and the last mutation was an 
amino acid substitution of glutamine to histidine (Q406H). The latter was also, 
only found in the heterozygous state. The relevance of these mutations was 
tested in a study group, which consists of 190 cases with vascular disease and 
601 controls. The influence of these three mutations on homocysteine levels 
was investigated. None of the three mutations led to significantly changed 
homocysteine levels.  In addition, no differences in genotype distribution 
between cases and controls were found. So far, our results provide no evidence 
for a role of defective BHMT functioning in hyperhomocysteinemia or 
subsequently in vascular disease. 
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Introduction  
 
 
Hyperhomocysteinemia (HHcy) is caused by a combination of genetic and 
nutritional disturbances. Homocysteine (Hcy) may accumulate due to altered 
functioning of the remethylation pathways, but also from a defect in the 
transsulphuration pathway due to defective functioning of cystathionine beta-
synthase (CBS) (figure 2.1). HHcy can be classified into two forms, severe and 
mild HHcy. Patients with severe HHcy (Hcy >50 µmol/l) due to deficiency of 
methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MS) or 
CBS (figure 2.1) often suffer from vascular disease. Mild HHcy has also been 
associated with vascular disease80,81. Several years ago, a common mutation in 
the MTHFR gene (677 C>T) has been found, leading to mildly elevated Hcy-
levels. This mutation, however, can only explain the observed increased Hcy-
levels in some cases18,16. Therefore, deficiencies of other enzymes of 
methionine/homocysteine metabolism are expected to contribute to HHcy. 
Genes coding for CBS and methionine synthase (MTR) have been investigated, 
but whether mutations in these genes lead to mild HHcy remains 
questionable82,4,21,83. 
 
 
Betaine-homocysteine methyltransferase (BHMT; EC 2.1.1.5) is the enzyme, 
along with methionine synthase, which remethylates Hcy to methionine. 
Altered functioning of BHMT may result in elevated Hcy-levels, and could 
therefore contribute to the risk for vascular disease. BHMT is also involved in 
choline metabolism, where it converts betaine into dimethylglycine, which is 
then transferred to sarcosine to form glycine (figure 2.1)84. BHMT is primarily 
expressed in liver and kidney. In liver, BHMT is responsible for 50% of Hcy 
remethylation. Oral betaine supplementation lowers Hcy concentrations in 
severe hyperhomocysteinemic patients, but this effect is poorly studied in 
other forms of HHcy85. This Hcy lowering effect of betaine is accomplished via 
two pathways86. Firstly, via donation of methyl groups for direct remethylation 
of Hcy to methionine by BHMT. Secondly, the demethylation of dimethylglycine 
Figure 2.1: Simplified scheme of 
Methionine/Homocysteine metabolism. 
Main regulating enzymes are depicted and 
co-factors are encircled; BHMT: betaine-
homocysteine methyltransferase; CBS: 
cystathionine beta-synthase; MTHFR: 
methylenetetrahydrofolate reductase; MTR: 
methionine synthase; MTRR: methionine 
synthase reductase; AdoMet: S-
adenosylmethionine and AdoHcy: S-
adenosylhomocysteine; 1: transsulfuration; 
2: remethylation. 
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to glycine introduces one-carbon units into the folate pool that will stimulate 
the folate-dependent Hcy remethylation, resulting in decreased Hcy-levels.  
Recently, it was indicated that BHMT is a zinc metalloenzyme87,88. Cysteine 
residues of BHMT protein function as zinc binding domains, which in turn are 
required for the binding of Hcy to BHMT. Replacement of three highly 
conserved cysteine residues with either alanine or serine resulted in complete 
loss of activity87. These results suggest that mutated BHMT may lead to 
decreased binding of Hcy to BHMT, resulting in accumulated Hcy-levels. 
Enzymatic measurement of BHMT activity cannot be performed in fibroblasts or 
lymphocytes, which explains in part why defects of BHMT have not been 
observed previously. Molecular analysis enables screening for BHMT defects 
and could answer the question: is mutated BHMT involved in HHcy and 
subsequently in vascular disease? 
Recently, the gene coding for betaine-homocysteine methyltransferase has 
been cloned86,89,90. The BHMT gene has been localized to chromosome 5q13.1-
q15 and consists of 8 exons and 7 introns. In the present study, we report the 
molecular genetic analysis of the BHMT gene and investigate the influence of 
the three mutations discovered in this gene on Hcy metabolism in a study 
group of 190 vascular cases and 601 controls. 
 
 
Material and Methods 
 
Patient material 
A patient group, with diagnosed vascular disease and mildly elevated Hcy-
levels, was pre-selected according to availability of fibroblasts. This enabled 
the use of this patient group for different strategies of mutation analysis. In 
total 16 patients were selected of whom material was used for genomic 
sequencing. Fibroblasts were cultured according to standard procedures and 
DNA was isolated with the Puregene DNA extraction kit (Biozym, The 
Netherlands), essentially as indicated by the manufacturer. To investigate 
whether mutations of the BHMT gene lead to elevated Hcy-levels and may 
therefore contribute to the risk for vascular disease, we used a second group 
of cases and a large group of controls, which we will call the study group (table 
2.1). One part consists of 130 cases with severe coronary occlusions and 101 
population-based controls as described by Verhoef et al91. Another group of 
60 cases with documented premature cardiovascular disease as described by 
Kluijtmans et al, was also used92. Furthermore, we used 500 additional 
controls, which were recruited from a general practice in The Hague, The 
Netherlands7. Finally, 13 patients with severe HHcy (Hcy > 100 µmol/l) were 
also screened for the three mutations. 
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Table 2.1: Characteristics of study group 
 Cases  
mean (95% CI), n=190 
Controls  
mean (95% CI), n=601 
P  value 
Age (years)  
Gender (% male) 
Fasting homocysteine (µmol/l)2 
Post-load homocysteine (µmol/l) 2 
49.0 (47.5-50.4) 
75.3 
14.3 (13.7-15.0) 
41.3 (39.1-43.2) 
50.6 (49.5-51.6) 
47.1 
13.1 (12.7-13.4) 
40.0 (39.1-41.1) 
0.08 
< 0.001 
0.0051 
0.101 
1adjusted for age and gender differences ; 2geometric mean 
 
Homocysteine measurements 
Hcy concentrations were measured in EDTA plasma after an overnight fast and 
6 hours after a methionine load93. The Hcy-values of cases and controls 
described by Verhoef et al91 were re-measured at our laboratory in order to 
make a proper comparison with other Hcy-values of the study group. 
 
Molecular analysis 
Molecular analysis was performed by genomic sequencing of the different 
exons. Intronic primers were developed based on the published genomic 
sequence (Genbank accession number AF118371, table 2.2 and figure 2.2). 
PCR of the different exons was carried out in a total volume of 50 µl on a 
Perkin Elmer 9600 thermocycler (PE Biosystems, The Netherlands), containing 
50 ng of the forward and reverse primers (table 2.2), 200 µM dNTPs, 10 mM 
Tris-HCl buffer (pH 8.3), 1.0 mM MgCl2 and 0.5 unit Taq polymerase (all from 
Life Technologies, The Netherlands).  
 
Table 2.2: Primer sequences used for molecular analysis of the BHMT gene 
Primer 
 
Sequence (5’ → 3’)1 
 
Tm 
(°C) 
Product size 
(bp) 
1 for 
1 rev 
2 for 
2 rev 
3 for 
3 rev 
4 for 
4 rev 
5 for 
5 rev 
6 for 
6 rev 
7 for 
7 rev 
8 for 
8 rev 
MB-PCR2 for 
MB-PCR2 rev 
MB-WT3 
MB-MUT3 
8 rev4 PIRA 
gggctcgcctagtcggtc 
cggcagggtccgagggc 
cctccctcatctgtaattttag 
gctgggattacaggcatgag 
tcctgcttgtttatctgagagcc 
caaactctgaagaggttgaaccc 
tagatgtgaatgtttgaataataat 
tttatctttcaccacatctttc 
agtactctaaccttaactgattccag 
ggcactagtgtgttcttttaag 
tgccctgctggtttctgg 
ggtatagatttacttgagtttatatg 
ctacttgtagctacttatcttg 
ctaatcataaattagtttggg 
gagtctgttgtctggtgtcatg 
gtgacccaaacacctagaattc 
CTTGACCCCACCATTAG 
CAGGAGTGTGGTAAGCC 
GCGACGGCTGCCGACTGAGTCGC 
GCGACAGGCTGCCAACTGAGTCGC 
CATCAAAAATAGCTTCTATCGAGGGT 
58 
 
51 
 
58 
 
55 
 
47 
 
50 
 
50 
 
47 
 
59 
 
59 
 
58 
188 
 
226 
 
304 
 
300 
 
235 
 
313 
 
347 
 
270 
 
110 
 
 
 
248 
1Exonic sequences are indicated by uppercase and intronic sequences are indicated by lowercase; 2Used for PCR in molecular 
beacon analysis to screen for the 716G>A polymorphism ; 3Molecular beacons which hybridize to wildtype (WT) or mutant 
(MUT) alleles, 716 G or A is indicated in bold; 4Used for screening of the 1218 G>T mutation with PCR-PIRA, altered 
nucleotide is depicted in bold 
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PCR parameters were as follows: 92°C/120s (initial denaturation) followed by 
35 cycles of 92°C/30s (denaturation), 47-58°C/30s (annealing), 72°C/30s 
(elongation) followed by a final elongation step of 7 minutes at 72°C. The 
obtained PCR products were separated on a 2% agarose gel and subsequently 
sequenced on the ABI Prism 377 automated sequencer using the ABI Prism 
BigDye Terminator cycle sequencing kit according to the instructions of the 
manufacturer (PE Biosystems, The Netherlands).  
To determine whether mutations of the BHMT gene lead to elevated Hcy-levels 
and therefore are possible risk factors for vascular disease, a detection method 
was developed to screen for these mutations in the total study group. The first 
mutation in the BHMT gene, the 595 G>A mutation was screened for using 
restriction enzyme analysis. This mutation, which is present in exon 5 of the 
BHMT gene, resulted in an abolishment of an Nci I restriction site.  A 235-bp 
region containing exon 5 was amplified using PCR with exon 5 for and rev 
primers (table 2.2). Nci I digestion of wild-type sequence (595 GG) then leads 
to two fragments of 143 and 92 bp, respectively. The products were analyzed 
on a 2% agarose gel.  
The second mutation, which was found in exon 6 of the BHMT gene, did not 
lead to a formation or abolishment of a restriction site. To screen for this 
mutation we first tried primer-introduced restriction analysis (PCR-PIRA) but 
the results were not satisfactory. Subsequently, we decided to use molecular 
beacons for the detection of this mutation94,95. Two new primers were 
developed, which created 110 bp PCR products (table 2.2). Two molecular 
beacons were designed, one to detect the G allele (MB-WT) and one that 
detects the A allele (MB-MUT). PCR was carried out in a total volume of 50 µl 
containing 50 ng of the forward and reverse primers, 150 ng of the wild-type 
TET beacon and 250 ng of the mutant HEX beacon, 200 µm dNTPs, 10 mM Taq 
gold amplification buffer, 4 mM MgCl2 and 1.5 unit of AmpliTaq Gold (PE 
Biosystems, The Netherlands). PCR conditions were as follows: cycling was 
preceded by 95°C/10 min (activation AmpliTaq Gold) followed by 40 cycles of 
95°C/30s (denaturation), 59°C/30s (annealing) and 72°C/30s (elongation). PCR 
was performed on the ABI-Prism 7700 (PE Biosystems, The Netherlands) and 
fluorescence was measured during the second step of stage 2 (annealing). 
Results were analyzed by Sequence Detection System software (PE Biosystems, 
The Netherlands). The third mutation found in exon 8 of the BHMT gene, 
namely the 1218 G>T substitution does not result into an abolishment or 
formation of a restriction site. Therefore, PCR-PIRA was used to induce an 
alternative restriction site. For the 1218 G>T substitution, guanine at position 
1221 was substituted with cytosine by the reverse PIRA primer, thereby 
creating a restriction site for Rsa I (table 2.2) This allows Rsa I to cut the PCR-
PIRA fragment of 248 basepairs into two fragments of 222 bp and 26 bp in the 
case of the wild-type sequence (1218 GG). These fragments were analyzed on 
a 3% agarose gel. 
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Statistics 
Differences between cases and controls were calculated using Student’s t test 
for continuous variables and Pearson chi-square for frequencies. P-values were 
age- and sex adjusted by linear regression analysis. To determine if mutated 
BHMT contributes to elevated Hcy-levels, means, confidence intervals and P-
values were calculated. Homocysteine showed positive skewness, and therefore 
in all cases geometric means were calculated. Statistical significance between 
geometric means of different genotypes was estimated by one-way analysis of 
variance (ANOVA) and Student’s t test, P values were age and sex- adjusted by 
linear regression analysis. In addition, P values were adjusted for MTHFR 677 
C>T mutation, which is evidently associated with increased Hcy-levels18,16,91,92. 
P < 0.05 was considered statistically different, all P values were two tailed. To 
estimate the possible risk of different genotypes on vascular disease, odds 
ratios (OR) and 95% confidence intervals (95% CI) were calculated. 
 
 
Results 
 
The relevance of BHMT in HHcy and vascular disease was tested by genomic 
sequencing of the BHMT gene. Sixteen pre-selected patients with mildly 
elevated Hcy-levels were subjected to mutation analysis. Genomic sequencing  
of all 8 exons of the BHMT gene revealed three mutations, which were located 
in different exons (figure 2.2).  
 
 
The first mutation detected, was the 595 G>A transition in exon 5 of the BHMT 
gene, which leads to a substitution of glycine to serine at amino acid position 
199 (G199S). This mutation was found in one patient in heterozygous state. A 
second mutation was found in exon 6 of the BHMT gene at nucleotide position 
716, which was already reported by Park and Garrow86. This 716 G>A mutation 
leads to a substitution of arginine to glutamine at amino acid position 239 
(R239Q). Two of the 16 patients were homozygous mutant (716 AA) and 4 
patients were heterozygous (716 GA) for this mutation. A third mutation was 
found in exon 8 of the BHMT gene at nucleotide position 1218 (1218 G>T). 
Figure 2.2: Location of human BHMT 
mutations. Gene structure of BHMT 
gene shows schematically the 
different exons and corresponding 
intronic primers used for sequencing 
analysis. Exons are indicated by 
shaded areas. The mutations are 
depicted (*) with their position on 
mRNA level and corresponding amino 
acid substitution. 
5’ 3’
1          2                   3        4           5           6          7          8
595 G>A   716 G>A     1218 G>T
(G199S)     (R239Q)      (Q406H)
mRNA
DNA
0     33     166             285                  477                625    808          1037     1221position
AAAAA
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This mutation leads to an amino acid substitution of glutamine to histidine at 
position 406 (Q406H). Only one patient was heterozygous for this mutation. 
The relevance of these mutations to HHcy and subsequently to vascular disease 
was tested in a study group. The characteristics of this study group are 
depicted in table 2.1. Screening of the total study group revealed the presence 
of the 595 G>A mutation only in heterozygous state in 2.8% of the cases and 
in 1.9% of the controls, which did not lead to an increased risk for vascular 
disease (OR 1.5, 95% CI [0.5-4.5]) (table 2.3).  
 
Table 2.3: Prevalence of the BHMT 595 G>A and BHMT 716 G>A mutations among cases and controls 
Mutation Cases 
 (n) 
Controls  
(n) 
Odds ratio 
 [95% CI] 
595 G>A 
595 GG 
595 GA 
595 AA 
716 G>A 
716 GG 
716 GA 
716 AA 
 
97.2 %  (171) 
2.8% (5) 
- 
 
52.6% (90) 
40.4% (69) 
7.0% (12) 
 
98.1% (461) 
1.9% (9) 
- 
 
47.7% (248) 
42.5% (221) 
9.8% (51) 
 
1.01 
1.5 [0.5-4.5] 
- 
 
1.01 
0.9 [0.6-1.2] 
0.6 [0.3-1.3] 
1Reference category; - not observed 
 
Moreover, the effect of this mutation on Hcy-levels was investigated (table 
2.4). Among cases as well as controls, Hcy-levels for those with the 595 GA 
genotype did not differ from those with 595 GG genotype (table 2.4).  
 
Table 2.4: Geometric means of homocysteine levels of BHMT 595 G>A and BHMT 716 G>A genotypes among study group 
  Cases 
mean1 (95% CI)n 
Controls 
 mean1 (95% CI)n  
All subjects 
mean1 (95% CI)n  
595 G>A 
 
 
 
 
 
 
 
716 G>A 
Fasting Hcy (µmol/l) 
GG 
GA 
AA 
Post-load Hcy (µmol/l) 
GG 
GA 
AA 
Fasting Hcy (µmol/l) 
GG 
GA 
AA 
Post-load Hcy (µmol/l) 
GG 
GA 
AA 
 
14.2 (13.6-14.9)164 
11.3 (7.1-18.0)4 
- 
 
40.5 (38.4-42.6)153 
37.1 (24.1-57.1)5 
- 
 
14.3 (13.4-15.4)86 
13.8 (12.9-14.8)66 
15.66 (12.8-19.1)11 
 
41.7 (38.9-45.2)81 
39.7 (37.1-42.5)63 
43.37 (34.0-55.2)11 
 
13.1 (12.7-13.4)454 
16.02 (12.1-21.3)9 
- 
 
39.8 (38.7-40.9)438 
43.34 (33.4-56.3)8 
- 
 
12.8 (12.3-13.3)247 
13.3 (12.7-13.8)215 
13.2 (12.1-14.4)60 
 
40.1 (38.6-43.3)240 
41.4 (39.6-43.3)206 
39.5 (36.7-42.5)47 
 
13.4 (13.0-13.7)618 
14.43 (11.5-18.1)13 
- 
 
40.0 (39.0-41.0)591 
40.85 (33.6-49.6)13 
- 
 
13.2 (12.7-13.6)333 
13.4 (12.9-13.9)281 
13.6 (12.6-14.7)61 
 
40.5 (39.1-41.9)321 
41.0 (39.5-42.6)269 
40.2 (37.4-43.2)58 
- not observed;1geometric mean; no significant differences were observed before- and after adjustment for confounders. 
2P = 0.42, 3P = 0.79, 4P = 0.83; 5P = 0.60; 6P = 0.83; 7P = 0.60  (after adjustment for age, sex and MTHFR 677 C>T 
genotype)  
 
Additionally, 13 vascular patients with severe HHcy (fasting Hcy > 100 µmol/l) 
were screened for the 595 G>A mutation (data not shown), in order to find a 
possible 595 AA genotype. The mutation was not detected in any of these 
patients. The second mutation, the 716 G>A mutation was found 
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homozygously mutant (AA) in 7 % of the cases compared to 9.8% of the 
controls (table 2.3), which was not significantly different. In addition, the effect 
of this mutation on Hcy-levels was tested. This mutation did not lead to 
significant divergent Hcy-levels neither fasting nor post-load (table 2.4). 
Three individuals were heterozygous for both the 595 G>A and the 716 G>A 
mutation and also had increased Hcy-levels (fasting Hcy 18.7 µmol/l and post-
load Hcy 50.4 µmol/l) when compared to the wild-type (table 2.5). However, 
after statistical analysis by ANOVA and after adjustment for confounders this 
increase in Hcy was not significant (P = 0.09 for fasting Hcy and P = 0.19 for 
post-load Hcy). One genotype combination did result in significantly elevated 
post-load Hcy-levels (table 2.5, 595 GA/716 GA vs 595 GA/716 GG; P = 0.03). 
 
Table 2.5: Geometric means of fasting and post-load homocysteine values for combinations of BHMT 595 G>A and 716 
G>A genotypes 
 595 G>A genotype 
716 G>A genotype 595 GG 
mean1 (95% CI) (n) 
595 GA 
mean1 (95% CI) (n) 
595 AA 
mean1 (95% CI) 
Fasting homocysteine (µmol/l) 
716 GG 
716 GA 
716 AA 
 
Post-load homocysteine (µmol/l) 
716 GG 
716 GA 
716 AA 
 
13.2 (12.7-13.7) (283) 
13.3 (12.8-13.8) (244) 
13.3 (12.2-13.6) (52) 
 
 
40.0 (38.5-41.5) (272) 
40.5 (38.9-42.2) (252) 
39.7 (36.7-43.1) (50) 
 
13.8 (11.4-16.7) (9) 
18.72,3 (3.8-91.7) (3) 
- 
 
 
39.1 (30.5-50.2) (8) 
50.44,5 (34.2-74.2) (4) 
- 
 
- 
- 
- 
 
 
- 
- 
- 
- not observed; 1geometric mean; 2P = 0.09 595 GA/716 GA vs 595 GG/716 GG , 3P = 0.06 595 GA/716 GA vs 595 GG/716 
GA, 4P = 0.19 595 GA/716 GA vs 595 GG/716 GG and 5P = 0.03 595 GA/716 GA vs 595 GA/716 GG. 
 
Screening of the total study group for the 1218 G>T mutation resulted in the 
detection of one heterozygous control. The presence of this heterozygous 
mutation did not lead to higher Hcy-levels (data not shown). BHMT protein 
sequence of various species was compared to determine if amino acid 
substitutions of the BHMT gene can be found in a conserved region between 
different species. Only the 595 G>A mutation (G199S) is conserved between 
different species (human, mouse, rat and pig). The other two mutations are not 
in any conserved region of the gene (data not shown). Furthermore, possible 
secondary structure influences due to different mutations were studied by 
Chou & Fasman analysis (Omiga 2.0, Oxford Molecular Ltd, England). Only the 
G199S substitution was predicted to result in a different secondary structure 
(data not shown). 
 
 
Discussion 
 
Deficiency of BHMT can theoretically result in elevated Hcy-levels and may 
therefore contribute to the risk for vascular disease. Until now, no defects of 
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BHMT have been described. Recently, the gene coding for BHMT has been 
published enabling molecular analysis, which facilitates the detection of 
mutants with possible BHMT deficiency in patients. In this study, 16 vascular 
patients with HHcy were subjected to genomic sequencing of the BHMT gene 
and three mutations were detected in the coding region of the BHMT gene.  
The first mutation is a 595 G>A transition, which results in an amino acid 
substitution of glycine to serine at position 199 of the BHMT protein (G199S). 
This mutation seems to be a rare polymorphism with no relevance to HHcy or 
vascular disease, at least in heterozygous state. As indicated in table 2.4, Hcy-
levels (fasting as well as post-load) of cases and controls are slightly elevated 
when the 595 GA genotype is present, although this increase is not significant. 
Presence of the homozygous mutated genotype (595 AA) may theoretically 
result in significant elevated Hcy-levels. Screening of 170 cases and 460 
controls did not reveal any homozygous mutated alleles. Thus, the 595 A allele 
seems rare and will hardly contribute to mild HHcy or subsequently to the risk 
for vascular disease. Additionally, 13 patients with severe HHcy (fasting Hcy > 
100 µmol/l) were screened for this mutation. None of them had the possible 
595 AA genotype (data not shown). Comparison of the BHMT amino acid 
sequence of different species indicated that glycine at position 199 is 
conserved between human, mouse, rat and pig (data not shown). Recently, 
Breska et al 87 showed that replacement of conserved cysteine residues 
(Cys217, Cys299 and Cys300) in human, mouse, rat and pig BHMT already 
resulted in complete loss of activity, which suggested that glycine at position 
199 could also be a functional amino acid. Secondary structure prediction by 
Chou & Fasman analysis indicated that the protein, which normally has a turn 
structure, changes into a coil structure when serine is introduced. Furthermore, 
the substitution at amino acid position 199 (G199S) converts the non-polar 
amino acid glycine, which is commonly present on the surface of proteins, into 
the polar amino acid serine, which is frequently located in the interior part of 
the protein. Therefore, this substitution could result in secondary structure 
changes, which supports the findings by Chou & Fasman analysis. Based on 
these findings we hypothesize that the G199S mutation may result in altered 
functioning of BHMT although further studies are required to confirm this 
hypothesis.  
The second mutation found in the BHMT gene (716 G>A transition) results in a 
substitution of arginine to glutamine at position 239 (R239Q). Screening of 
171 cases and 520 controls did not show a significant difference on allele 
frequencies between cases and controls. Neither did the mutation influence 
Hcy concentrations, fasting nor post-load (table 2.4). This polymorphism was 
also noticed by Park and Garrow89, which suggests that this polymorphism is 
not unique to the Dutch population. Comparing the BHMT protein of different 
species (human, mouse, rat and pig) indicated presence of either arginine or 
glutamine at position 239, suggesting that this polymorphism is also present 
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in species other than humans. Therefore, presence of glutamine instead of 
arginine at position 239 probably does not seem to have major impact on 
folding of the protein and subsequently on protein functioning. Furthermore, 
secondary structure prediction by Chou & Fasman analysis does not lead to 
divergent structures. In summary, we have no evidence that this common 716 
G>A mutation influences Hcy metabolism and therefore we consider this as a 
benign polymorphism. 
The third mutation found in exon 8 of the BHMT gene, the 1218 G>A (Q406H), 
was only found in heterozygous state in one of the pre-selected patients and 
one of the controls of the study group. Therefore, this mutation seems to be a 
very rare polymorphism, which is not assumed to be a risk factor for HHcy or 
vascular disease. Glutamine at position 406 is not conserved, assuming no 
effect of this mutation on protein functioning. Presence of this mutation on 
both alleles (1218 AA) is therefore not expected to have a major impact on 
protein functioning. 
Combination of two mutations of the BHMT gene may have an additive effect 
on the phenotype. Therefore, we examined the combined effect of the 595 
G>A mutation and the 716 G>A mutation on Hcy-levels. This combination 
does not lead to significantly elevated Hcy-levels, when compared to the wild-
type. However, elevated post-load Hcy-levels were observed in one other 
genotype combination (P = 0.03, 595GA/716GA vs 595 GA/716GG). To 
exclude a possible role of genotype combinations on Hcy-levels, extension of 
the study group is necessary. In addition, combination of mutated BHMT with 
mutated genes coding for other enzymes (MS, MTHFR, CBS, methionine 
synthase reductase (MTRR)) of the Hcy metabolism also could influence Hcy 
concentrations (figure 2.1).  
Choline is the precursor of betaine (figure 2.1). When choline intake is low, less 
betaine is formed and subsequently less Hcy is remethylated to methionine, 
which may result in elevated Hcy concentrations. Choline is present in both 
animal and vegetable fats, but predominates in animal fats96. Thus, when 
mutations are present in the BHMT gene, we hypothesize that the availability of 
betaine may become limiting, and therefore a stronger effect of mutations 
could be expected in populations with low choline intake. Based on fat-intake, 
the Dutch population is presumed to have normal to high choline levels, 
therefore mutations of the BHMT gene may have less effect on Hcy in this 
population. An increased effect of these mutations could be expected in 
populations with less animal fat intake, e.g. the Chinese population. 
Mutated BHMT may contribute to other disorders related to a disturbed Hcy or 
folate metabolism such as neural tube defects or habitual abortions, due to 
different interaction of genetic- and nutritional factors97,98. Therefore, it would 
be interesting to investigate the role of mutated BHMT in relation to these 
disorders.  
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In this study three mutations were found in the BHMT gene, one of these three 
mutations (G199S) is conserved and could probably have an effect on BHMT 
protein functioning. To investigate whether mutations of the BHMT gene are 
pathogenic, mutations could be expressed in a bacterial expression system87. 
Using such a system would evaluate any possible effects of the homozygous 
mutated genotype (595 AA).  
Mutations in the BHMT gene could result in altered functioning of this gene 
and could therefore lead to HHcy. This is the first study in which molecular 
genetic analysis of the BHMT gene is performed in relation to HHcy and 
vascular disease. The results of this study indicate that mutated BHMT is not a 
major cause of mild HHcy or vascular disease. Further molecular genetic and 
enzymatic studies on BHMT are required to answer the question if defective 
BHMT functioning contributes to HHcy and vascular disease.  
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Abstract  
 
Neural tube defects (NTD) arise in the first weeks of pregnancy due to a 
combination of environmental and genetic factors. In mothers of a child with 
NTD elevated homocysteine (Hcy) levels and decreased plasma folate levels 
were observed, which suggests a defect in the folate dependent Hcy 
metabolism. Therefore, mutations in genes coding for enzymes of this 
metabolism could be involved in NTD. Serine hydroxymethyltransferase (SHMT) 
catalyzes the reversible reaction of serine and tetrahydrofolate (THF) to glycine 
and 5,10-methylene THF. Two different isoforms of SHMT are known; one is 
present in the cytosol (cSHMT) and the other in the mitochondrion (mSHMT). 
Theoretically, mutated SHMT could lead to elevated Hcy levels and to an 
altered distribution of the different folate derivatives and might therefore 
become a risk factor for NTD. This study concerns the molecular genetic 
analysis of genes coding for both isoforms of the SHMT enzyme by single 
stranded conformation polymorphism analysis. Several mutations as well as 
polymorphisms were found in both genes. The relevance of two variations, the 
1420 C>T mutation of the cytosolic isoform and the 4 bp deletion of the 
mitochondrial isoform (delTCTT1721-1724), to NTD risk was tested in a study 
group, which consisted of 109 NTD patients, 120 mothers of a child with NTD 
and 420 controls. Neither of the two polymorphisms led to an increased risk of 
NTD. In mothers with the 1420 CC genotype, significant increased Hcy levels 
are present. Also, significantly decreased red blood cell folate and plasma 
folate levels were present in individuals with the 1420 CC genotype. Probably, 
the 1420 C>T polymorphism causes a shift in distribution of the different 
folate derivatives. The 4 bp deletion of the mSHMT gene, did not lead to 
altered Hcy or folate levels. So far, the results of this study provide no direct 
evidence for a role of defective SHMT functioning in NTD. Still, the influence of 
the 1420 C>T polymorphism of the cSHMT gene on the folate-related risk of 
NTD needs further investigation. 
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Introduction  
 
Neural Tube Defects (NTD) are congenital malformations, which arise during 
the first weeks of pregnancy, due to incomplete closure of the neural tube. 
NTD are considered to be the result of a combination of environmental and 
genetic factors. Periconceptional folate administration reduces the NTD birth 
prevalence about 70%99,100. Mothers of a child with NTD are not folate deficient 
but have folate levels in the lower range of the controls101,102,103. Furthermore, 
elevated homocysteine (Hcy) levels were observed in these mothers, 
suggesting an abnormal folate metabolism102,104,103. Hcy is a sulfur containing 
metabolite, which is formed by demethylation of the essential amino acid 
methionine. Subsequently, Hcy can be irreversibly degraded by cystathionine 
β-synthase (CBS) or it can be remethylated to methionine by methionine 
synthase (MTR) or betaine-homocysteine methyltransferase (BHMT) (figure 
3.1). Mutations in genes coding for these enzymes might be involved in the 
etiology of NTD. Some years ago, the first genetic risk factor for NTD was 
identified by our group in the gene coding for methylenetetrahydrofolate 
reductase (MTHFR), the 677 C>T polymorphism (A222V)105. In Dutch and Irish 
populations, this 677 C>T polymorphism is associated with a 2-4 fold 
increased risk for NTD and results in elevated plasma Hcy levels and lowered 
plasma folate levels106,107. Several years ago, we identified a possible second 
genetic risk factor for NTD, the 1298 A>C polymorphism of the MTHFR 
gene17,108. Besides MTHFR, genes coding for enzymes of the remethylation or 
transsulfuration pathway of Hcy metabolism could play a role in the etiology of 
NTD. In MTR, a common polymorphism was found (D919G), which is not a 
major risk factor for NTD or hyperhomocysteinemia (HHcy)21,83. In addition, a 
polymorphism in the methionine-synthase reductase gene (MTRR, I22M) has 
been shown to be associated with increased risk for NTD in combination with 
low cobalamin levels109. Enzymatic and molecular genetic studies of CBS did 
not indicate a major role of CBS gene in NTD etiology102,110. Recently, we 
investigated BHMT in relation to mild HHcy, and also this enzyme does not 
seem to influence Hcy metabolism at least not in cardiovascular disease111. In 
addition, deficiencies of methylenetetrahydrofolate dehydrogenase (MTHFD) or 
serine hydroxymethyltransferase (SHMT) might be involved in NTD etiology 
(figure 3.1). Molecular genetic analysis of the gene coding for the tri-functional 
enzyme MTHFD did not indicate an involvement of this gene in NTD etiology23.  
SHMT (EC 2.1.2.1) is a major entry point for one-carbon units from serine into 
folate dependent metabolism and might therefore be a possible candidate to 
be involved in NTD. SHMT is a pyridoxal phosphate-dependent enzyme, which 
catalyzes the reversible conversion of serine and tetrahydrofolate (THF) to 
glycine and 5,10-methyleneTHF (5,10-MeTHF)(figure 3.1)112,113.  
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In humans SHMT is present as two iso-enzymes, one located in the 
mitochondrion (mSHMT) and the other in the cytoplasm (cSHMT)112,113. It has 
been suggested that cSHMT favors the reaction of 5,10-MeTHF and glycine to 
THF and serine, whereas mSHMT might catalyze the opposite reaction113. 
However, a recent in vivo study on one-carbon metabolism provides evidence 
that cSHMT can operate in both directions114. In the early nineties Garrow et al. 
cloned the genes coding for the human isoforms of SHMT115 and several years 
later the genomic sequences of both genes were published116,117. The cSHMT 
gene is localized to chromosome 17p11.2, whereas the mSHMT gene is 
localized to chromosome 12q13.2. The cSHMT gene consists of 12 exons and 
12 introns and is alternatively spliced in human cells117. In addition, a 
pseudogene with 93% sequence identity with the cSHMT has been identified118. 
This cSHMT derived pseudogene is localized to chromosome 1.  The gene 
coding for mSHMT consists of 10 exons and 10 introns116. Both cSHMT and 
mSHMT share about 63% sequence identity and mSHMT shows 61% sequence 
identity with the cSHMT derived pseudogene115. 
In the present study, we describe the molecular genetic analysis of both 
isoforms of human SHMT in relation to NTD in combination with Hcy and folate 
levels.  
 
 
Material and Methods 
 
Patients and controls 
The study group, which was recruited by the participation of the Dutch society 
for patients with CNS defects (BOSK) consisted of spina bifida (SB) patients 
(n=70) and their mothers (n=73)105. As a control group, material from 317 
controls recruited from a general practice in The Hague was used7,21. In 
addition to this first study group, material from a second study group was 
included consisting of 39 SB patients (mean age 10.6 ± 4.1 years), 47 mothers 
Figure 3.1: Simplified scheme of
folate/homocysteine metabolism of the cell.
Main regulating enzymes are depicted and
co-factors are encircled; CBS, cystathionine
β-synthase; MTHFR, methylenetetrahydro-
folate reductase; MTR, methionine synthase;
MTRR, methionine-synthase reductase;
cSHMT, cytosolic serinehydroxymethyl-
transferase; mSHMT, mitochondrial serine-
hydroxy methyltransferase; BHMT, betaine-
homocysteine methyltransferase; MTHFD,
methylene-tetrahydrofolate dehydrogenase;
AdoMet, S-adenosylmethionine and AdoHcy,
S-adenosylhomocysteine. 1: remethylation;
2: transulfuration 
 
Mitochondrion
Serine Glycine
THF 5,10-MeTHF
mSHMT
Methionine
MTR
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AdoHcy AdoMet
5-MeTHF THF
5,10-MeTHF
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of a child with SB (mean age 38.6 ± 5.1 years), and 103 healthy hospital 
employees (mean age 36.6 ± 5.0 years)119. The exclusion criteria of these 103 
controls were overt liver and renal dysfunction, hormonal therapy, neoplastic 
disease, cleft lip, NTD, and the use of vitamins. The local ethics committee 
approved this study. 
 
RNA/DNA isolation and cDNA synthesis 
RNA was isolated from cultured lymphoblasts as described120. Isolated RNA 
was DNAse treated to eliminate genomic DNA contamination followed by 
reversed transcription to cDNA by standard techniques. Furthermore, reverse 
transcriptase was omitted from at least one RNA sample to check for possible 
DNA contamination. In addition, DNA was isolated from whole blood according 
to Miller et al 121. 
 
Molecular genetic analysis 
Both human SHMT iso-enzymes were subjected to single stranded 
conformation polymorphism (SSCP)122. Primers were designed according to 
Genbank published cSHMT and mSHMT mRNA sequences (Accession no 
L11931 and NM_005412, respectively and table 3.1) resulting in overlapping 
PCR fragments of ~ 250 bp. Due to the presence of a pseudogene for the 
cSHMT with a homology of 93% in mRNA sequence, primers were designed to 
eliminate pseudogene amplification, which was confirmed by sequencing 
analysis on an ABI 377 automated sequencer using the DyeDeoxy terminator 
cycle sequencing kit according to instructions of the manufacturer (PE 
biosystems, The Netherlands). PCR was carried out in a total volume of 25 µl 
on an Omnigene thermocycler (Biozym, The Netherlands), containing 50 ng of 
both primers, 200 mM dNTPs, 10 mM Tris-HCl buffer, 1.0-2.0 mM MgCl2 and 
0.5 unit Taq polymerase (all from Life Technologies, The Netherlands). SSCP 
was performed as described previously23,119. 
 
Cytosolic SHMT 
In the coding region of the human cytosolic SHMT gene two sequence 
variations were found by SSCP. The first one, the 1181 G>A transition, was 
confirmed at DNA level by restriction enzyme analysis. This mutation resulted 
in an abolishment of a Hha I restriction site.  A 218 bp region was amplified by 
PCR using primer 1181-for and 1181-rev (table 3.1). Hha I digestion of wild 
type sequences (1181 GG) then leads to two fragments of 185 and 33 bp. The 
products were analyzed on a 2% agarose gel. The second variation, the 1420 
C>T transition, was also confirmed on DNA by restriction enzyme analysis. PCR 
products were generated by primer 8-for and 8-rev, thereby creating a product 
of 217 bp. Eam1104 I cuts the wild type sequence into two products of 131 
and 86 bp. The products were analyzed on a 2% agarose gel. 
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Mitochondrial SHMT 
In the gene coding for the mitochondrial isoform, one missense variation was 
found by SSCP in the coding region, the 850 C>T mutation. This mutation was 
screened on DNA by PCR using primer 850-for and 850-rev (table 3.1) 
followed by Nci I restriction enzyme analysis. PCR products containing exon 7 
of 208 bp in length were obtained, which were cut by Nci I in two fragments of 
123 and 85 bp, when the wild type was present. The products were analyzed 
on a 2% agarose gel. Furthermore, in the 3’ untranslated region (UTR) a 4 bp 
deletion was found at position 1721-1724 of the mRNA. This deletion was 
screened by PCR using primer del-for and del-rev (table 3.1). Subsequently, 
PCR products were separated on a 20% PAA gel for 5 hours at 140 V, followed 
by ethidiumbromide staining for 15 minutes. 
 
Table 3.1: Primers used for molecular genetic analysis of the cSHMT and mSHMT gene 
 Fragment 
No. 
Size 
(bp) 
Forward primer 
(5’ → 3’) 
Reverse primer 
(5’ → 3’) 
cSHMT 
 
 
 
 
 
 
 
 
 
mSHMT 
1 
2 
3 
4 
5 
6 
7 
82 
1181 G>A 
 
11 
2 
3 
4 
5 
6 
7 
8 
9 
850 C>T 
delTCTT1721-17241 
232 
263 
264 
243 
251 
242 
241 
218 
250 
 
251 
229 
278 
277 
173 
249 
251 
280 
266 
208 
89 
TAGGCAGCTTCGAACCAGTG1 
TTGCCTCGGAGAATTTCGCC 
TTTGCTGTGTACACTGCCCTG 
AGCTGATCATCGCAGGAACC 
AAGACCCTGCGAGGCTGC 
CTGAAGCAAGCTATGACTCTGG 
CTATTGCCTGCAACAAGAACACC 
AGAGTTCAAGGAGAGACTGGCAG 
GTGCCTCCTTGTGCCTTGG3 
 
CGCAGCCCAGACTCAGAC 
CCCTGGGGTCCTGTCTGAAC 
CGTCTACACAGCCCTTCTGC 
CCTATGCTCGCCTCATTGAC 
GGCCGGGAGATCCTTTACAC 
GGCCTGCACCCCCATGTTC 
GAGCTTGTATCCATCACTGCC 
CTGCCAAGCTCCAGGATTTC 
TATTTTTTGGTGCGGGAGG1 
GACCATCCACCTCTCACACAG3 
GTCATGATCACAGTGTCAGAGACGC 
ATTTAAGCAAGAGCCTAGGGC 
GATGCGCCCATGGGGTTC 
GGCATATTCCAGGTTTCGGG 
CCACACTTTTCACTCCTTTCCTG 
TCAGACAGAGCCCTGCAGTTG 
GAGCGCTTCTGTCACCTGG 
CTATTGCCTGCAACAAGAACACC 
GTCAACAGTTCCCTTTGGAGC1 
GGGACGTCAGTGCTGGGG 
 
CATCCACCACCTCTGCTCC 
CCCATGATCCGGTCGTGAG 
CACACACCTCTCTCATGCGG 
ACGGCAAAGTTGATTCGGTC 
ATGGCCCGAGCATTCTTCAG 
AGGCCGCCCGGTGTGATGGC 
TTGGCCAGACGCTGACTTG 
TTCTGGGAAGGGAGACTATACC1 
GATAAAAACAGGAAGGAGGGTG1 
TACAAAGACAGGATCCCCAAC3 
CCTACCCACCCCTGCCTGC 
1Located in 5’UTR or 3’UTR; 2Used for screening of the 1420 C>T polymorphism; 3Located in intron 
 
Hcy and folate analysis 
Hcy levels from 107 patients, 120 mothers and 410 controls of the total study 
group were measured in EDTA plasma by HPLC93. Plasma folate as well as red 
blood cell (RBC) folate was measured by Dualcount Solid Phase Boil Radio Assay 
(Diagnostic procedures, USA)102. Plasma folate levels were obtained from 90 
patients, 116 mothers and from 103 controls of the second study group. RBC 
folate levels were obtained from 87 patients, 113 mothers and from the 103 
controls of the second study group. 
 
Statistical analysis 
Differences in genotype frequencies between patients, mothers and controls 
were calculated using Pearson chi-square. Hcy, RBC folate and plasma folate 
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levels showed positive skewness, and therefore in all cases geometric means 
were calculated instead of means. Significance between geometric means of 
different genotypes was estimated by one-way analysis of variance (ANOVA) 
and Student’s t test. Tests for linear trend were performed by linear regression 
analysis. P values were age- and sex adjusted in some cases by linear 
regression analysis. Differences were significant at P < 0.05. All P values were 
two tailed. 
 
 
Results 
 
The relevance of mutated SHMT to the etiology of NTD was tested by molecular 
genetic analysis of genes coding for the mitochondrial and the cytosolic 
isoform of SHMT. cDNA from 70 NTD patients was subjected to SSCP analysis, 
thereby screening the whole coding region of both genes (including a small 
part of the 5’ and 3’ UTR).   
 
Cytosolic SHMT  
Two variations were found by SSCP in the coding region of the gene coding for 
the cytosolic isoform of SHMT (table 3.2). The first one, the 1181 G>A 
transition was located in exon 12 and leads to a substitution of serine to 
aspargine at position 394 (S394N). This mutation was heterozygously detected 
only in one NTD patient, thereby not contributing to a general risk for NTD. 
Screening of 400 control alleles did not reveal any mutated alleles. This 
mutation was also tested in the mother of this heterozygously mutated patient, 
who was wild type for the 1181 G>A transition. Material of the father was not 
available. 
 
Table 3.2: Sequence variations found in genes coding for the mitochondrial and cytosolic isoform of SHMT 
 Sequence variation Amino acid  substitution Screening method 
cSHMT 
 
 
 
mSHMT 
1181 G>A 
1420 C>T 
exon 9 alt. splicing 
 
850 C>T 
906 T>G 
delTCTT 1721-1724 
S394N 
L474F 
 
 
R284W 
silent 
3’ UTR 
Hha I1 
Eam1104 I1 
- 
 
Nci I1 
- 
PAGE 
1Restriction enzyme analysis; -not screened in study group, detected by SSCP and sequencing analysis 
 
The second variation found in this gene was located in exon 13, which is the 
last exon of this gene. This 1420 C>T transition results in an amino acid 
substitution of leucine to phenylalanine at position 474 of the protein (L474F). 
To test whether this sequence variation contributes to the risk for NTD, we 
screened all controls and also the mothers of these patients, because a 
disturbed folate metabolism of the mother could also contribute to the risk of 
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giving birth to a child with NTD102. This 1420 C>T polymorphism does not lead 
to an increased risk for NTD (table 3.3).  
 
Table 3.3: Prevalence of the cSHMT and mSHMT variations in total study group 
 Variation Patients Mothers Controls 
cSHMT 
 
 
 
 
 
 
mSHMT 
1420 C>T1 
CC 
 
CT 
 
TT 
 
delTCTT 1721-17242 
wt/wt 
 
wt/del 
 
53.6% 
(n=52) 
39.2% 
(n=38) 
7.2% 
(n=7) 
 
95.2% 
(n=80) 
4.8% 
(n=4) 
 
53.8% 
(n=57) 
36.8% 
(n=39) 
9.4% 
(n=10) 
 
96.7% 
(n=87) 
3.3% 
(n=3) 
 
45.0% 
(n=185) 
46.0% 
(n=189) 
9.0%3 
(n=37) 
 
94.5% 
(n=397) 
5.5%4 
(n=23) 
1χ2 = 4.56, df=4, P = 0.33;  2χ2= 0.73, df=2, P = 0.69; 3Allele frequency 1420 T allele = 0.319; 4Allele frequency TCTT 
deletion = 0.027; *cSHMT 1420 C>T allele frequencies are in Hardy-Weinberg equilibrium 
 
The effect of this polymorphism on Hcy was investigated in the total study 
group. Mothers with 1420 CC genotype show significantly higher Hcy levels 
compared to those with the 1420 CT genotype. Hcy levels of other groups did 
not differ between the different genotypes (table 3.4).  
Additionally, folate levels were measured in material of patients, mothers and 
only in a subset of the controls, namely the 103 controls of the second study 
group. 
 
Table 3.4: Plasma homocysteine levels of different cSHMT and mSHMT genotypes  
Mean homocysteine (95% CI)1 
(µmol/L) 
Variation 
 
Patients Mothers Controls All individuals 
cSHMT 1420 C>T 
 
CC 
 
CT 
 
TT 
 
mSHMT TCTTdel1721-17243 
 
wt/wt 
 
wt/del 
 
ANOVA P = 0.95 
 
11.7 (10.6-13.0) 
(n=39) 
12.0 (10.7-14.1) 
(n=33) 
11.6 (8.0-16.9) 
(n=7) 
 
 
11.8 (10.9-12.9) 
(n=69) 
13.4 (6.3-28.7) 
(n=3) 
ANOVA P = 0.03 
 
14.1 (12.6-15.6)2  
(n=47) 
11.4 (10.4-12.3) 
(n=31) 
11.6 (10.5-12.9)  
(n=9) 
 
 
12.8 (12.0-13.7) 
(n=85) 
9.4 (8.5-10.3) 
(n=2) 
ANOVA P = 0.69 
 
12.9 (12.3-13.5) 
(n=160) 
12.6 (11.9-13.1) 
(n=168) 
13.2 (12.2-14.4) 
(n=32) 
 
 
12.8 (12.4-13.2) 
(n=342) 
12.7 (11.6-13.8) 
(n=18) 
ANOVA P = 0.59 
 
12.7 (12.3-13.3) 
(n=291) 
12.4 (11.8-12.8) 
(n=225) 
12.6 (11.8-13.7) 
(n=48) 
 
 
12.6 (12.3-12.9) 
(n=496) 
12.7 (11.2-13.9) 
(n=23) 
1Geometric mean; 2P = 0.03 1420 CC vs 1420 CT (corrected for age differences); 3No significantly altered Hcy levels. 
 
These folate levels were investigated in relation to the 1420 C>T 
polymorphism, and RBC folate as well as plasma folate levels are significantly 
elevated due to presence of the 1420 C>T substitution (table 3.5 and 3.6, all 
individuals ANOVA P = 0.02 and P = 0.04, respectively). However, increased 
RBC folate levels were only observed in the total study group or in controls (P 
for linear trend = 0.04), whereas no significant increased RBC folate levels 
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were present in patients and mothers (table 3.5). Plasma folate levels were only 
elevated in the total study group and not in individual groups (table 3.6). 
 
Table 3.5: RBC folate levels of different cSHMT and mSHMT genotypes in a subset of the study group 
Mean RBC folate1 (95% CI)  
(nmol/L) 
Variation 
Patients Mothers Controls All individuals 
cSHMT  
1420 C>T 
 
CC 
CT 
TT 
 
mSHMT 
TCTTdel1721-17245 
wt/wt 
wt/del 
 
ANOVA P = 0.75 
 
485.8 (431.1-547.4)
(n=33) 
498.7 (428.7-580.3)
(n=25) 
501.4 (412.0-610.3) 
(n=7) 
 
 
486.9 (456.6-573.4)
(n=66) 
599.6 (429.5-837.1)
(n=3) 
 
ANOVA P = 0.23 
 
498.9 (455.1-547.1)
(n=43) 
578.1 (486.6-686.8)
(n=31) 
576.9 (464.2-717.2) 
(n=9) 
 
 
533.2 (491.2-578.2)
(n=81) 
640.3 (-) 
(n=2) 
 
ANOVA P = 0.12 
 
526.1 (466.9-592.6) 
(n=39) 
584.8 (533.4-641.3) 
(n=44) 
641.2 (554.2-741.8)2 
(n=12) 
 
 
570.0 (530.6-612.3) 
(n=87) 
530.3 (437.8-642.4) 
(n=8) 
 
ANOVA P = 0.02 
 
506.7 (474.0-536.1) 
(n=115) 
559.9 (519.4-603.8)3 
(n=100) 
582.8 (527.9-643.5)4 
(n=28) 
 
 
533.8 (509.9-558.9) 
(n=230) 
561.5 (477.0-661.1) 
(n=13) 
1Geometric mean; 2P for linear trend 0.04; 3P = 0.02 1420 CT vs 1420 CC; 4P = 0.03 1420 TT vs 1420 CC; All P values were  
corrected for age and  sex differences; 5No significantly altered RBC folate levels; (-) not informative. 
 
Alternative splicing of exon 9 was observed by SSCP analysis in RNA of 
lymphoblastoid cells. All NTD patients have both alleles, one with exon 9 and 
the other one without exon 9. This alternative splicing was already reported by 
Girgis et al. and seems to differ between cell types117. 
 
Table 3.6: Plasma folate levels of different cSHMT and mSHMT genotypes in a subset of the study group 
Mean plasma folate1 (95% CI)  
(nmol/L) 
Variation 
 
Patients Mothers Controls All individuals 
cSHMT 1420 C>T 
CC 
 
CT 
 
TT 
 
mSHMT  TCTTdel1721-17244 
wt/wt 
 
wt/del 
 
ANOVA P = 0.09 
10.8 (9.4-12.5) 
(n=33) 
13.5 (10.9-16.7) 
(n=25) 
10.3 (7.7-13.7) 
(n=7) 
 
11.8 (10.6-13.4) 
(n=67) 
9.7 (2.2-43.5) 
(n=3) 
ANOVA P = 0.61 
11.7 (10.4-13.2) 
(n=43) 
13.9 (11.2-17.1) 
(n=31) 
13.5 (10.4-17.7) 
(n=9) 
 
12.7 (11.4-14.0) 
(n=81) 
13.8 (2.2-86.2) 
(n=2) 
ANOVA P = 0.25 
13.5 (12.1-15.1) 
(n=39) 
14.5 (12.6-16.8) 
(n=44) 
16.9 (13.1-21.9)2 
(n=12) 
 
14.5 (13.3-15.9) 
(n=87) 
12.8 (9.6-17.2) 
(n=8) 
ANOVA P = 0.04 
12.0 (11.2-12.0) 
(n=115) 
14.0 (12.7-15.6)3 
(n=100) 
13.9 (11.9-16.3) 
(n=28) 
 
13.1 (12.4-13.9) 
(n=230) 
12.2 (9.6-15.4) 
(n=13) 
1Geometric mean; 2P value for linear trend is 0.10; 3P = 0.01 (1420 CT vs 1420 CC); All P values were corrected for age and 
sex differences. 4No significantly altered plasma folate levels 
 
Mitochondrial SHMT  
Two sequence variations were found by SSCP of the gene coding for the 
mSHMT isoform (table 3.2). The first mutation was found homozygously in one 
of the 70 NTD patients. This 850 C>T transition leads to an amino acid 
substitution of arginine to tryptophan at position 284 of the protein (R284W). 
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Screening of 400 control alleles did not reveal any other mutant alleles, 
meaning that this 850 C>T transition is not a general risk factor for NTD.  
Furthermore, the mother and father of this NTD patient were screened, both 
parents are heterozygous for this 850 C>T mutation (data not shown). In the 
3’ UTR, a second mutation was found concerning a 4-bp deletion at position 
1721 (delTCTT1721-1724). This deletion was heterozygously present in 4 NTD 
patients. To study whether this deletion contributes to the folate related risk of 
NTD, this deletion was evaluated in the entire study group, which consists of 
109 cases, 120 mothers and 420 controls. This deletion had an allele 
frequency of 0.027 in the controls and its frequency was not significantly 
different in patients or mothers (table 3.3) assuming that this deletion is not 
involved in NTD. Furthermore, Hcy levels and folate levels were not altered due 
to the presence of this deleted allele (table 3.4, 3.5 and 3.6). Finally, a 
nonsense mutation, the 906 T>G substitution was observed in one NTD 
patient (table 3.3).  
 
 
Discussion 
 
Defective functioning of SHMT could contribute to the risk for NTD. This study 
concerns the molecular genetic analysis of cDNA of two genes coding for the 
mitochondrial (mSHMT) and cytosolic (cSHMT) isoform of SHMT. Two sequence 
variations were found in the coding region of the cSHMT gene, the 1181 G>A 
transition and the 1420 C>T transition. The 1181 G>A mutation was found 
heterozygously in one NTD patient and therefore is not a risk factor for NTD. 
The second variation found in this gene, the 1420 C>T transition, had an allele 
frequency of 0.268 for the T-allele in patients. This polymorphism did not 
result in an increased risk of NTD. Mothers with the wild type genotype (1420 
CC) have higher Hcy levels. However, these higher Hcy levels were not 
observed in patients or controls. Furthermore, significantly decreased RBC 
folate levels as well as plasma folate levels were observed in individuals with 
the wild type genotype (1420 CC). Probably, the 1420 C>T transition in the 
cSHMT gene alters the distribution of folates in red blood cells and in plasma, 
which is reflected for the wild type by increased Hcy levels in mothers and 
decreased folate levels. However, more data is needed to assess a possible 
influence of this polymorphism on folate metabolism and NTD risk. 
Alternative splicing of exon 9 was present on RNA of lymphoblastoid cells in all 
patients (data not shown). This alternative splicing was already reported by 
Girgis et al 117, who observed a cell specific alternative splicing of exon 9, as 
well as exon 2 and 10. As postulated by Girgis et al, alternative splicing might 
influence catalytic activity of cSHMT, serine cleavage and synthesis of different 
folate derivatives117. Recently, a study on the kinetics of human one-carbon 
metabolism provides evidence that folate metabolism in the overall whole body 
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differs from that of the liver114. This result is consistent with the reported cell 
specific alternative splicing of the cSHMT gene117. However, further studies are 
required to assess a possible influence of this alternative splicing event on 
Hcy- and folate metabolism.  
In the mSHMT gene two variations were found. The first one, the 850 C>T 
substitution, is found as a homozygous mutation in one patient and therefore 
this mutation is not a common risk factor for NTD. The second variation found 
in this gene is a 4 bp deletion in the 3’ UTR of this gene. Sequence variations 
located in the 3’ UTR might cause variable expression and might disrupt RNA 
stability. This delTCTT 1721-1724 did not contribute to an increased risk for 
NTD. Furthermore, presence of the deleted allele did also not result in elevated 
Hcy levels or altered folate levels. Therefore, this deletion does not seem to 
contribute to the risk for NTD. However, due to the very low allele frequency, 
more data is needed to assess a possible relationship of this deletion to NTD 
risk.  
Thus far, the results of this study show that the 1420 C>T polymorphism of 
the cSHMT might contribute to a disturbed folate dependent Hcy metabolism 
but more data is needed to study this effect. A redistribution of folates due to 
the 1420 C>T polymorphism in the cSHMT gene may occur, but whether this 
polymorphism really influences SHMT activity cannot be concluded from this 
study. Expression of SHMT mutations in a bacterial expression system might 
evaluate any possible effects on SHMT activity123. The complex mechanism 
behind the genetic- and environmental interaction, which is involved in NTD is 
far from solved and will require several more years of research. 
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Abstract  
 
Endothelial dysfunction is an early event in the development of vascular 
complications in hyperhomocysteinemia. Endothelial cells release a number of 
vasodilators, including NO and prostacyclin. Several lines of evidence have 
indicated the existence of a third vasodilator pathway, mediated by 
endothelium-derived hyperpolarizing factor (EDHF). EDHF is a major 
determinant of vascular tone in small resistance vessels. The influence of 
hyperhomocysteinemia on EDHF is unknown. The present in vivo study 
evaluates the integrity of the EDHF-pathway in the renal microcirculation of 
rats with acute and chronic hyperhomocysteinemia. EDHF-mediated 
vasodilation was evaluated as the renal blood flow (RBF) response to intrarenal 
acetylcholine during systemic NO synthase and cyclooxygenase inhibition. 
Acute hyperhomocysteinemia induced by intravenous L-homocysteine (Hcy) 
did not affect EDHF-mediated vasodilatation. In contrast, intravenous 
methionine with subsequent hyperhomocysteinemia impaired the EDHF-
mediated RBF response. When the methionine infusion was preceded by  
periodate oxidized adenosine to prevent the cleavage of S-
adenosylhomocysteine to Hcy and adenosine, a similar impairment of EDHF 
was observed, however, with normal Hcy levels. Animals with chronic 
hyperhomocysteinemia induced by a high methionine, low B vitamin diet 
during 8 weeks had a severely depressed EDHF-mediated vasodilation, as 
compared to those on a standard diet. Endothelium-independent vasodilation 
to deta-NONOate and pinacidil was not affected in acute and chronic 
hyperhomocysteinemia, demonstrating intact vascular smooth muscle 
reactivity. EDHF-dependent responses are impaired in the kidney of 
hyperhomocysteinemic rats. Since EDHF is a major regulator of vascular 
function in small vessels, these findings have important implications for the 
development of microangiopathy in hyperhomocysteinemia. 
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Introduction 
  
A large body of evidence has indicated that hyperhomocysteinemia portends 
an increased risk for atherothrombotic cardiovascular disease. The underlying 
molecular mechanism remains, however, conjectural. An early manifestation of 
atherosclerosis is endothelial dysfunction. Hyperhomocysteinemia is known to 
be associated with impaired endothelium-dependent vasodilatation in both 
experimental animals30,124,125 and humans126,31,32,127,70,128. The leading 
mechanism suggested for the adverse vascular effects of homocysteine (Hcy) 
on endothelial function involves increased oxidant stress with a depletion of 
bioactive NO125. 
Although NO has generally been considered to be the principal mediator of 
endothelium-dependent relaxations, evidence is mounting that endothelium-
derived hyperpolarizing factor (EDHF) is a major determinant of vascular tone 
especially in small resistance vessels61. These vessels control tissue perfusion 
and may thus be of larger physiological relevance than conductance arteries. 
The nature of EDHF is still not entirely elucidated50. Current evidence suggests 
that EDHF-mediated responses are initiated by activation of endothelial K+-
channels with resultant hyperpolarization of endothelial cells. This endothelial 
hyperpolarization spreads to the underlying smooth muscle layer through 
myo-endothelial gap junctions or the efflux of K+ from the endothelial cells 
elicits hyperpolarization of the adjacent smooth muscle cells. 
Epoxyeicosatrienoic acids likely have a regulatory role in this pathway50. The 
contribution of EDHF to relaxation is dependent on vessel size, being more 
prominent in smaller arteries than in larger ones61,50. The majority of the 
studies on the effect of hyperhomocysteinemia on endothelial function were 
performed in large conduit arteries such as the brachial artery, where 
endothelium-dependent vasodilatation is largely NO-dependent, and therefore 
a potential effect on EDHF may have been overlooked. Whether 
hyperhomocysteinemia interferes with the EDHF-pathway is currently 
unknown.  
The aim of the present study was to examine the effect of acute and chronic 
hyperhomocysteinemia on EDHF-mediated vasodilatation in vivo. The 
contribution of EDHF to endothelium-dependent vasodilatation is generally 
evaluated by probing the response to an endothelium-dependent agonist 
during combined blockade of NO synthase and cyclooxygenase. The renal 
microcirculation of the rat was selected for this study. This vascular bed is 
characterized by a large residual response to acetylcholine during NO 
synthase- and cyclooxygenase inhibition, that is abolished by inhibition of gap 
junctional communication, indicative of a prominent EDHF-pathway61,53. 
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Material and Methods 
 
Renal blood flow (RBF) measurements 
The studies were performed in 59 female Wistar rats with a body weight of ± 
250 g (Iffa Credo, Brussels, Belgium), receiving care in accordance with NIH and 
national guidelines for animal protection. The rats were anesthetized with 
thiobutabarbital (Inactin, RBI, Natick, USA, 100 mg/kg i.p.). The trachea was 
intubated, a jugular vein was cannulated for continuous infusion of isotonic 
saline (3 ml/h) and administration of drugs, and a carotid artery was 
cannulated for continuous monitoring of arterial blood pressure. The right 
renal and suprarenal arteries were exposed via a small abdominal incision. The 
suprarenal artery was cannulated for intrarenal administration of drugs. A 
blood flow sensor with an inner diameter of 0.5 to 0.7 mm was placed on the 
renal artery, allowing continuous RBF monitoring (T106 flow meter, Transonic, 
Ithaca, NY, USA)61,53. The RBF response to intrarenal acetylcholine (Sigma, 1 to 
50 ng in bolus), to the NO donor deta-NONOate (Alexis, Grünberg, Germany, 
16 to 80 µg in bolus) and to the K+-channel opener pinacidil (Sigma, 25 to 125 
µg in bolus) was examined. All experiments were performed in the combined 
presence of systemic NO synthase and cyclooxygenase blockade: L-NG-
nitroarginine methylester HCl (L-NAME, Sigma Chemical Co, St. Louis, MO, 10 
mg/kg bolus followed by 20 mg/kg/h) and indomethacin (Sigma, 4 mg/kg 
bolus followed by 8 mg/kg/h). Before administration of the next dose of 
acetylcholine, deta-NONOate and pinacidil, RBF was allowed to return to 
baseline values. The upper limit of the dose-response curve to acetylcholine, 
deta-NONOate and pinacidil was chosen as the highest dose that was devoid of 
systemic blood pressure effects.  
 
Acute hyperhomocysteinemia 
Series 1 
The RBF response to acetylcholine, deta-NONOate and pinacidil in the 
presence of L-NAME and indomethacin was examined at baseline and 5 min, 
30 min and 60 min after infusion of L-Hcy (40 mmol/kg BW dissolved in 1 ml 
saline administered over 5 min) (n=6) (figure 4.1). L-Hcy was prepared from its 
thiolactone form129. Briefly, 30.7 mg L-Hcy thiolactone hydrochloride (Sigma) 
was dissolved in 0.2 ml of 4 N NaOH and incubated for 5 min at 37 °C. 
Subsequently, Tris-HCl (pH 8.6) and dithiothreitol were added and the pH was 
adjusted to 7-8. The final concentration of Hcy and dithiothreitol were 100 mM 
and 20 mM, respectively. To exclude interference by dithiothreitol, the effect of 
20 mM dithiothreitol alone dissolved in saline on the RBF response to 
acetylcholine, deta-NONOate and pinacidil in the presence of L-NAME and 
indomethacin was studied (n=6). 
Chapter 4 
           58 
 
Series 2 
The RBF response to acetylcholine, deta-NONOate and pinacidil in the 
presence of L-NAME and indomethacin was examined subsequently at 
baseline, 30 minutes after the infusion of 1 ml saline, 60 and 120 min after the 
infusion of methionine (Sigma, 0.125 g/kg BW dissolved in 2 ml saline 
administered over 10 min) and 30 min after the infusion of 5-
methyltetrahydrofolate (Sigma, 800 µg/kg BW in 1 ml saline administered over 
5 min) (n=6) (figure 4.1). The protocol was repeated after adding 20 mM 
dithiothreitol to the methionine solution (n=5). 
 
Series 3 
The RBF response to acetylcholine, deta-NONOate and pinacidil in the 
presence of L-NAME and indomethacin was examined subsequently at 
baseline, 30 minutes after the infusion of periodate oxidized adenosine 
(Sigma, 20 µmol/kg BW dissolved in 1 ml saline administered over 5 min), 60 
and 120 min after the infusion of methionine (0.125 g/kg BW) and 30 min after 
the infusion of 5-methyltetrahydrofolate (800 µg/kg BW) (n=6) (figure 4.1). 
Periodate oxidized adenosine (ADOX) is a competitive inhibitor of S-
adenosylhomocysteine hydrolase (AHCY) and thus blocks the cleavage of 
AdoHcy to Hcy and adenosine. 
 
Series 4 
The RBF response to acetylcholine, deta-NONOate and pinacidil in the 
presence of L-NAME and indomethacin was examined subsequently at 
baseline, 30 minutes after the infusion of 1 ml saline, 60 and 120 min after the 
infusion of methionine (0.125 g/kg BW) and 30 min after the infusion of 1 ml 
saline (n=6), in order to provide a time control for the 5-
methyltetrahydrofolate administration (figure 4.1). 
Figure 4.1: Time course of 
the different experimental 
series 
 
     5’         25’            30’ 
Hcy or DTT 
  30’                            60’                                60’                                30’
 Saline  Methionine or methionine + DTT    Folate 
 30’                          60’                                 60’                                 30’ 
ADOX              Methionine    Folate
 30’                         60’                                 60’                                  30’ 
Saline             Methionine     Saline 
Series 1 
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Chronic hyperhomocysteinemia 
The animals received a diet enriched in methionine with depleted levels of 
folate, vitamin B6 and vitamin B12 (Harlan Teklad TD97345, Harlan Teklad, 
Madison, Wisconsin, USA) (n=8), a diet enriched in methionine with high levels 
of folate, vitamin B6 and vitamin B12 (Harlan Teklad TD98002) (n=8) or 
standard rodent chow (n=8) during 8 weeks (table 4.1). 
Thereafter, the RBF response to acetylcholine, deta-NONOate and pinacidil was 
examined in the presence of L-NAME and indomethacin. The experiments were 
repeated 15 and 30 min after the infusion of 5-methyltetrahydrofolate (800 
µg/kg BW). 
 
Table 4.1: Composition of the diets (g/kg) 
 Methionine Folic acid Vitamin B12 Pyridoxine Choline 
High methionine/ low B vitamin 
High methionine / high B vitamin 
Standard rodent chow 
7.7 
7.7 
3.8 
- 
0.002 
0.002 
- 
0.00003 
0.00003 
- 
0.07 
0.07 
2.5 
2.5 
2.5 
 
Biochemical analyses 
Methionine concentrations were determined by a reversed phase high-
performance liquid chromatography (HPLC) technique with a SymmetryShieldTM 
C18 column (Waters, Ettenleur, The Netherlands). Samples were deproteinized 
by sulfosalicylic acid. Norleucine was added as internal standard. Pre-column 
derivatization was performed using AccQ.Fluor reagent (Waters). For separation 
AccQ.Tag eluens (Waters) was applied with a gradient of acetonitril-water 
(60:40%), starting at 35 % and increasing to 100%. Quantification was 
performed by fluorescence detection. Total plasma homocysteine 
concentrations were measured using a HPLC procedure with reverse-phase 
separation and fluorescence detection, as described previously93. 
 
Statistical analysis 
The data are presented as mean±SEM. The RBF response to the different 
agonists is expressed as the area under the curve of the change in RBF (ml/min 
x min), as detailed previously61,53. Analysis of variance, paired and unpaired t-
tests were used as appropriate. The significance level was set at P < 0.05. 
 
 
Results 
 
Acute hyperhomocysteinemia by intravenous L-Hcy 
The intravenous administration of L-Hcy resulted in a steep rise of tHcy levels: 
they were 12.9 ± 1.0 µmol/L before, 183.4 ± 50.9 µmol/L 5 min after, 101.5 ± 
28.2 µmol/L 30 min after and 53.3 ± 18.5 µmol/L 60 minutes after the bolus 
administration. Methionine levels did not change: they were 46.3 ± 4.7 µmol/L 
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before, 57.0 ± 3.0 µmol/L 5 min after, 58.3 ± 3.7 µmol/L 30 min after and 
53.7 ± 3.8 µmol/L 60 minutes after the bolus administration. The RBF response 
to acetylcholine during L-NAME and indomethacin infusion was, however, not 
different before and at different time points after the administration of L-Hcy 
(figure 4.2a). Similarly, the RBF response to deta-NONOate and pinacidil were 
unaffected by the L-Hcy infusion (data not shown). Dithiotreitol alone did not 
alter the RBF response to acetylcholine, deta-NONOate and pinacidil (data not 
shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: The renal blood flow increase in response to intrarenal acetylcholine after intravenous L-NAME and indomethacin 
in different experimental series. The area under the curve (AUC) of the change from baseline values was calculated for each 
bolus acetylcholine and the data are expressed as mean±SEM. A. Before (), 5 min after (z), 30 min after ( ) and 60 min 
after (Ο) intravenous infusion of 40 mmol/kg BW homocysteine. B. Before (), after 1 ml saline ( ), 60 min after intravenous 
infusion of 0.125 g/kg BW methionine (z), 120 min after methionine (Ο) and 30 min after 800 µg/kg BW 5-
methyltetrahydrofolate (♦). *P<0.05 versus before and after 1 ml saline; §P<0.05 versus 120 min after methionine. C. 
Before (), after 20 µmol/kg BW periodate oxidized adenosine ( ), 60 min after intravenous infusion of 0.125 g/kg BW 
methionine (z), 120 min after methionine (Ο) and 30 min after 800 µg/kg BW 5-methyltetrahydrofolate (♦). *P<0.05 versus 
before and after 1 ml saline; §P<0.05 versus 120 min after methionine. D. Before (), after 1 ml saline ( ), 60 min after 
intravenous infusion of 0.125 g/kg BW methionine (z), 120 min after methionine (Ο) and 30 min after 1 ml saline (♦). 
*P<0.05 versus before and after 1 ml saline. 
 
Acute hyperhomocysteinemia by intravenous methionine 
Intravenous administration of methionine resulted in a pronounced rise of the 
plasma methionine levels and a moderate rise of the tHcy concentrations (table 
4.2). When the administration of methionine was preceded by the infusion of 
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periodate oxidized adenosine, a competitive inhibitor of AdoHcy hydrolase, a 
similar increase in methionine levels was observed, but tHcy levels did not rise 
(table 4.2). The RBF response to acetylcholine during systemic NO synthase 
and cyclooxygenase blockade was significantly lower 60 and 120 min after 
methionine infusion.  
 
Table 4.2: Methionine and total homocysteine (tHcy) concentrations after methionine infusion 
 
 
Baseline 30 min after 
saline/adenosine 
60 min after 
methionine 
120 min after 
methionine 
30 min after 
5-MTHF 
Methionine (µmol/L) in saline group 
(series 2) 
Methionine (µmol/L) in ADOX group 
(series 3) 
tHcy (µmol/L) in saline group 
(series 2) 
tHcy (µmol/l) in ADOX group 
(series 3) 
49.3 ± 10.1 
 
38.3 ± 1.6 
 
9.8 ± 1.3 
 
12.5 ± 0.7 
41.2±1.6 
 
51.5 ± 18.6 
 
11.2 ± 1.3 
 
9.4 ± 0.9 
 
1315±4551 
 
1370 ± 7121 
 
25.3 ± 4.11 
 
9.5 ± 1.8 
 
1511±2791 
 
1509 ± 6241 
 
33.4 ± 1.71 
 
9.3 ± 1.3 
1149±651 
 
552 ± 1091 
 
33.7 ± 0.61 
 
9.7 ± 0.1 
1P<0.05 vs. baseline and 30 min after saline/adenosine. 5-MTHF=5-methyltetrahydrofolate; ADOX=periodate oxidized 
adenosine 
 
5-Methyltetrahydrofolate administration resulted in a partial recovery of the 
RBF response to acetylcholine (figure 4.2b). A similar suppression of the RBF 
response to acetylcholine by methionine and a partial restoration by 5-
methyltetrahydrofolate were observed in the animals that were pretreated with 
ADOX (figure 4.2c). The infusion with ADOX itself had no hemodynamic effects 
(figure 4.2c). Administration of saline instead of 5-methyltetrahydrofolate did 
not affect the RBF response to acetylcholine (figure 4.2d), indicating that the 
partial recovery after 5-methyltetrahydrofolate administration is not due to the 
time lag after methionine infusion. Addition of dithiotreitol to methionine 
resulted in a similar suppression of the RBF response to acetylcholine as 
methionine alone (data not shown). The RBF responses to both deta-NONOate 
and pinacidil during systemic NO synthase and cyclooxygenase blockade were 
unaffected by methionine exposure with or without pre-treatment with 
periodate oxidized adenosine (figure 4.3). 
 
 Table 4.3: Total homocysteine and methionine concentrations (µmol/L) in the different diet groups 
 Baseline After 4 weeks After 8 weeks 
Total homocysteine 
High methionine / low B vitamin diet 
High methionine / high B vitamin diet 
Standard rodent chow 
 
Methionine 
High methionine / low B vitamin diet 
High methionine / high B vitamin diet 
Standard rodent chow 
 
10.3 ± 0.2 
8.5 ± 0.22 
10.0 ± 0.4 
 
 
74.5 ± 13.3 
61.2 ± 6.4 
67.0 ± 3.4 
 
60.4 ± 9.61 
17.0 ± 0.92 
9.2 ± 0.2 
 
 
ND 
ND 
ND 
 
74.2 ± 9.51 
32.4 ± 2.52 
7.7 ± 0.5 
 
 
167.7 ± 48.43 
203.6 ± 57.53 
78.6 ± 12.9 
1P<0.001 versus high methionine high B vitamin diet and standard rodent chow; 2P<0.001 versus high methionine low B 
vitamin diet and standard rodent chow; 3P<0.001 versus standard rodent chow; ND = not determined 
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Chronic hyperhomocysteinemia 
Animals receiving a high methionine low B vitamin diet during 8 weeks 
developed a progressive hyperhomocysteinemia (table 4.3). Those fed a high 
methionine high B vitamin diet had lower tHcy levels, but they were still 
significantly elevated as compared to the control group (table 4.3). Methionine 
levels were significantly higher in both animal groups receiving an excess 
methionine diet as compared to those on standard rodent chow (table 4.3).  
 
 
 
Figure 4.4 (A) The renal blood flow increase in response to intrarenal acetylcholine after intravenous L-NAME and
indomethacin in animals receiving a diet enriched in methionine and deficient in folate, vitamin B6 and vitamin B12 (), a
diet enriched in methionine with high levels of folate, vitamin B6 and vitamin B12 ( ) and standard rodent chow (Ο) during
8 weeks. *P<0.01 versus standard rodent chow; §P<0.05 versus high methionine high B vitamin diet. (B) The renal blood
flow increase in response to intrarenal acetylcholine after intravenous L-NAME and indomethacin in animals receiving a
diet enriched in methionine and deficient in folate, vitamin B6 and vitamin B12 during 8 weeks before (), 15 min after
intravenous administration of 800 µg/kg BW 5-methyltetrahydrofolate (z) and 30 min after 5-methyltetrahydrofolate (♦).
The area under the curve (AUC) of the change from baseline values was calculated for each bolus acetylcholine and the
data are expressed as mean±SEM. 
Figure 4.3 The renal blood flow increase in response to intrarenal deta-NONOate (A) or pinacidil (B) after intravenous L-
NAME and indomethacin before (), 60 min after intravenous infusion of 0.125 g/kg BW methionine (z) and 120 min after
methionine (Ο). The area under the curve (AUC) of the change from baseline values was calculated for each bolus deta-
NONOate or pinacidil and the data are expressed as mean±SEM. Data from series 2 and 3 were pooled. 
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The RBF response to acetylcholine during systemic NO synthase and 
cyclooxygenase blockade was suppressed in the high methionine low B vitamin 
diet group, as compared to the standard rodent chow group and those fed a 
high methionine high B vitamin diet (figure 4.4a). 
 
 
 
 
 
 
 
 
 
 
 
 
The acute administration of 5-methyltetrahydrofolate was unable to restore 
the impaired EDHF-mediated vasodilation in the high methionine low B vitamin 
diet group (figure 4.4b). The RBF responses to both deta-NONOate and 
pinacidil were not different in animals fed a high methionine low B vitamin diet 
or a high methionine high B vitamin diet as compared to those fed a standard 
diet (figure 4.5). 
 
 
Discussion 
 
In resistance vessels, the EDHF pathway may be at least as -or even more- 
important as NO in mediating endothelium-dependent vasodilatation. In the 
renal microcirculation, EDHF is known to represent a considerable part of 
endothelium-dependent responses61,53. We evaluate EDHF-mediated 
vasodilatation in the kidney as the NO synthase- and cyclooxygenase-
independent component of acetylcholine-induced increase in renal blood flow. 
Incomplete inhibition of NO has been excluded by the abolishment of this 
response by connexin-mimetic peptides that are known to block EDHF-
mediated signal transduction but not the NO-mediated vasodilatation61. 
The salient observation of the present study is that the L-NAME- and 
indomethacin-resistant vasodilatation in response to acetylcholine is 
profoundly impaired in the renal microcirculation of rats with acute and 
 
Figure 4.5 The renal blood flow increase in response to intrarenal deta-NONOate (A) or pinacidil (B) after intravenous L-
NAME and indomethacin in animals receiving a diet enriched in methionine and deficient in folate, vitamin B6 and vitamin
B12 (), a diet enriched in methionine with high levels of folate, vitamin B6 and vitamin B12 ( ) and standard rodent chow 
(Ο) during 8 weeks. The area under the curve (AUC) of the change from baseline values was calculated for each bolus deta-
NONOate or pinacidil and the data are expressed as mean±SEM. 
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chronic hyperhomocysteinemia. This defect cannot be explained by a non-
selective impairment of vascular smooth muscle relaxation, since in both 
models of hyperhomocysteinemia vasodilatation in response to pinacidil and 
deta-NONOate was not influenced under the same conditions. 
In the methionine-Hcy cycle, methionine is first transformed to S-adenosyl-
methionine (AdoMet), which is an essential methyl donor. Transmethylation 
yields S-adenosylhomocysteine (AdoHcy) and a methylated acceptor, including 
DNA and proteins. AdoHcy is hydrolysed to Hcy and adenosine. A methionine 
load will thus result in a rise of AdoHcy levels and subsequent 
hyperhomocysteinemia. In the present study, acute intravenous or chronic oral 
methionine loading resulted in a profound inhibition of the EDHF-mediated 
renal vasodilatation. In order to address the question whether the interference 
with the EDHF-pathway was caused by Hcy itself or by another metabolite, 
additional experiments were performed. Systemic L-Hcy infusion was unable to 
affect EDHF-mediated renal vasodilatation, although Hcy levels rose steeply. 
Conversely, pre-treatment with ADOX prevented the methionine-induced rise 
in Hcy levels, but not the inhibition of the EDHF-pathway. ADOX is a 
competitive inhibitor of AHCY and thus blocks the conversion of AdoHcy to Hcy 
and adenosine. Under these circumstances, a methionine load will result in 
elevated AdoHcy but not Hcy levels. Taken together, these results suggest that 
Hcy itself does not cause the endothelial toxicity. Another component of the 
methionine-Hcy cycle may be responsible for the observed effects.  
Hyperhomocysteinemia can be corrected by folate treatment. 
Methyltetrahydrofolate, the active form of folate, provides a methyl group in 
the remethylation of Hcy to methionine. Folate therapy thus forces the Hcy-
methionine cycle through the remethylation pathway, resulting in an improved 
ratio of AdoMet to AdoHcy. 5-Methyltetrahydrofolate partially corrected the 
abnormalities in the EDHF-pathway during the methionine load, without 
affecting the rise in Hcy levels. Acute administration of 5-
methyltetrahydrofolate was, however, unable to improve EDHF-mediated 
vasodilatation in chronically hyperhomocysteinemic rats, suggesting a more 
profound impairment in endothelial function in these animals. In contrast, 
chronic dietary supplementation of folate, vitamin B6 and vitamin B12 partially 
prevented the development of hyperhomocysteinemia and the associated 
endothelial dysfunction induced by the methionine enrichment of the diet. As 
restoration of endothelial dysfunction is a surrogate endpoint for reduction of 
cardiovascular risk, these data support a role for B vitamins in the prevention 
and therapy of cardiovascular disease. 
Although the effect of Hcy on the EDHF-pathway has not been previously 
studied, indirect evidence has suggested that hyperhomocysteinemia may 
interfere with EDHF. Mice heterozygous for a cystathionine β-synthase gene 
disruption with mild hyperhomocysteinemia are characterized by an attenuated 
acetylcholine-induced aortic relaxation125. However, these animals 
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demonstrate a much more pronounced endothelial dysfunction in the 
mesenteric microcirculation, with even a paradoxical vasoconstriction after 
methacholine or bradykinine125. The mesentery is a vascular bed known for his 
pronounced EDHF activity130. Although these findings were interpreted as 
impaired nitric oxide bioactivity, they may be explained by an additional 
abnormality in the EDHF-pathway. 
Although the exact pathophysiological role of EDHF requires further 
characterization, it is known to control microvascular resistance and tissue 
perfusion131. The present findings thus have important implications for the 
development of microvascular disease in hyperhomocysteinemia. Other risk 
factors for atherothrombotic cardiovascular disease have also been reported to 
affect the EDHF pathway, including hypertension132,133, hyper-
cholesterolemia134, diabetes mellitus53 and aging135. Interference with the 
integrity of the EDHF-pathway may thus be a final common pathway through 
which these risk factors cause microangiopathy and end organ damage. 
In conclusion, EDHF-mediated vasodilatation is impaired in the renal 
microcirculation of acute and chronically hyperhomocysteinemic rats. Not Hcy 
itself, but another component of the methionine-Hcy cycle may be responsible 
for the endothelial dysfunction. 
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Abstract  
 
 
EDHF-mediated vasodilatation is impaired in renal arterioles of 
hyperhomocysteinemic rats. Gap junctions are involved in the EDHF-mediated 
vasodilatation. Blocking of the structural subunits of gap-junctions, connexin 
40 (Cx40) and connexin 43 (Cx43), led to a decreased EDHF-mediated 
vasodilatation. We, therefore, determined whether Cx40 and Cx43 mRNAs are 
differentially expressed in hyperhomocysteinemic rats. Additionally, we 
measured kidney S-adenosylmethionine (AdoMet) and S-adenosyl-
homocysteine (AdoHcy) levels of hyperhomocysteinemic rats to identify the 
potential causative metabolic factor(s). Rats were either fed a high methionine 
/ low B vitamin diet to induce hyperhomocysteinemia or standard rodent chow. 
Endothelial cells were isolated by lasermicrodissection from renal arterioles 
and application of real-time quantitative PCR demonstrated that Cx40 mRNA 
levels were 1.7-fold down regulated in kidney of hyperhomocysteinemic rats. 
Cx43 mRNA expression levels were not different. Intracellular AdoMet and, 
particularly, AdoHcy levels were higher, resulting in a decreased 
AdoMet:AdoHcy ratio in kidneys of hyperhomocysteinemic rats. Interestingly, a 
correlation was found between decreased kidney Cx40 mRNA expression and 
elevated AdoHcy levels. These findings suggest a key role for AdoHcy in 
relation to decreased Cx40 mRNA expression and impaired EDHF-mediated 
vasodilatation in hyperhomocysteinemic rats. 
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Introduction 
 
An early and important phase in the development of atherosclerosis in micro- 
and macrovascular systems is endothelial dysfunction. A large body of 
evidence indicates that hyperhomocysteinemia is associated with an impaired 
endothelium-dependent vasodilatation31,32,30,125, but it remains conjectural 
whether homocysteine itself or another metabolite of the 
methionine/homocysteine metabolism is pathogenic.  
Recently, we have demonstrated that the endothelium-derived hyperpolarizing 
factor (EDHF)-mediated vasodilatation, which was evaluated during nitric oxide 
synthase and cyclooxygenase inhibition, was impaired in the renal 
microcirculation of acute and chronic hyperhomocysteinemic rats, indicating a 
prominent role of EDHF in the development of microvascular dysfunction in 
hyperhomocysteinemia136. Interestingly, we demonstrated that pre-treatment 
of rats with periodate-oxidized adenosine (ADOX), which is an inhibitor of S-
adenosylhomocysteine hydrolase (AHCY), prevented the methionine-induced 
rise in homocysteine levels, but not the inhibition of the EDHF-pathway136.  We, 
therefore, hypothesized that not homocysteine itself but a component prior to 
homocysteine, presumably S-adenosylhomocysteine (AdoHcy), is responsible 
for the disturbed EDHF-mediated vasodilatation. 
The nature of EDHF has still not been entirely elucidated, but it is likely that 
several EDHFs exist, which are specific to different species and vascular beds52. 
Currently, it is hypothesized that EDHF-mediated responses are initiated by an 
increase in intracellular Ca2+, which results in hyperpolarization of endothelial 
cells by activation of K+-channels. This endothelial cell hyperpolarization is 
transmitted to the underlying smooth muscle cell layer via gap-junctions to 
induce smooth muscle cell hyperpolarization by activation of K+ 
channels50,137,138. 
Gap junctions are intercellular channels, which connect the cytoplasm of 
adjacent cells allowing passage of ions and small molecules54. Each gap 
junction is composed of 12 connexin (Cx) molecules, assembled from two 
hemichannels54. Endothelial cells and smooth muscle cells of rat kidney 
express connexin37 (Cx37), connexin40 (Cx40) and connexin43 (Cx43), of 
which Cx40 expression is the most abundant55,56,139. Previously, we have 
shown by renal blood flow measurements that the inhibition of gap junctional 
communication with connexin-mimetic peptides against Cx40 blocks the 
EDHF-mediated signal transmission in vivo 61, which supports the involvement 
of gap-junctions in EDHF-mediated vasodilatation. Altered connexin 
expression might therefore account for the impaired EDHF-mediated 
vasodilatation, which we have observed in chronic hyperhomocysteinemic 
rats136. 
The aims of the present study were i) to examine whether Cx40 and Cx43 
mRNAs are differentially expressed in chronic hyperhomocysteinemic rats, and 
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ii) to determine the potential causative metabolic factor(s). We, therefore, 
studied mRNA expression of Cx40 and Cx43 in lasermicrodissected endothelial 
cells from renal arterioles by real-time quantitative PCR, and measured 
intracellular S-adenosylmethionine (AdoMet) and S-adenosylhomocysteine 
(AdoHcy) levels in kidney of hyperhomocysteinemic and control rats. 
 
 
Material and Methods 
 
Diet-induced hyperhomocysteinemic rats 
Female Wistar rats received a diet enriched in methionine (7.7 g/kg) and low 
levels of folate, vitamin B6 and vitamin B12 (Harlan Teklad TD97345, N=8) or 
standard rodent chow (N=8) during 8 weeks136. Rats were anesthetized with 
100 mg/kg thiobutabarbital (Inactin, RBI, USA). Kidneys were removed, cut in 
four pieces each and immediately frozen in liquid nitrogen. Frozen tissues 
were stored at –80°C.  
 
Measurement of metabolites 
Serum total homocysteine were measured using a HPLC technique as described 
before93,136. S-adenosylhomocysteine (AdoHcy) and S-adenosylmethionine 
(AdoMet) levels were measured by tandem mass spectrometry according to 
Struys et al140, with some modifications.  Briefly, approximately 25 mg of 
frozen kidney was sonicated on ice in the presence of 800 µL of 0.9% NaCl. 
550 µL of the sonicated homogenate was mixed with 110 µL of internal 
standard containing stable isotopes AdoMet-d3 (s-methyl-d3, CDN isotopes) 
and AdoHcy-d5 (gift from Prof. Dr. C. Jacobs)140. This solution was applied to a 
solid-phase extraction (SPE) phenylboronic acid column (Varian), which was 
conditioned with 5 ml 0.1 M formic acid and subsequently with 5 ml 20 mM 
ammoniumacetate (pH = 7.4). The column was washed twice with 1 ml of 20 
mM NH4Ac (pH = 7.4). AdoMet and AdoHcy were eluted from the column with 
1 ml 0.1 M formic acid and the eluate was subsequently injected into the LC-
MS-MS (Waters). Liquid chromatography was performed on a Symmetry-shield 
HPLC C-18 column (Waters) using a gradient of 0.02% butyric acid in H20 and 
0.02% butyric acid in MeOH, in 10 minutes. The multiple reaction monitoring 
(MRM) transitions used are: AdoMet-d3 402>249.8, AdoMet 399>249.8, 
AdoHcy-d5 390>135.7, and AdoHcy 385>135.7. Protein content was 
determined according to Lowry et al141.  
 
Lasermicrodissection  
Frozen tissue sections (8 µm) were cut from kidney at –20°C with a cryostat 
(Micron, Adamas, The Netherlands), and were mounted on a glass slide 
containing a specific PEN membrane (Leica, Microsystems B.V., The 
Netherlands). Tissue sections were stained with haematoxilin for 2 minutes 
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(Boom B.V., The Netherlands). Cells were microdissected using the Leica AS-
LMD system (Leica, Microsystems B.V., The Netherlands) with a pulsed UV 
laser. Finally, lasermicrodissected cells were allowed to fall by gravity into a 
tube cap containing 30 µl Trizol (Invitrogen, The Netherlands) and were stored 
in liquid nitrogen until RNA isolation. Endothelial cells of 30 renal arterioles 
were captured (magnification 1000x). The smallest arterioles of the cortex 
containing a lamina elastica interna were dissected; these were mainly distal 
interlobular arterioles.  
 
Real-time quantitative PCR (Q-PCR) 
RNA was isolated from the lasermicrodissected cells using Trizol (Invitrogen, 
The Netherlands) according to Baugh et al142. The isolated RNA was reverse 
transcribed to cDNA using random hexamers in a final reaction volume of 20 
µL. Q-PCR was carried out in a total volume of 50 µL containing 2 µl 1.5-fold 
diluted cDNA, 100 ng of molecular beacon, 200 nM of forward and reverse 
primers, 200 µM dNTPs, 10 x AmpliTaq Gold amplification buffer, 4 mM MgCl2 
and 1.5 unit of AmpliTaq Gold DNA polymerase (Applied Biosystems, The 
Netherlands). Oligonucleotides used for the Q-PCR experiments were designed 
according to the Genbank sequences (table 5.1, rat Cx40 mRNA NM_019280, 
rat Cx43 mRNA NM_012567, rat β-2-microglobuline (B2M) mRNA 
NM_012512).  
 
Table 5.1: Oligonucleotides and molecular beacons 
Target Sequence  
(5’→ 3’) 
Size  
(bp) 
Cx40  
Sense oligo1 
Anti-sense oligo 
Molecular beacon2 
Cx43  
Sense oligo1 
Anti-sense oligo 
Molecular beacon2 
B2M 
Sense oligo1 
Anti-sense oligo 
Molecular beacon2 
 
GAC AGT TGA ACA GCA GCC AGA G 
CCA GTC ACC CAT CTT GCC AAG 
FAM-CGCACG CTG AAG AAG CCA ACT CCA GGG CGG A CGTGCG-dabcyl 
 
TTA AGT GAA AGA GAG GTG CCC AG 
GCG GTG GAG TAG GCT TGG AC 
FAM-CGCACG GTG CCT TGG GGA AGC TTC TGG ACA CGTGCG-dabcyl 
 
CGT GCT TGC CAT TCA GAA AAC 
TCT GAG GTG GGT GGA ACT GAG 
TxR-CGCACG TTC AAG TGT ACT CTC GCC ATC CAC C CGTGCG-dabcyl 
 
106 
 
 
 
84 
 
 
 
113 
 
 
1Exon spanning; 2Molecular beacon sequences with corresponding fluorophore (5’), quencher (3’), and stem sequences 
(underlined); FAM = fluorescein; TxR = texas red 
 
All oligonucleotides and molecular beacons were synthesized by Biolegio BV, 
Malden, The Netherlands. PCR conditions were as follows: cycling was 
preceded by 95°C/10 min, followed by 46 cycles of 95°C/30s, 58°C/45s and 
72°C/30s. Samples were run in duplicate on the iCycler iQ real-time PCR 
detection system (Biorad, The Netherlands), and fluorescence was measured 
during each annealing step. 
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Calculation of relative expression levels 
The efficiency of each molecular beacon assay was determined using a 10-fold 
dilution series of 106 amplicons spiked with 2 µL 10-fold diluted cDNA 
(transcribed from 1 µg total rat kidney RNA, Clontech). For each assay the 10log 
of input material was plotted against the corresponding threshold cycle (CT).  
Linearity of each assay was derived from the correlation coefficient of the 
standard curve (R2). Relative quantification can only be applied when the PCR 
efficiencies of the target gene and reference gene are approximately equal143. 
The PCR efficiencies did not differ more than 10% between each target and the 
reference gene B2M that were analyzed per run (data not shown), and we 
normalized the expression levels by comparative quantitation using the ∆∆CT 
method143. For each sample the ∆CT was calculated (CT,target – CT,B2M) in 
duplicate, from which the mean relative expression was calculated as 2-∆∆CT. 
  
Statistical analysis 
Differences in mean levels of biochemical parameters between 
hyperhomocysteinemic and control rats were tested with the Mann Whitney U 
test for independent variables. Spearman rank correlation was applied to test 
for possible associations. All P values were two-tailed. 
 
 
Results 
 
Diet-induced hyperhomocysteinemic rats 
Total homocysteine levels were higher in serum of rats that were fed a high 
methionine / low B vitamin diet during 8 weeks than in rats that were fed 
standard rodent chow (83.8 ± 34.9 µmol/L versus 5.9 ± 1.9 µmol/L, P < 
0.001).  
 
AdoMet and AdoHcy levels  
AdoHcy and AdoMet levels in rat kidney were both significantly higher, 
resulting in a lower AdoMet:AdoHcy ratio in rats that were fed the high 
methionine / low B vitamin diet as compared with rats that were fed the 
control chow (figure 5.1).  
 
Figure 5.1: AdoMet, AdoHcy and
AdoMet:AdoHcy ratio in kidney of
hyperhomocysteinemic and control rats.
Mean ± SD levels of AdoMet (nmol/mg
protein), AdoHcy (nmol/mg protein) and
the AdoMet:AdoHcy ratio in
hyperhomocysteinemic rats (n=8) and
control rats (n=8) are plotted. *P < 0.05 
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A strong positive correlation was found between plasma homocysteine levels 
and kidney AdoHcy levels of hyperhomocysteinemic rats but not with AdoMet 
levels (table 5.2). The AdoMet:AdoHcy ratio showed a strong negative 
correlation with plasma homocysteine levels (table 5.2). 
 
Table 5.2: Correlation of serum tHcy levels with kidney AdoMet and AdoHcy levels of hyperhomocysteinemic rats 
Serum Homocysteine Rs1 P value 
AdoMet 
AdoHcy 
AdoMet:AdoHcy 
0.20 
0.96 
-0.91 
0.63 
< 0.001 
0.002 
1Spearman’s Rho correlation coefficient 
 
Lasermicrodissection of endothelial cells  
Endothelial cells were dissected from the vascular wall by positioning the laser 
beam just around the lamina elastica interna. The area within the laser beam 
was dissected containing the lumen of the arteriole and mainly endothelial 
cells (figure 5.2).  
 
Q-PCR analysis demonstrated that the dissected cells of the vascular wall of 
renal arterioles contained endothelial cells (PECAM-1) and also some smooth 
muscle cells (α-actin)(see chapter 6). 
 
Cx40 and Cx43 mRNA expression 
Cx40 mRNA levels were determined by Q-PCR in lasermicrodissected 
endothelial cells of 7 hyperhomocysteinemic rats and 7 controls rats. Cx40 
mRNA expression was highly abundant in endothelial cells, as was 
demonstrated by the CT value that was comparable with that of the high copy 
gene B2M (<∆CT, table 5.3).  
 
Table 5.3: Relative quantification of connexin 40 and connexin 43 mRNA levels in lasermicrodissected endothelial cells  
from renal arterioles of hyperhomocysteinemic and control rats  
 ∆CT 1 ∆∆CT 2 2-∆∆CT 3 [range] P  value4 
Cx40 
Control (n=7) 
HHcy (n=7) 
Cx43 
Control (n=7) 
HHcy (n=7) 
 
1.0 ± 0.7 
1.7 ± 0.9 
 
5.2 ± 2.3 
5.1 ± 0.7 
 
0.0 ± 0.7 
0.7 ± 0.9 
 
0.0 ± 2.3 
-0.1 ± 0.7 
 
1.0 [0.6 -1.6] 
0.6 [0.3 -1.1] 
 
1.0 [0.2 - 4.9] 
1.1 [0.7-1.7] 
 
0.10 
 
 
0.46 
1CT, target – CT,B2M ; 2∆CT,HHcy - ∆CT,con; 32-∆∆CT is the difference in relative expression of HHcy rats versus control rats; 
Figure 5.2: Lasermicrodissection of 
endothelial cells of an arteriole. A. A renal 
arteriole is shown (magnification 400 x); B. 
the laser beam is positioned at the lamina 
elastica interna and cuts a contour through 
the tissue section to dissect the endothelial 
cells. 
A B
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 4Student’s t-test of ∆CT of control and HHcy rats of Cx40 and Cx43 mRNA 
A high ∆CT value corresponds with a low mRNA expression. The expression of 
Cx40 mRNA was 1.7-fold down regulated in endothelial cells of interlobular 
arterioles of hyperhomocysteinemic rats compared with control rats (figure 
5.3).  
 
 
 
 
 
 
 
 
 
 
 
A positive correlation was found between the ∆CT values of Cx40 and 
intracellular levels of AdoHcy in kidney of hyperhomocysteinemic and control 
rats (Rs = 0.46, figure 5.4), indicating that decreased Cx40 mRNA expression is 
associated with higher levels of AdoHcy. AdoMet levels and AdoMet:AdoHcy 
ratio in kidney also correlated with Cx40 mRNA levels, although less 
convincing (Rs = 0.39, P = 0.17 and Rs = -0.42, P = 0.14, respectively). Serum 
homocysteine levels did not correlate with endothelial Cx40 mRNA levels.  
Cx43 mRNA levels were determined in lasermicrodissected endothelial cells of 
6 hyperhomocysteinemic rats and 7 control rats. 
Cx43 mRNA was less abundantly expressed in endothelial cells of interlobular 
arterioles than Cx40 mRNA as was demonstrated by the CT value relative to 
that of the high-copy gene B2M (table 5.3). Cx43 mRNA expression in 
endothelial cells of hyperhomocysteinemic rats was not different from that in 
Figure 5.4: Correlation of Cx40 mRNA expression with
kidney AdoHcy levels. Plot of individual values for
Cx40 mRNA expression normalized to B2M
expression in rat endothelial cells versus kidney
AdoHcy levels of hyperhomocysteinemic (•) and
control rats (ο) is shown (n=14). 
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Figure 5.3: Quantification of Cx40 mRNA in
lasermicrodissected endothelial cells by real-time
quantitative PCR. Cx40 mRNA expression is down
regulated by 1.7 fold in hyperhomocysteinemic rats
(n=7) compared to control rats (n=7).  The mean
relative expression normalized to B2M has been
plotted (2-∆CT ± SD). *P < 0.10 
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control rats (table 5.3), and was not correlated with homocysteine, AdoMet, 
AdoHcy or AdoMet:AdoHcy ratio (data not shown). 
 
 
Discussion 
 
In this study, we show that Cx40 mRNA levels were 1.7-fold down regulated in 
endothelial cells of renal arterioles of hyperhomocysteinemic rats. Intracellular 
AdoHcy levels were higher in kidney of hyperhomocysteinemic rats, which 
correlated with the decreased expression of Cx40 mRNA. 
Endothelial cells and smooth muscle cells are interconnected via gap junctions, 
which are composed of connexins. Down regulation of Cx40 has been 
associated with impaired vasodilatation and hypertension61,144,145,146. Mice 
lacking Cx40 have reduced vasodilatation along the vessel wall, which 
supports a role of Cx40 in vascular intercellular communication144. Simon et al 
have shown that mice deficient in Cx40 have a great reduction in dye-transfer 
within the aortic endothelium compared with wild type mice, demonstrating 
that Cx40 expression is crucial for endothelial cell communication147. In 
resistance arteries, gap junctions might be involved in the EDHF-mediated 
signal transmission. Previously, we have shown that inhibition of gap junctional 
communication by synthetic peptides against Cx40 blocked the EDHF-
mediated vasodilatation, indicating that Cx40 is essential for EDHF-mediated 
signal transmission in the microcirculation of rat kidney61.  
Not much is known about connexin expression in relation to elevated 
homocysteine levels. In one other study altered expression of connexins due to 
hyperhomocysteinemia has been demonstrated; exposure of human umbilical 
vein endothelial cells (HUVECs) to 50 µM of DL-homocysteine resulted in the 
up regulation of Cx43 protein and gene expression leading to a redistribution 
of the protein from the plasma membrane to the mitochondria148. Cx40 
expression, however, was not examined in that study. In the present study, we 
show that endothelial Cx40 mRNA expression is 1.7-fold down regulated in 
renal arterioles of hyperhomocysteinemic rats, suggesting that altered 
expression of Cx40 mRNA might be responsible for the observed impaired 
EDHF-mediated vasodilatation in hyperhomocysteinemic rats. However, these 
results need to be confirmed in larger studies. Additionally, future 
physiological experiments using e.g. dye-transfer techniques may be 
performed to confirm that gap-junction mediated coupling is disturbed and 
accounts for the impaired EDHF-mediated vasodilatation in 
hyperhomocysteinemic rats. Despite that the expression of endothelial Cx43 
mRNA was not altered in renal arterioles of hyperhomocysteinemic rats, the 
protein may not be inserted correctly in the cell membrane148. Future 
localization studies using confocal microscopy may therefore be performed to 
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evaluate the distribution of Cx43 protein in renal arterioles of 
hyperhomocysteinemic rats. 
Recently, we have demonstrated that EDHF-mediated vasodilatation is 
impaired in acute and chronic hyperhomocysteinemic rats136. Interestingly, 
pre-treatment with ADOX, which is an inhibitor of AHcy, prevented the 
methionine-induced rise in homocysteine levels, but not the inhibition of the 
EDHF-pathway136. We hypothesized that not homocysteine but another 
metabolite of the methionine-cycle, presumably AdoHcy, is responsible for the 
disturbed EDHF-mediated vasodilatation in hyperhomocysteinemic rats136. 
Under normal physiological conditions, AdoHcy is hydrolyzed to homocysteine 
and adenosine in a reversible reaction catalyzed by AHCY. Notably, the 
equilibrium constant of AHCY favors AdoHcy formation, and, therefore, 
AdoHcy levels will increase in conditions of elevated homocysteine levels. In 
this study, we showed that kidney AdoHcy levels were significantly elevated 
(~2.5 fold) in hyperhomocysteinemic rats. We observed a strong correlation 
between elevated serum total homocysteine levels and intracellular kidney 
AdoHcy levels, whereas no association with AdoMet levels was found. Caudill 
et al have shown in mice that were fed a methyl-deficient diet that a decrease 
in AdoMet:AdoHcy ratio was predictive of reduced DNA methylation capacity 
only when associated with elevated AdoHcy levels149. In the present study, we 
confirm that elevated plasma homocysteine levels result in increased AdoHcy 
levels, and therefore speculate that this will result in unbalanced methylation 
as was also suggested previously by us and others149,76,79,150. Interestingly, we 
show that decreased Cx40 mRNA levels correlated with increased kidney 
AdoHcy levels of hyperhomocysteinemic rats. These findings suggest that 
AdoHcy is involved in the decreased expression of Cx40 mRNA, and thus favor 
a key role for AdoHcy in relation to the impaired EDHF-mediated vasodilatation 
in hyperhomocysteinemic rats. As DNA methylation has been shown to 
influence gene expression151, we hypothesize that unbalanced methylation 
accounts for the decreased Cx40 mRNA expression in hyperhomocysteinemic 
rats. However, future studies that examine the methylation status of the Cx40 
gene are needed to evaluate this hypothesis.  
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Abstract   
 
Cytochrome P450 (CYP) isoenzymes (CYP2C and CYP2J) are involved in the 
production of epoxyeicosatrienoic acids (EETs), which are postulated as 
endothelium-derived hyperpolarizing factors (EDHFs). We hypothesized that if 
CYP2C11 is involved in the EDHF-mediated responses, its mRNA should be 
expressed in endothelial cells. We, therefore, examined the mRNA expression 
of CYP2C11 in endothelial cells of renal arterioles. Lasermicrodissection was 
applied to isolate endothelial cells from renal arterioles of 4 male and 4 female 
Wistar rats. As a positive control on CYP2C11 expression, hepatocytes were 
also dissected from these rats. RNA was isolated and real-time quantitative 
PCR analysis (Q-PCR) was applied. Q-PCR analysis showed that CYP2C11 mRNA 
was not expressed in lasermicrodissected endothelial cells of renal arterioles of 
male and female rats. CYP2C11 mRNA expression was highly abundant in 
hepatocytes dissected from male livers, but in female livers hardly any 
CYP2C11 mRNA was detected. We have shown that endothelial cells can be 
dissected from small renal arterioles by lasermicrodissection to study mRNA 
expression of specific genes by Q-PCR. Using this novel tool, we demonstrated 
that the CYP2C11 mRNA was not expressed in endothelial cells of renal 
arterioles. We, therefore, speculate that CYP2C11 does not contribute to the 
EDHF-mediated responses in renal arterioles. 
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Introduction  
 
The best-characterized vasodilating agents are nitric oxide (NO) and 
prostacyclins (PGl2). Several studies have shown that a third not yet identified 
pathway exists that elicits vasodilatation49. This so-called endothelium-derived 
hyperpolarizing factor (EDHF) contributes to endothelium-dependent 
vasodilatation in many mammalian arteries, in particular in resistance 
arteries51. It is likely that several EDHFs exist, which are specific to different 
species and vascular beds52. Several candidates for EDHF have been described, 
including cytochrome P450 metabolites, K+ ions, H2O2, and gap junctions50. 
Cytochrome P450 (CYP) is involved in the production of epoxyeicosatrienoic 
acids (EETs), which are considered to play a role in vasodilatation and are 
postulated as EDHFs, although data remain conflicting152,153,138.  
Recently, we have demonstrated that the EDHF-dependent vasodilatation is 
impaired in the renal microcirculation of diabetic and hyperhomocysteinemic 
rats53,136. Particularly, the smaller preglomerular arterioles showed the most 
pronounced impairment as was shown by intravital microscopy53. Epoxidation 
of arachidonic acid in rat kidney has been attributed to the members of the 
cytochrome CYP2C and CYP2J subfamilies154. Three CYP2C subfamily isoforms 
(CYP2C11, CYP2C23 and CYP2C24) are expressed in rat kidney154. CYP2C11 
and CYP2C24 share a cDNA and protein sequence homology of 78%, whereas 
CYP2C23 has been postulated to have diverged from other CYP2C genes at an 
early evolutionary stage154. Because CYP2C11 has the highest homology with 
the human CYP2C8 isoform, we questioned whether this isoform could be 
involved in the EDHF-mediated responses in rat kidney, and we therefore 
examined CYP2C11 mRNA expression in endothelial cells of renal arterioles. 
Frequently, mRNA expression of genes of interest is determined in cultured 
cells; however, mRNA expression in these cells may change due to different 
passage numbers. Quantification of mRNA expression in cells that are isolated 
directly from tissue will result in a better reflection of the in vivo situation. 
Therefore, we dissected endothelial cells from renal arterioles by 
lasermicrodissection (LMD), and applied real-time quantitative PCR to 
determine whether CYP2C11 mRNA is expressed. 
 
 
Material and Methods 
 
Tissue 
Wistar rats (4 female and 4 male rats) were anesthetized with 100 mg/kg 
thiobutabarbital (Inactin, RBI, USA). Kidney and liver were removed from the 
rats, cut in small pieces and immediately frozen in liquid nitrogen. Tissues 
were stored at –80°C.  
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Lasermicrodissection 
Frozen tissue sections (8 µm) from respectively liver and kidney were cut at     
–20°C in a cryostat (Micron, Adamas, The Netherlands), and were mounted on a 
glass slide containing a specific PEN membrane (Leica, Microsystems B.V., The 
Netherlands). Tissue sections were stained with haematoxilin for 2 minutes 
(Boom B.V. The Netherlands). Cells were microdissected using the Leica AS-
LMD system (Leica, Microsystems B.V., The Netherlands) with a pulsed UV 
laser. Finally, lasermicrodissected cells were allowed to fall by gravity into a 
tube cap containing 30 µl Trizol (Invitrogen, The Netherlands) and were stored 
in liquid nitrogen until RNA isolation. Endothelial cells of 30 renal arterioles 
were captured (magnification 1000x). The smallest arterioles containing a 
lamina elastica interna were used; these were mainly interlobular arterioles. 
From liver, 10 hits containing approximately 30 hepatocytes in total were 
captured as a positive control (magnification 400x). We used the endothelial 
cell marker Platelet-Endothelial Cell Adhesion Molecule-1 (PECAM-1) and the 
smooth muscle cell marker α-actin to analyze the purity of the sample. 
 
Real-time quantitative PCR (Q-PCR) 
RNA was isolated from the lasermicrodissected cells using Trizol (Invitrogen, 
The Netherlands) according to Baugh et al142. The isolated RNA was reverse 
transcribed to cDNA using random hexamers in a final reaction volume of 20 
µL. Q-PCR studies were carried out in a total volume of 50 µL containing 2 µl 
cDNA, 100 ng of molecular beacon, 200 nM of forward and reverse primers, 
200 µM dNTPs, 1 x AmpliTaq Gold amplification buffer, 4 mM MgCl2 and 1.5 
unit of AmpliTaq Gold DNA polymerase (Applied Biosystems, The Netherlands).  
 
 
Table 6.1: Oligonucleotides and molecular beacons 
Target Sequence  
(5’→ 3’) 
Size 
(bp) 
B2M 
Sense oligo1 
Anti-sense oligo  
Molecular beacon2 
CYP2C11 
Sense oligo 
Anti-sense oligo3 
Molecular beacon2 
PECAM 
Sense oligo 
Anti-sense oligo1 
Molecular beacon2 
α-actin 
Sense oligo 
Anti-sense oligo1 
Molecular beacon2 
 
CGT GCT TGC CAT TCA GAA AAC 
TCT GAG GTG GGT GGA ACT GAG 
TxR-CGCACG TTC AAG TGT ACT CTC GCC ATC CAC C CGTGCG-dabcyl 
 
CCT TGG ACA AGG ACA ATC CT 
ACA TGT CAG TTA CAG TAG CCA CC 
FAM-CGCTGC TCC GCA GTC TGA GTT TAC CCT T GCAGCG-dabcyl 
 
CTA GCA AGG AGC AGG AAG GC 
CTT CCA CGG AGC AAG AAA GAC 
FAM-CGCACG GTT CAA CAG AGC CAG CAT TGT GAC CAG CGTGCG-dabcyl 
 
CTA TGC TAA CAA CGT CCT CTC GG 
GCG TTC TGG AGG AGC AAT AT CT 
FAM-CGCACG GGC ATT GCT GAC AGG ATG CAG AAG GAG CGTGCG-dabcyl 
 
113 
 
 
 
123 
 
 
 
123 
 
 
 
127 
 
1Exon spanning; 2Molecular beacon sequences with corresponding fluorophore (5’), quencher (3’), and stem sequences 
(underlined); 3Mismatch of 10 nucleotides with pseudogene (Genbank Ac.No. M18336); FAM = fluorescein; TxR = Texas Red 
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Oligonucleotides used for the Q-PCR experiments were designed according to 
the Genbank sequences (table 6.1, rat β-2-microglobuline (B2M): NM_012512; 
rat CYP2C11: NM_019184, rat PECAM-1: U77697; rat α-actin: X06801). All 
oligonucleotides and molecular beacons were synthesized by Biolegio BV, 
Malden, The Netherlands. PCR conditions were as follows: cycling was 
preceded by 95°C/10 min, followed by 46 cycles of 95°C/30s, 58°C/45s and 
72°C/30s. Q-PCR was performed with the iCycler iQ real-time PCR detection 
system (Biorad, The Netherlands), and fluorescence was measured during each 
annealing step.  
 
PCR efficiency of molecular beacon assays 
The linearity of each assay was derived from the correlation coefficient of the 
standard curve (R2). The efficiency of each Q-PCR assay was analyzed by 
determining the threshold cycle (CT) values of five different dilutions of cDNA 
(corresponding with 1 µg/µL to 320 pg/µL of total rat kidney RNA) by plotting 
the CT values against the log value of each dilution. 
 
Relative quantification 
The CT values of CYP2C11, PECAM-1 and α-actin were normalized to B2M 
expression by comparative quantitation155. For each sample (kidney and liver 
cDNAs) the ∆CT was calculated (CT,target – CT,B2M), from which the relative 
expression was calculated as 2-∆CT. In addition to Q-PCR analysis, the PCR 
products were also visualized by agarose gel electrophoresis and 
ethidiumbromide staining.  
 
 
 
 
 
 
Results  
 
Lasermicrodissection of endothelial cells  
The area within the lamina elastica interna was dissected containing the lumen 
and endothelial cell layer of the arteriole (figure 6.1).  
Figure 6.1: Lasermicrodissection of endothelial cells of an
arteriole. (A) A renal arteriole is shown (magnification
400x); (B) The position of the laser beam is placed around
the lamina elastica interna; (C) The laser beam cuts a
contour through the tissue section and (D) the lumen and
the cells from the vascular wall were dissected. 
 
A B
DC
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Q-PCR analysis demonstrated that the dissected cells of the vascular wall of 
renal arterioles indeed contained endothelial cells (PECAM-1) but also some 
smooth muscle cells (α-actin) were present (figure 6.2a and 6.2b).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Real-time quantitative PCR (Q-PCR) 
Molecular beacon assays for B2M, PECAM-1, α-actin and CYP2C11 were 
optimized to obtain linear and efficient standard curves. Regression equations 
of the different molecular beacons assays were: B2M: y = -3.37x + 31.46, R2 = 
0.999; PECAM-1: y = -3.56 + 39.93, R2 = 0.994; α-actin: y = -3.28 + 39.59, 
R2 = 0.999; CYP2C11: y = -3.30 + 33.12, R2 = 0.998. Q-PCR efficiencies were 
calculated from the slopes of the standard curves (10(-1/slope)), which resulted in 
PCR efficiencies of 98% for B2M, 91% for PECAM-1, 102% for α-actin and 101% 
for CYP2C11. 
 
In silico analysis 
Protein homologies were determined using the CLUSTAL W (1.81) multiple 
sequence alignment algorithm. Human CYP2C8 protein showed the highest 
homology with rat CYP2C11 (78%). The homology of CYP2C8 with CYP2C23 
and CYP2C24 was 58% and 70% respectively. The rat isoforms CYP2C11 and 
CYP2C24 have a protein sequence similarity of 71%, whereas their similarity 
with CYP2C23 isoform is less, 58% and 57% respectively. 
 
CYP2C11 mRNA expression 
Gel electrophoresis of the PCR products and Q-PCR analysis showed that 
CYP2C11 was not detectable in dissected endothelial cells from the vascular 
Figure 6.2. Q-PCR analysis of PECAM and α-actin. Endothelial cells (PECAM-1) and also smooth muscle cells (α-actin) were
obtained by lasermicrodissection of endothelial cells from renal arterioles of control rats (n=8). A. The mean relative
expression normalized to B2M has been plotted (2-∆CT ± SD). B. Gel electrophoresis of CYP2C11, PECAM-1 (endothelial cell
marker), α-actin (smooth muscle cell marker) and B2M (housekeeping gene) pooled PCR products. Lanes 1 and 2 are
dissected endothelial cells of renal arterioles of male (n=4) and female rats (n=4), respectively; lanes 3 and 4 are a positive
control of CYP2C11 expression containing dissected hepatocytes from liver of respectively male (n=4) and female rats (n=4).
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wall of rat renal arterioles of male and female rats (figure 6.2b and 6.3). Q-PCR 
analysis demonstrated that mRNA expression of CYP2C11 is highly abundant 
in dissected hepatocytes from male rats (figure 6.3a), whereas in female 
hepatocytes hardly any CYP2C11 mRNA could be detected (figure 6.3b).  
 
A                    B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3: Q-PCR analysis of CYP2C11 and PECAM-1 of different tissues of male (A) and female rats (B). A. Endothelial cells 
were dissected from renal arterioles (kidney) of male rats as is demonstrated by the expression of PECAM-1 mRNA. 
CYP2C11 mRNA is expressed in hepatocytes (liver) and not in renal arterioles of male rats. B. Endothelial cells were 
dissected from renal arterioles (kidney) of female rats as is demonstrated by the expression of PECAM-1 mRNA. In female 
rats, CYP2C11 mRNA is not expressed in renal arterioles or hepatocytes. The mean relative expression of male (N=4) and 
female rats (N=4) of each gene normalized to B2M has been plotted (2-∆CT ± SD). 
 
 
Discussion 
 
In this study, we have shown that endothelial cells can be dissected from small 
arterioles by lasermicrodissection to study mRNA expression of specific genes 
by Q-PCR analysis. Using this novel tool, we demonstrated that the mRNA of 
the rat-specific isoform CYP2C11 was not expressed in endothelial cells of 
renal arterioles. 
The development of lasermicrodissection (LMD) has enabled the isolation of 
relatively pure cell populations from different tissues156, from which the RNA 
can be isolated and used to evaluate differences in gene expression patterns 
by e.g. Q-PCR157,158. We have demonstrated by Q-PCR that LMD can be applied 
to isolate endothelial cells from small arterioles. To our knowledge only two 
other studies have dissected endothelial cells from the vasculature by 
LMD159,160. Stagliano et al have dissected the tunica media from human arteries 
and vessels, in which Q-PCR for PECAM-1 demonstrated the presence of 
endothelial cells160. Archer et al have dissected relatively pure endothelial cells 
from left internal mammary artery as was demonstrated by Q-PCR of the 
endothelial marker VonWillebrand’s factor159. In both studies, endothelial cells 
and smooth muscle cells were dissected from large arteries. In the present 
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study, we are the first to demonstrate the dissection of endothelial cells from 
small arterioles (interlobular arterioles) of rat kidney. Application of Q-PCR 
using the endothelial cell-marker PECAM-1 confirmed the presence of 
endothelial cells. Besides endothelial cells also some smooth muscle cells were 
dissected from the vascular wall, which was shown by Q-PCR of the smooth 
muscle cell marker α-actin. Due to the diameter of the laser beam at a 
magnification of 1000 times relative to the size of the arteriole, the dissection 
of some smooth muscle cells could not be avoided. 
Epoxygenases contribute to endothelium-dependent vasodilatation and are 
therefore postulated to be essential for the EDHF-mediated responses, at least 
in some vascular beds. It was shown by application of anti-sense 
oligonucleotides that the orthologue of the human CYP2C8/9 is a candidate for 
an EDHF-synthase in hamster resistance arteries and porcine aortic cultured 
cells65,161. Human CYP2C8/9 most likely fits the criteria of an EDHF-synthase 
because i) the induction of CYP2C8 by beta-naphtoflavone enhances the 
EDHF-mediated hyperpolarization and relaxation, and ii) its mRNA could be 
detected in human cultured endothelial cells by RT-PCR65,162.  Recently, Archer 
et al confirmed the presence of the human CYP2C9 mRNA in dissected 
endothelial cells from left internal mammary artery by RT-PCR159. In contrast, 
pharmacological evidence against EETs as EDHFs was provided in human 
forearm and rat mesenteric artery studies163,164.   
In the rat renal vasculature three isoforms of the CYP2C subfamily are 
expressed (CYP2C11, CYP2C23 and CYP2C24).  All three isoforms (CYP2C11, 
CYP2C23 and CYP2C24) were detected by nucleic-acid hybridization analysis in 
rat kidney154,165,166. More specifically, CYP2C11 and CYP2C23 proteins were 
detected in renal microvessels165,166. No data is available about mRNA 
expression of the CYP2C isoforms in rat endothelial cells. We have observed by 
in silico analysis that CYP2C11 has the highest homology with the human 
CYP2C8 isoform (78%), and we therefore hypothesized that CYP2C11 might be 
involved in the EDHF-mediated responses in renal arterioles. We showed by the 
application of lasermicrodissection and Q-PCR that the mRNA of the CYP2C11 
was not detectable in endothelial cells of renal arterioles. Although, CYP2C8 
may be a candidate for an EDHF-synthase in humans, the results of our study 
suggest that the rat orthologue (CYP2C11) is not involved in the EDHF-
mediated vasodilatation in kidney, as the mRNA is not expressed in endothelial 
cells of renal arterioles. The two other isoforms of the CYP2C family (CYP2C23 
and CYP2C24) could still be EDHF-synthases in rat kidney as both isoforms are 
expressed in rat kidney and possess epoxygenase activity154,165,166. However, it 
remains to be established whether the mRNAs of these isoforms are expressed 
in endothelial cells of the in vivo renal microcirculation. 
CYP2C11 is abundantly expressed in rat liver154. Therefore, we dissected 
hepatocytes from rat liver as a positive control of the lasermicrodissection 
technique. We could detect CYP2C11 mRNA in lasermicrodissected hepatocytes 
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of male rats, thereby demonstrating that the CYP2C11 mRNA was not 
degraded after application of lasermicrodissection. We confirmed that 
CYP2C11 mRNA expression is highly abundant in male rat livers, whereas in 
female livers hardly any CYP2C11 mRNA could be detected. This observation is 
in line with other studies, in which it was shown by immunochemical and 
Northern blot analysis that CYP2C11 protein expression is male-specific in 
liver167,168. This sex-specific expression of CYP2C is not only observed among 
rats. Recently, the same observation was published in liver of hamsters169.   
Several mechanisms have been postulated to be involved in the EDHF-
mediated vasodilatation. Presently, three distinct mechanisms involved in the 
EDHF-mediated vasodilatation have been postulated; i) the increase of 
endothelial Ca2+ triggers the synthesis of EETs which are responsible for the 
EDHF-mediated responses, ii) smooth muscle cell hyperpolarization is initiated 
by the release of K+ from the endothelial cell, iii) the hyperpolarization is 
transmitted to the smooth muscle cell via gap-junctions138. CYP metabolites 
seem to be involved in the endothelial cell hyperpolarization or might have a 
modulatory role in the transfer of this hyperpolarization from one cell to 
another138. It has been demonstrated that CYP expression becomes more 
apparent when endothelial cells are activated138. CYP expression and EET 
generation of rats have been shown to increase during hypertension170,171; 
therefore, we cannot exclude the possibility that CYP2C11 might be expressed 
in endothelial cells during exposure to stress or other physiological situations. 
In conclusion, we have shown that endothelial cells can be dissected from 
small arterioles by lasermicrodissection to study mRNA expression of specific 
genes by Q-PCR. This novel tool was applied and we demonstrated that under 
normal physiological conditions the mRNA of the rat-specific isoform CYP2C11 
was not expressed in endothelial cells from renal arterioles. The CYPC11 is, 
therefore, not expected to contribute to the EDHF-mediated responses in rat 
kidney, however, a potential role of other CYP2C isoforms cannot be excluded. 
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Abstract  
 
T7-based RNA amplification is applied when there is not sufficient RNA. 
Overall extent of amplification can be measured spectrophotometrically (i.e. 
quantifying RNA yields), but this measurement does not provide information 
about RNA amplification of individual genes. We describe a method applying 
real-time quantitative PCR (Q-PCR), which enables monitoring of RNA 
amplification of individual genes. The amount of RNA before and after T7-
based RNA amplification was determined by Q-PCR for three housekeeping 
genes: β-2-microglobulin (B2M), porphobilinogen deaminase (PBGD), and 
serine dehydratase (SDH), which are, respectively, a high, intermediate/low and 
low copy transcript. Q-PCR appeared to be suitable to determine the extent of 
RNA amplification as was reflected by the low intra- and inter run coefficients 
of variation of threshold cycle (CVCT) of 1.1% to 2.1%. Application of Q-PCR 
showed that T7-based RNA amplification is reproducible but might introduce a 
sequence-specific bias. Q-PCR is a novel approach to monitor RNA 
amplification, and is particularly suited to study RNA amplifications of 
individual genes. 
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Introduction 
 
With the completion of the human genome project, unraveling the function of 
genes and their relation to a certain phenotype is, at present, the principal 
challenge in genetic research. Microarray techniques have recently proven 
useful in the discovery of genes involved in physiological processes172,173,174. 
One of the rate-limiting steps in microarray experiments is the availability of 
relatively large amounts of total RNA (10-100 µg) needed for use in standard 
microarray platforms. When only a limited amount of RNA is available (e.g. 
small tissue samples or laser-microdissected material), one must use methods 
to either amplify the RNA or to increase the signal intensity to overcome the 
RNA shortage175,176,177. Several amplification protocols have been developed, of 
which T7-based RNA amplification is the most frequently used 
approach178,179,180.  
The extent of RNA amplification is in general quantified by use of a 
spectrophotometer or fluorometer. Roughly, the polyA+ RNA content of a cell is 
estimated to be ~3.3% of the total RNA content178 so a spectrophotometric 
measurement of the anti-sense RNA (aRNA) can be used to calculate a rough 
estimate of the overall extent of amplification142. Microarray techniques and 
real-time quantitative PCR (Q-PCR) however, could be used to determine the 
extent of RNA amplification of single genes142,177 and, more importantly, they 
could also give additional information about the linearity of T7-based RNA 
amplification (i.e. whether the relative abundance of different genes is 
preserved after RNA amplification).  
In this report, we describe a detailed method to study T7-based RNA 
amplification of single genes by real-time Q-PCR using molecular beacons94. 
Three housekeeping genes were used for this purpose, i.e. β-2-microglobulin 
(B2M), porphobilinogen deaminase (PBGD), and serine dehydratase (SDH), 
which are, respectively, a high, intermediate/low and low copy transcript. This 
is the first study, in which a detailed method utilizing Q-PCR to monitor 
characteristics of T7-based RNA amplification is described.  
 
 
Material and Methods 
 
Characteristics of Q-PCR 
Oligonucleotides used for the Q-PCR experiments were designed according to 
the Genbank® sequences (rat PBGD mRNA X06827; rat B2M mRNA NM_012512; 
rat SDH mRNA J03863; and rat SDH gene X13119) using Oligo design software 
version 3.4 (table 7.1). Molecular beacon probes were designed using the 
online folding program mfold (http://www.bioinfo.rpi.edu/applications/mfold, 
table 7.1). The PBGD (I) molecular beacon was designed at 435 bp, PBGD (II) at 
1344 bp, B2M at 501 bp and SDH at 477 bp upstream from the 
T7-based RNA amplification and Q-PCR 
93 
polyadenylation signal. All oligonucleotides and molecular beacons were 
synthesized by Biolegio BV, Malden, The Netherlands. 
 
Table 7.1: Rat sequences of oligonucleotides and molecular beacons 
Target Sequence  
(5’→ 3’) 
B2M 
Sense oligo 
Anti-sense oligo 
Molecular beacon1 
PBGD I 
Sense oligo 
Anti-sense oligo 
Molecular beacon1 
PBGD II 
Sense oligo 
Anti-sense oligo 
Molecular beacon1 
SDH 
Sense oligo 
Anti-sense oligo 
Molecular beacon1 
 
CGT GCT TGC CAT TCA GAA AAC 
TCT GAG GTG GGT GGA ACT GAG 
TxR-CGCACG TTC AAG TGT ACT CTC GCC ATC CAC C CGTGCG-dabcyl 
 
CCA GGT CCC TGT TCA GCA AG 
CCC AGG TTC TCA GCA GCT AGC 
TxR-CCGACG GTT CCG GGC AGT GAT TCC AAC CAA CGTCGG-dabcyl 
 
CGG TAA CGG CGG CGC GGC 
CGG TCT GTA TGC GAG CCA GCT GAC 
TxR-CGGACC GAA GAA AAC GGC TCA ATG ATG AGG G GGTCCG-dabcyl 
 
CTG CCC AAG ATC ACC AGT G 
CTC GAT AGC AGT CAC AGC CTC C 
Cy5-CGCACG CCC TGA AGC TGT TTT ACG AAC ACC CCA CGTGCG-BHQ2 
1Molecular beacon sequences with corresponding fluorophore (5’), quencher (3’), and stem sequences (underlined); BHQ2 = 
Black hole 2 quencer; TxR = Texas Red 
 
Q-PCR studies were carried out in a total volume of 50 µL containing 2 µl 
cDNA, 100 ng of molecular beacon, 200 nM of forward and reverse primers, 
200 µM dNTPs, 10 X AmpliTaq Gold amplification buffer, 4 mM MgCl2 and 1.5 
unit of AmpliTaq Gold DNA polymerase (Applied Biosystems, The Netherlands). 
PCR conditions were as follows: cycling was preceded by 95°C/10 min, 
followed by 46 cycles of 95°C/30s, 58°C/45s and 72°C/30s. Q-PCR was 
performed on the iCycler IQ (Biorad, The Netherlands), and fluorescence was 
measured during each annealing step. The baseline was set at 10 times the 
standard deviation of the noise of 10 amplification cycles. Genomic rat DNA 
was included as a template in a separate reaction to assess amplification of 
potential pseudogenes.   
Linearity of each assay was derived from the correlation coefficient of the 
standard curve (R2). The efficiency of each Q-PCR  was analyzed by determining 
the CT values of 5 different dilutions of cDNA (corresponding with 1 µg/µL to 
320 pg/µL total RNA) by plotting the CT values against the log value of each 
dilution. A slope of –3.32 represents an efficiency of 100%, i.e. the amount of 
amplicons is doubled during each cycle (2N, where N is the number of cycles). 
Each Q-PCR was optimized so that for each gene the 95% confidence interval 
of the slope (95% CI) included –3.32.  
Reproducibility of Q-PCR, as determined by whether or not serial reactions 
result in the same CT value, was assessed by performing 20 times the same 
cDNA standard in two dilutions (5 and 250 times) within one run (intra run 
variation) and between 20 separate runs (inter run variation) using the PBGD (I) 
molecular beacon. 
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Linearity of first-strand cDNA synthesis 
The linearity of first-strand cDNA synthesis was tested over a broad range of 
RNA concentrations by diluting total RNA from 1 µg/L to 100 pg/µL. First-
strand cDNA transcription was performed, and CT values were obtained by Q-
PCR using the B2M molecular beacon. The CT values were plotted against the 
log value of each RNA dilution for this experiment, and a slope of –3.32 would 
indicate equal first-strand cDNA synthesis efficiency for each dilution. 
 
Monitoring T7-Based RNA amplification with Q-PCR 
One round of RNA amplification was performed on total rat kidney RNA (N=4) 
(Clontech, BD Biosciences, Belgium) according to Baugh et al142 using their 10 
µL scale protocol. One tenth of the aRNA (N=4) and of the unamplified RNA 
control (N=1) was reverse transcribed to cDNA using 0.5 µg Random Hexamers 
(Promega, The Netherlands) and 200 U Superscript II Reverse Transcriptase 
(Invitrogen, The Netherlands) in a final reaction volume of 20 µL according to 
standard procedures. cDNA was diluted ten times, and 2 µL were subsequently 
used in the Q-PCR for the housekeeping genes PBGD, B2M or SDH.  
 
Quantification of the extent of RNA amplification 
The extent of amplification was quantified by measuring the A260 of the 
obtained aRNAs (N=4) on a spectrophotometer (Shimadzu Benelux, The 
Netherlands), with the assumption that total RNA consists for 3.3% of polyA+ 
RNA.  
In comparison, Q-PCR was used to determine the extent of the amplification of 
three housekeeping genes by comparative quantitation155,181 using the 
following equation:  
 
 
 
 
 
 
 
In equation 1, Ra/R0 is the amount of aRNA (Ra) relative to the unamplified RNA 
(R0).  ∆CT is the difference in threshold cycle of unamplified RNA and aRNA 
(CT,R0 – CT,Ra) after first-strand cDNA synthesis (figure 7.1). The unamplified 
control is a RNA sample, which underwent the same RNA amplification 
procedure, except for the in vitro transcription step, during which the sample 
was stored at –80°C. During each PCR cycle the amount of target is doubled 
(2CT). 
 
 
=  2     ∆CT      (1) 
Ra 
 
 
R0 
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Statistical analysis 
The difference in extent of amplification monitored by PBGD I and PBGD II 
quantitative PCR assays was determined by Student’s t-test, and differences 
between the three housekeeping genes were estimated by one-way analysis of 
variance (ANOVA). Differences were accepted as significant when P < 0.05. All 
P values were two-tailed. Linear regression was performed using the Excel 
Regression Analysis ToolPak (Microsoft Office 2000). 
 
 
Results and Discussion  
 
Characteristics of Q-PCR 
All Q-PCR assays for B2M, PBGD (I) and (II), and SDH were optimized to obtain 
linear standard curves. Regression equations for the different molecular 
beacon assays were: PBGD (I): y=-3.57x+29.6, R2=0.995; PBGD (II): y=-
3.18x+31.9, R2=0.999; B2M: y=-3.27x+24.1, R2=0.999; SDH: -3.17x+32.9, 
R2=0.990. Q-PCR efficiencies were calculated from the slopes of the standard 
curves (10(-1/slope)), which resulted in efficiencies of 102% (Ε = 2.02) for B2M, 
91% (E = 1.91) for PBGD I, 106% (E = 2.06) for PBGD II and 107% (E = 2.07) for 
SDH. Each Q-PCR efficiency did not differ significantly from 100%, i.e. the 95% 
CI of each slope included –3.32 (B2M 95% CI [-3.11 to -3.43], PBGD (I) 95%CI [-
3.91 to -3.23], PBGD (II) 95% CI [-3.35 to -3.01], and SDH 95% CI [-3.61 to -
2.74]).  
Reproducibility of the Q-PCR assay (i.e. whether serial reactions result in the 
same threshold cycle) was determined by Q-PCR using PBGD (I) molecular 
beacon. Intra run variation resulted in a mean CT of 28.4 ± 0.3 (CVCT = 1.1%) 
and 33.9 ± 0.7 (CVCT = 2.1%) for respectively, a 5 and 250 times diluted cDNA 
standard (N=20). The mean inter run CT values for both dilutions were 
respectively 28.2 ± 0.4 (CVCT =1.4%, N=20) and 34.1 ± 0.7 (CVCT =2.1%, N=20).  
These CVCT are in line with a previously published study182. Therefore, Q-PCR is 
 
Figure 7.1: Example of calculation of the extent of T7-
based RNA amplification by Q-PCR. Q-PCR results of
B2M showing the plot of amplified RNA (Ra) and the
unamplified control (R0). The extent of amplification
can be calculated by 2∆CT. 
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reproducible, and can be suitably applied in assays in which a precise estimate 
of target abundance is desirable, e.g. in the determination of the extent of RNA 
amplification of separate genes. Although, Q-PCR leads to a small variation in 
CT values of only 1-2%, the variation in the extent of amplification, however, 
will automatically be much larger (~10-30%) due to the exponential character 
of this calculation (2∆CT). 
 
Spectrophotometric measurement of the extent of amplification 
The extent of amplification of four separate RNA amplification reactions versus 
one unamplified control reaction was determined spectrophotometrically. This 
resulted in 3.3 ± 0.9 µg aRNA, which corresponded with a mean amplification 
of 100.4 ± 28.4 times, with the assumption that total RNA consists of 3.3% of 
polyA+ RNA, which is in line with the results of Baugh et al142. 
 
Monitoring T7-based RNA amplification with Q-PCR 
Q-PCR analysis was applied to the aRNA and the unamplified control to 
calculate the extent of gene-specific RNA amplification of three housekeeping 
genes, and resulted in a mean ∆CT for B2M of 5.6 ± 0.2, 6.6 ± 0.2 for PBGD (I), 
and 4.0 ± 0.4 for SDH. Mean extent of amplification was calculated from the 
∆CT using equation 1 and this resulted in 47.7 ± 7.1 times for B2M, 99.1 ± 11.9 
times for PBGD (I), and 16.1 ± 5.1 times for SDH. Comparing the results of 
PBGD (I), B2M and SDH showed that a significant bias of amplification had 
occurred (ANOVA P < 0.001). Particularly, the low copy transcript SDH showed 
a significantly lower extent of amplification, which raises the question whether 
the extent of amplification is related to the copy number. Similar studies using 
microarrays to study target-dependent amplification were recently published, 
which showed that RNA amplification is not dependent on the initial copy 
number but rather on differences in the sequence itself142,177. Therefore, we 
speculate that the observed bias of amplification might already be introduced 
during first-strand cDNA synthesis preceding the amplification step. Due to 
GC-richness of some targets, secondary structures can easily be formed, which 
could perturb the efficiency of reversed transcription. Obviously, when mRNA 
copies of different targets are not equally reversed transcribed to cDNA, this 
will result in a bias after amplification.  In addition, it is not known whether 
first-strand cDNA synthesis is linear for different amounts of input RNA. To 
test the linearity of first-strand cDNA synthesis, we performed a Q-PCR 
experiment using B2M on a range of RNA dilutions. This resulted in a linear 
standard curve (R2 = 0.992, figure 7.2), and in a similar PCR efficiency (E = 
93%, 95% CI –4.08 to -2.90) as obtained for the cDNA dilution series (E = 
102%, 95% CI –3.11 to –3.43). For a given target gene, these results 
demonstrated that first-strand cDNA synthesis is linear for different amounts 
of total RNA (1 µg/µL to 100 pg/µL). However, the results of this experiment 
do not give information about the extent of reversed transcription efficiency 
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for each separate target. Therefore, when gene-expression levels of limited 
RNA samples are compared using T7-based RNA amplification, only relative 
quantification is valid, as this compares the intra-target differences (i.e. gene-
expression of a particular gene in sample versus control). 
 
In our study, Q-PCR was applied to monitor the reproducibility of RNA 
amplification, i.e. whether several separate RNA amplification reactions would 
result in the same extent of amplification. Results from four separate reactions 
showed that T7-based RNA amplification was reproducible (mean ∆CT for B2M 
of 5.6 ± 0.2, 6.6 ± 0.2 for PBGD (I), and 4.0 ± 0.4 for SDH), as small standard 
deviations were obtained for each of the three genes tested (SD <0.5). Other 
studies, in which microarray techniques were used, have also shown that T7-
based RNA amplification is a reproducible technique142,177,183. 
During in vitro transcription, aRNA is transcribed from the 3’end resulting in 
products with a length of about ~500-1500 bp. Therefore, the position of the 
molecular beacon towards the polyadenylation signal could influence the 
calculation of the extent of amplification. For this purpose, two molecular 
beacons were developed for one gene, located at a distance of 435 bp (PBGD I), 
and 1344 bp upstream from the polyadenylation signal (PBGD II). Q-PCR 
experiments using both molecular beacons resulted in a significantly lower 
mean extent for PBGD (II) compared with PBGD (I) (16.1 ± 5.1 times versus 99.1 
± 11.9 times, respectively, P < 0.001). Therefore, we fixed the position of other 
molecular beacons (B2M and SDH) at a distance of ~500 bp upstream from the 
polyadenylation signal. Importantly, these results also show that when aRNA is 
used in Q-PCR or microarray experiments, the oligonucleotides or cDNA clones 
spotted on an array should represent the 3’end of the transcripts. 
In the present study, we give a detailed description of Q-PCR using molecular 
beacons to monitor T7-based RNA amplification, and we applied this method 
to monitor several characteristics of T7-based RNA amplification. Currently, 
microarray techniques are also being used to study differences after T7-based 
RNA amplification142,177,183, but this requires more expertise and expensive 
facilities. At the moment Q-PCR is a frequently used technique184, which is 
Figure 7.2: Efficiency of first-strand cDNA
synthesis for different amounts of total RNA.
Standard curve of Q-PCR using B2M for RNA
dilution series of 1 µg/µL to 100 pg/µL with
corresponding regression equation is shown. 
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relatively simple and inexpensive, and therefore accessible to most genetic 
laboratories. Results of the present study show that Q-PCR can be easily 
applied to monitor the extent of RNA amplification of individual genes. 
Application of Q-PCR demonstrated that T7-based RNA amplification is 
reproducible even though it might introduce a sequence-specific bias for the 
three housekeeping genes studied here. Ideally, the extent of amplification of 
all targets should be preserved during RNA amplification. Nevertheless, gene 
expression profiling is usually executed to compare profiles between two 
samples, for identification of up- or down regulated genes. For this purpose, a 
reproducible bias in amplification is acceptable between different targets, as 
long as two samples that are compared have both been amplified using the 
same amplification technique. In combination with very promising techniques 
like laser-capture microdissection, T7-based RNA amplification will widen the 
frontier with which to perform gene expression profiling of even isolated single 
cells.  
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Abstract  
 
 
Hyperhomocysteinemia is associated with impaired endothelium-dependent 
vasodilatation and an increased risk of atherosclerosis and thrombosis. Despite 
intensive research, the pathophysiology of this association remains conjectural. 
Here we show by gene-expression profiling using oligonucleotide arrays that, 
among a few other genes, the modifying subunit of glutamate-cysteine ligase 
(GCLM) was up-regulated in the aorta of hyperhomocysteinemic rats. 
Glutamate-cysteine ligase is the rate-limiting enzyme of glutathione synthesis. 
In addition, we show that total cysteine levels were decreased and total 
glutathione levels were increased, which corroborates the up-regulation of 
GCLM. In humans a single-nucleotide polymorphism (SNP) in the promoter 
region of GCLM (-588 C>T) has been reported, which reduces GCLM mRNA 
expression under conditions of ambient oxidative stress. In a case-control 
study including patients with recurrent venous thrombosis, we show that the 
presence of the -588 C>T SNP increased the risk of venous thrombosis more 
than 2-fold when also homocysteine levels were elevated (OR 2.5 [1.0-6.2]). 
These findings suggest that GCLM is up-regulated to compensate for the 
adverse oxidative effects of elevated homocysteine on the vascular wall, and 
thus describe a previously undefined role for GCLM in the pathophysiology of 
hyperhomocysteinemia. 
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Introduction 
 
Homocysteine is a sulfur-containing amino acid that is derived from 
methionine. Almost fifty years ago, McCully et al observed that patients with 
severe hyperhomocysteinemia had an increased risk for the clinical 
manifestation of vascular disease3. Since then, epidemiological evidence 
demonstrated that also moderate hyperhomocysteinemia was an independent 
risk factor for vascular disease. Despite a variety of mechanisms proposed to 
underlie this association, it is still not known whether homocysteine itself is 
proatherogenic or whether increased homocysteine levels are rather a 
reflection of a disturbed metabolism. 
Endothelial dysfunction appears to be an early event in the promotion of 
atherogenesis. A large body of evidence indicates that hyperhomocysteinemia 
is associated with impaired endothelium-dependent vasodilatation31,32,30,125. 
Recently, we have demonstrated that endothelium-derived hyperpolarizing 
factor (EDHF)-mediated vasodilatation is decreased in renal arterioles of 
hyperhomocysteinemic rats136. Although the exact mechanism of endothelial 
dysfunction is unknown, there is growing evidence that homocysteine exerts 
its effect on the progression of vascular disease by promoting oxidative 
damage43,44.  
Several studies have been performed in which differential display or microarray 
technology was applied to reveal the pathophysiological mechanism behind 
hyperhomocysteinemia. Most of these in vitro studies have been performed on 
human umbilical vein endothelial cells (HUVEC), in which genes involved in 
endoplasmatic reticulum-stress response34,35, acute translational response, 
inflammatory response36,37, and oxidative stress response have been 
identified38. However, in the majority of these studies physiologically irrelevant 
concentrations or forms of homocysteine were applied to analyze gene-
expression differences. Recently, two studies were performed in which 
microarrays were applied to study gene-expression differences in liver and 
brain of CBS-deficient mice, resulting in the identification of genes involved in 
cellular growth, proliferation, and oxidative stress perturbations185,186. 
However, regarding the findings of ourselves and others that the adverse 
effects of homocysteine might involve impaired bioavailability of nitric oxide 
leading to endothelial dysfunction187,31,125,30,32, the analysis of gene expression 
differences in physiologically relevant tissues like aorta of an in vivo model of 
hyperhomocysteinemia is of potential interest.  
In the present study, we therefore induced hyperhomocysteinemia in rats by a 
diet with high levels of methionine in combination with low levels of B 
vitamins136, and applied microarrays to explore the pathophysiological 
mechanism involved. 
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Material and Methods 
 
Diet-induced hyperhomocysteinemic rats 
Female Wistar rats were fed a diet enriched in methionine (7.7 g/kg) with 
depleted levels of folate, vitamin B6 and vitamin B12 (Harlan Teklad TD97345, 
N=8) or standard rodent chow (N=8) during 8 weeks136. Rats were 
anesthetized with 100 mg/kg thiobutabarbital (Inactin, RBI, USA). The 
abdominal part (~15 mm) of the aorta was removed, and immediately frozen in 
liquid nitrogen, and stored at –80°C.  
 
RNA isolation  
RNA was isolated from aorta using Trizol in presence of the carrier linear 
polyacrylamide188. Homogenization was performed by cutting sections of 15 
µm from aorta at –20°C using a cryostat (Micron). The cryo-tissuesections were 
put into a tube containing 1 ml of Trizol (Invitrogen). A syringe with a sterile 
needle (0.4 mm) was used to further homogenize the sample. The RNA was 
isolated according to manufacturer’s protocol and was dissolved in 10 µL of 
DEPC-treated water. The RNA was incubated with 4 units of RNase-free DNase 
for 30 minutes at 37°C to remove all contaminating DNA (Epicenter). 
Subsequently, the RNA was extracted by the RNeasy clean-up protocol 
(Qiagen), and was eluted with 40 µL of elution buffer.  
 
Amplification and labeling of RNA isolated from aorta 
Approximately 1.5 µg of total RNA could be isolated from each aorta of 5 HHcy 
rats and 6 control rats each. An indirect design was chosen using rat universal 
reference pool (Stratagene) as reference RNA. Each of the 11 RNA samples and 
the universal reference pool were amplified using the MessageAmp aRNA kit 
(Ambion) according to the manufacturer’s protocol. During in vitro 
transcription aminoallyl UTPs were incorporated. Briefly, 4 µL 10 x T7 reaction 
buffer, 4 µL 10 x T7 enzyme mix, 4 µL 75 mM of ATP, CTP and GTP, 2.4 µL 50 
mM UTP and 2.4 µL 75 mM aminoallyl UTP (Ambion) was added to 15.2 µL 
cDNA. The aRNA was DNase treated and purified according to the protocol. 
The amount of anti-sense RNA (aRNA) was calculated by measuring the A260. 
Approximately, 5-15 µg of aRNA was obtained after a single round of 
amplification. The aRNA was vacuum-dried and 3 µg was used for labeling. 
Coupling of Cy3- or Cy5 dyes to the aminoallyl linker was performed according 
to ‘t Hoen et al 189. The samples were coupled to Cy5-dyes and the universal 
reference pool was coupled to Cy3-dyes. Briefly, Cy3- and Cy5 dyes were 
dissolved in 40 µL of dry DMSO and divided in aliquots of 2 µL, which were 
immediately vacuum-dried. 5 µL dry DMSO and 1.67 µL sodiumbicarbonate 
buffer (pH = 9.0) were added to 3.3 µL aRNA (3 µg), and the total volume was 
transferred to the vacuum-dried dyes. Coupling was performed for 1 hour at 
room temperature in the dark. The non-reacting dye molecules were quenched 
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by 4.5 µL of 4 M hydroxylamine solution (Sigma). Unincorporated nucleotides 
were removed using Microcon YM_30 columns (Millipore). Labeling efficiencies 
were determined by measuring 1/10th of the total volume of aRNA by A260 
(RNA), A550 (Cy3) and A650 (Cy5). Next, Cy3- or Cy5 labeled and purified aRNA 
was mixed and 1.5 µL 10 mg/ml polyA (AP Biosystems) and 10 µg COT1 DNA 
(Invitrogen) were added to prevent aspecific hybridization. The mixture was 
concentrated by vacuum centrifugation to 60 µL, and was subsequently 
denatured (95°C/2 min). Finally, 60 µL of hybridization buffer (50% formamide, 
5 x SSC, 0.1% SDS) was added, and the sample was incubated at 42°C prior to 
hybridization to the oligo array.  
  
Microarray design, hybridization, and analysis 
An indirect design was chosen using rat universal reference RNA (Stratagene) 
as reference RNA190. RNA that was isolated from aorta of 
hyperhomocysteinemic (n=5) and controls rats (n=6) was individually 
compared with the universal reference RNA on a separate slide, resulting in a 
total number of 11 hybridizations. 
A 5K oligonucleotide set (Sigma-Genosys) was printed (spotting solution: 3x 
SSC, pH=7.0, 1.5M betaine) in triplicate (12 fmol/spot) onto UltraGAPS glass 
slides (Corning) using a Omnigrid 100 arrayer (Genemachines, Genome 
Solutions) equipped with 16 SMP3 pins (ArrayIt). Printed slides were dried 
overnight and cross-linked with UV light at 600 mJ using a Strata-linker 2400 
(Stratagene). Slides were pretreated by incubation in ethanolamine blocking 
buffer (50 mM ethanolamine, 100 mM Tris-HCl, pH=9.0, 0.1% SDS) for 30 
minutes at 50°C. After the slides were washed with sterile water, the slides 
were transferred to a block-wash buffer (4 x SSC, 0.1% SDS) and incubated for 
30 minutes at 50°C. The slides were washed and finally incubated at 42°C for 
30 minutes in a prehybridization buffer (5 x SSC, 0.1% SDS and 1% BSA). 
Hybridization was performed at the GeneTAC hybridization station (Genome 
solutions) and 120 µL of probe was added to the module. Hybridization was 
performed overnight at 42 °C. After hybridization, the slides were washed at 
42°C in 1) a buffer containing 1 x SSC and 0.2% SDS for 5 minutes, 2) a buffer 
containing 0.1 x SSC and 0.2% SDS for 4 minutes, 3) a buffer containing 0.1 x 
SSC for 5 minutes, and finally 4) the slides were rinsed in a buffer containing 
0.01 x SSC and dried by centrifugation for 10 minutes at 300xg. The slides 
were analyzed on an Affymetrix 428 scanner (Affymetrix) using software 
package version 1.0 (Affymetrix). 
GenePixPro 4.0 software was used to analyze the obtained images (Axon 
instruments). The fluorescence ratio of the two dyes was automatically 
calculated after correcting for background signals. Spots were discarded from 
further analysis if the intensities of the spots were below a priori set thresholds 
(F635median ≤ 1.4x B635 or F532median ≤ 1.4x B532). The spots were flagged 
when they exhibited poor hybridization signals or when they were saturated 
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(F635median=65534 or F532=65534). Each slide was scanned at a high and 
low scanning intensity (40 and 65/70 dB) for each channel; if a spot was 
saturated at 65/70 dB, the software automatically calculates with the ratio 
obtained from the 40 dB scan. Normalization was performed per array block 
using lowess regression191. Normalized datasets were analyzed using the 
significance analysis of microarrays (SAM) method that corrects for multiple 
testing192.  
 
Real-time quantitative PCR (Q-PCR) 
2 µL of the amplified RNA from aorta was reverse transcribed to cDNA using 
random hexamers in a final reaction volume of 20 µL. Q-PCR was carried out in 
a total volume of 50 µL containing 2 µl of 10 times diluted cDNA, 0.5 x SYBR® 
Green solution (Molecular Probes), 200 nM of forward and reverse primers, 200 
µM dNTPs, 1 x AmpliTaq Gold amplification buffer, 4 mM MgCl2 and 1.5 unit of 
AmpliTaq Gold DNA polymerase (Applied Biosystems, The Netherlands). 
Oligonucleotides used for the Q-PCR experiments were designed according to 
the Genbank sequences (table 8.1). All oligonucleotides were synthesized by 
Biolegio BV, Malden, The Netherlands.  
 
Table 8.1: Primers used for real-time quantitative PCR experiments  
Gene Sense 
 (5’→ 3’) 
Antisense  
(5’ →  3’) 
Size 
bp  
GCLM 
NFI-A1 
RPA2 
ACLY 
PAI2A 
GTPCH1 
RAMP3 
RevErbA 
HZF-2 
B2M1 
PBGD1 
TAATCTTGCCTCCTGCTGTGTG 
CTGGAAATGGTTGGGCTGTG 
AGGAGGACCAGCAGAGCAGAG 
GGGCTTCATCGGGCACTATC 
CGGCTTGGAGATGCTGG 
CAAGACTGTCACTAGCACCATGC 
ATGTGTGACCTACGGACCTGC 
GCAAGGCAACACCAAGAATG 
GCTGATGGTGCGTCTGTTATG 
CGTGCTTGCCATTCAGAAAAC 
CCAGGTCCCTGTTCAGCAAG 
GAGCAGTTCTTTTGGGTCATTGTG 
CAGGAAGTTCGTGAGCAAGG 
CTTGGCCCTAGTATGGTTCGTTC 
GGGCTGCTGGCTCGGTTAC 
TTTGAACTTGGGAATGTAGACC 
GGGCTCGCACACGGAAG 
AGGTTCACTCTCTATCTTCAGGG 
CAAATTCTACCACCTCCCGC 
GTAAAGAATTCACAAACCCTAGCTG 
TCTGAGGTGGGTGGAACTGAG 
CCCAGGTTCTCAGCAGCTAGC 
100 
102 
94 
121 
109 
103 
123 
140 
102 
113 
108 
1Reference genes 
 
PCR conditions were as follows: cycling was preceded by 95°C/10 min, 
followed by 40 cycles of 95°C/30s, 62°C/45s and 72°C/30s. Samples were run 
in duplicate on the iCycler IQ (Biorad), and fluorescence was measured during 
each annealing step. After amplification, a melting curve was acquired by 
heating for 1 minute at 95°C, cooling to 25°C and again heating to 95°C with 
temperature intervals of 0.5°C. Relative quantification can only be applied when 
the PCR efficiencies of the target gene and reference gene are approximately 
equal143. The PCR efficiencies did not differ more than 10% between each 
target and reference gene that was analyzed per run (data not shown), and 
therefore relative quantification was applied. Expression levels were 
normalized to the housekeeping genes B2M and PBGD (reference genes) by 
comparative quantitation using the ∆∆CT method143. For each sample the ∆CT 
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was calculated (CT,target – CT,ref) in duplicate. The mean relative expression was 
calculated as 2-∆∆CT (∆∆CT = ∆CT-∆CT, con). The geNorm software was applied to 
combine both the results of B2M and PBGD to obtain a more accurate 
normalization193.  
 
Determination of thiols 
Serum total homocysteine, cysteine, γ-glutamylcysteine and cysteinylglycine 
levels were measured using a HPLC technique as described before194. Total 
serum methionine levels were determined by a reverse phase HPLC 
technique136.  
 
Patient material 
Patients (N=185) with two or more episodes of venous thrombosis were 
selected from an anticoagulant clinic of the Hague as previously described7,187. 
Controls (N=500) were selected from the general population in The Hague. 
 
Determination of the –588 C>T SNP 
Genomic DNA was isolated from peripheral blood lymphocytes according to 
standard procedures121. The -588 C>T SNP could be determined in 160 cases 
and 421 controls by PCR followed by restriction-enzyme analysis according to 
Nakamura et al195. Briefly, the –588 C>T SNP creates a novel restriction site for 
Msp I.  After PCR at an annealing temperature of 58°C in presence of 1.5 mM 
MgCl2 a PCR product of 329 bp was obtained, encompassing the -588 C>T site 
and an additional site for Msp I. The obtained fragment of 329 bp was cut by 
Msp I, resulting in fragments of 200 and 129 bp fragments for the -588 TT 
genotype. In case of the -588 C allele, the product of 129 bp is cut into two 
fragments of 84 and 45 bp. The fragments were separated by gel-
electrophoresis on a 3% agarose gel. 
 
Statistical analysis 
Differences in mean levels of biochemical parameters in rats were tested with 
the Mann Whitney U test for non-parametric independent variables. To test 
whether a possible relation existed between different metabolites and/or GCLM 
mRNA expression, and to test whether the results of the microarray analysis 
were comparable with the results of real-time quantitative PCR, Spearman rank 
correlation was applied.  
To estimate the relative risk of GCLM –588 C>T and/or combined with 
hyperhomocysteinemia on recurrent thrombosis risk, odds ratios (OR) and 95% 
confidence intervals (95% CI) were calculated. Hyperhomocysteinemia was 
defined as tHcy levels above the 90th percentile of the respective distribution of 
the controls. OR and P values were corrected for age and sex differences by 
multivariate analysis.  P < 0.05 was considered statistically different; all P 
values were two tailed. 
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Results 
 
Microarray analysis and confirmation by real-time quantitative PCR 
Application of oligonucleotide arrays demonstrated that nine genes were 
differentially expressed in aorta of hyperhomocysteinemic rats compared with 
control rats. No large changes in gene expression could be observed; the fold 
change of these nine genes varied from 1.4 till 2.7 (table 8.2).  
 
Table 8.2: Up- and down regulated genes in aorta of hyperhomocysteinemic rats obtained by microarray analysis 
Gene ID 
(accession no) 
Gene Gene ontology Fold change 
NM_017305 
 
X98490 
 
D78017 
NM_016987 
X64563 
 
M58364 
NM_020100 
 
M25804 
U15660 
Glutamate cysteine ligase, modifying subunit 
(GCLM), mRNA 
p32-subunit of replication protein A (RPA2), 
mRNA 
Nuclear factor 1 family protein (NFI-A1), mRNA 
ATP citrate lyase (ACLY), mRNA 
Plasminogen activator inhibitor 2 type a (PAI2A), 
mRNA 
GTP cyclohydrolase I (GTPCH1), mRNA 
Receptor activity modifying protein 3 (RAMP3), 
mRNA 
Rev-ErbA-alpha protein mRNA (RevErbA), mRNA 
Orphan nuclear receptor HZF-2 (HZF-2), mRNA 
cysteine metabolism [0006534] 
 
DNA replication [0006260] 
 
DNA replication [0006260] 
coenzyme A metabolism [0015936] 
acute-phase response [006953] 
 
nitric oxide biosynthesis [0006809] 
cell surface receptor linked signal 
transduction [0007166] 
transcription regulation [0006355] 
transcription regulation [0006355] 
1.7 
 
1.8 
 
2.7 
2.1 
1.4 
 
2.0 
1.5 
 
-2.1 
-1.8 
 
Validation by Q-PCR analysis confirmed that the expression of the modifying 
subunit of glutamate-cysteine ligase (GCLM) was up regulated in aorta of 
hyperhomocysteinemic rats (figure 8.1). Furthermore, the mRNA coding for 
GTP-cyclohydrolase I (GTPCH1) tended also to be increased (P = 0.10, figure 
8.1). In accordance, we found a strong correlation of the results obtained by 
microarray analysis and by Q-PCR analysis for GCLM (Rs = 0.62, P = 0.04). 
Also, for GTP cyclohydrolase I (GTPCH1) a correlation was found, although not 
significantly (Rs = 0.50, P = 0.12). The differences in expression of the other 
genes as observed with Q-PCR were similar to that observed in microarray 
analysis, with the exception of the p32-subunit of replication protein A (RPA2) 
and nuclear factor 1 family protein (NFI-A1), of which differential expression 
Figure 8.1 GCLM mRNA expression is up
regulated in aorta of hyperhomo-
cysteinemic rats. For each of the eight
differentially expressed genes obtained
by microarray analysis (for affiliation see
table 8.2), Q-PCR analysis was performed
in RNA isolated from aorta of
hyperhomocysteinemic and control rats.
Normalized expression levels (mean ±
SD) relative to B2M and PBGD are given
for each of the eight genes. * P  = 0.03. 
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could not be confirmed by Q-PCR analysis (figure 8.1). mRNA expression of 
plasminogen activator inhibitor 2a could not be detected by Q-PCR in aorta of 
hyperhomocysteinemic and control rats.  
 
Serum metabolite levels of hyperhomocysteinemic rats 
Total homocysteine and methionine levels were increased in serum of rats fed 
a high methionine / low B vitamin diet during 8 weeks as compared with rats 
that were fed standard rodent chow (table 8.3).  
 
Table 8.3: Total serum metabolites (µmol/L) of hyperhomocysteinemic and control rats 
Diet  
 
Standard rodent chow 
Mean ± SD (n=8) 
High methionine / low B vitamin 
Mean ± SD (n=8) 
P  value 
 
 
Homocysteine  
Methionine   
Cysteine  
γ-glutamylcysteine  
Glutathione  
Cysteinyl-glycine  
5.9 ± 1.9 
78.6 ± 12.9 
206.5 ± 51.2 
6.02 ± 1.65 
22.3 ± 3.9 
1.87 ± 0.65 
83.8 ± 34.9 
168 ± 78.6 
149.6 ± 32.5 
6.73 ± 1.12 
39.8 ± 8.6 
1.20 ± 0.53 
< 0.001 
< 0.001 
0.03 
0.35 
0.001 
0.04 
 
Total cysteine and cysteinylglycine levels were lower and glutathione levels 
were higher in serum of rats fed the high methionine / low B vitamin diet (table 
8.3). Total serum γ-glutamylcysteine levels were not significantly different 
between both groups (table 8.3).  
 
Figure 8.2 Glutathione levels in serum of hyperhomocysteinemic rats are associated with GCLM mRNA expression and 
homocysteine. (a) Plot of individual CT values of GCLM mRNA expression in aorta normalized to B2M and PBGD versus serum 
glutathione levels for hyperhomocysteinemic (dots) and control rats (squares). (b) Plot of individual total serum 
homocysteine levels versus serum glutathione levels of hyperhomocysteinemic rats; inserted plot illustrates the values in 
control rats. 
 
Correlation 
GCLM mRNA expression in aorta strongly correlated with total serum 
glutathione levels in hyperhomocysteinemic rats as well as in control rats 
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(figure 8.2a). Total serum homocysteine levels were strongly correlated with 
total serum glutathione levels in hyperhomocysteinemic rats but not in control 
rats (figure 8.2b). 
 
-588 C>T polymorphism 
The –588 C>T SNP in the promoter region of GCLM was investigated in relation 
to thrombosis risk. The frequency of the GCLM -588 TT genotype was higher 
among recurrent venous thrombosis (RVT) cases than among controls, which 
led to a slightly increased risk of RVT (table 8.4, OR 1.3 [0.6-2.9]).  
 
Table 8.4: Genotype distribution of GCLM -588 C>T variant among recurrent venous thrombosis cases and controls 
GCLM 
-588 C>T 
Cases 
N (%) 
Controls 
N (%) 
Crude OR 
[95%CI] 
Adjusted OR2 
[95% CI] 
CC 
CT 
TT 
105 (65.6%) 
44 (27.5%) 
11 (6.9%) 
263 (62.5%) 
135 (32.1%) 
23 (5.5%) 
1.01 
0.8 [0.5-1.2] 
1.3 [0.6-2.7] 
1.01 
0.8 [0.5-1.3] 
1.3 [0.6-2.9] 
1Reference category; 2OR adjusted for age and sex differences 
 
To investigate whether the risk of the –588 C>T SNP on thrombosis was more 
pronounced in combination with elevated homocysteine levels, we performed 
an interaction analysis and demonstrated that individuals who both had the     
-588 CT/TT genotype and elevated homocysteine levels, had a more than 2-
fold increased risk of RVT (OR 2.5 [1.0-6.1] (table 8.5).  
 
Table 8.5: Interaction analysis of GCLM –588 C>T with tHcy levels and the risk of recurrent venous thrombosis 
GCLM 
-588 C>T 
HHcy 
> 90th 
Cases 
N (%) 
Controls 
N (%) 
Crude OR  
[95%CI] 
Adjusted OR2 
[95% CI] 
CC 
 
 
CT 
 
 
TT 
 
 
CT/TT 
No 
Yes 
 
No 
Yes 
 
No 
Yes 
 
No 
Yes 
80 (50.0) 
25 (15.6) 
 
32 (20.0) 
 12 (7.5) 
 
10 (6.3) 
1 (0.6%) 
 
42 (23.6) 
13 (8.1) 
233 (55.3) 
30 (7.1) 
  
123 (29.2) 
 12 (2.8) 
 
23 (6.7) 
- 
 
146 (34.7) 
12 (2.9) 
1.01 
2.4 [1.4-4.4] 
 
0.7 [0.5-1.2] 
2.9 [1.3-6.7] 
 
1.3 [0.6-3.0] 
- 
 
0.8 [0.5-1.3] 
3.2 [1.4-7.2] 
1.01 
1.4 [0.8-2.8] 
 
0.7 [0.4-1.1] 
2.3 [1.0-5.9] 
 
1.4 [0.6-3.1] 
- 
 
0.8 [0.5-1.3] 
2.5 [1.0-6.1] 
1Reference category; 2OR adjusted for age and sex differences 
 
 
Discussion 
 
In this present study, we demonstrated by the application of oligonucleotide 
arrays that the mRNA of the modifying subunit of glutamate-cysteine ligase 
(GCLM) is up-regulated in aorta of hyperhomocysteinemic rats. 
Nine differentially expressed genes were identified by microarray analysis; no 
large changes in gene expression were observed. These results indicate that 
the in vivo effect of hyperhomocysteinemia on gene expression in aorta is 
relatively modest. Verification by real-time quantitative PCR confirmed the up-
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regulation of GCLM, and showed a trend towards up-regulation of GTPCH1. 
GCLM is a main regulator in maintaining the glutathione pool in conditions of 
increased ambient oxidative stress196.  
Glutamate-cysteine ligase (GCL) is the rate-limiting step in glutathione 
synthesis and catalyzes the formation of γ-glutamylcysteine from glutamate 
and cysteine. Glutathione-synthetase then couples glycine to γ-
glutamylcysteine to form glutathione196. GCL is a heterodimer of a heavy, 
catalytic subunit (GCLC) and a light, modifying subunit (GCLM); these subunits 
are encoded by two different genes, which both can be regulated at the level of 
transcription196. Mice homozygous for the null-allele of GCLM (-/-) have 
decreased glutathione levels, and are more sensitive to oxidative stress 
conditions than wild-type littermates197. Overexpression of GCLM mRNA in 
HeLa cells has been shown to increase GCL activity and intracellular 
glutathione levels, thereby rendering cells resistant to oxidative stress198.  
We measured key-metabolites of the γ-glutamylcycle to corroborate our initial 
finding of increased GCLM mRNA expression in hyperhomocysteinemic rats. In 
serum of hyperhomocysteinemic rats, increased glutathione and decreased 
cysteine levels were found which are in line with the up-regulation of GCLM 
mRNA expression. Importantly, we show that GCLM mRNA expression strongly 
correlated with total serum glutathione levels suggesting that elevated total 
serum glutathione levels originated from increased GCLM mRNA expression. 
Furthermore, we show that total serum homocysteine levels were strongly 
correlated with total serum glutathione levels in hyperhomocysteinemic rats 
but not in control rats, emphasizing that glutathione production is increased in 
hyperhomocysteinemia, most likely due to elevated GCLM mRNA expression 
(figure 8.3). Additional tracer studies may confirm whether the higher levels of 
glutathione are actually due to increased expression of GCLM in 
hyperhomocysteinemic rats. 
 
 
As GCLM mRNA expression is up-regulated under oxidative stress 
conditions199, we speculate that hyperhomocysteinemia increases the 
formation of reactive oxygen species (ROS) (figure 8.3) with concurrent up-
Figure 8.3: GCLM is up-regulated to compensate for
the adverse oxidative effects of elevated homocysteine.
Hyperhomocysteinemia is associated with increased
production of ROS. GCLM is a main regulator in
maintaining the glutathione pool, and is upregulated in
conditions of increased ambient oxidative stress like
hyperhomocysteinemia to produce glutathione for the
detoxification of ROS. Defective upregulation of GCLM
reduces detoxification of ROS, and causes endothelial
dysfunction (indicated by the dotted arrow), which is an
early marker of atherosclerosis and thrombosis. 
 Detoxification
Reactive oxygen species
Hyperhomocysteinemia
GCLM
Glutathione
Cysteine
Endothelial dysfunction
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regulation of GCLM mRNA expression in hyperhomocysteinemic rats, most 
likely to compensate for the adverse oxidative effects of homocysteine on the 
vascular wall (figure 8.3). 
The human GCLC and GCLM genes both have putative oxidative stress 
response elements in their promoter-enhancer regions200. GCL genes can be 
transcriptionally up-regulated by oxidants to increase glutathione synthesis, 
providing a defense mechanism against oxidative stress199,200. Recently, a SNP 
in the 5’- flanking region of the human GCLM gene has been described, which 
has been associated with decreased promoter activity under oxidative stress 
conditions and increased risk of myocardial infarction195. We hypothesized that 
a hampered upregulation of GCLM due to this -588 C>T SNP increases the risk 
of atherosclerosis and thrombosis, in particular in the presence of oxidative 
conditions such as hyperhomocysteinemia. The frequency of the GCLM -588 
TT genotype was higher among RVT cases than among controls, which led to a 
slightly increased risk of RVT (OR 1.3 [0.6-2.9]). To investigate whether the 
risk associated with this –588 C>T SNP on thrombosis was more pronounced 
in combination with elevated homocysteine levels, we performed an interaction 
analysis and demonstrated that individuals who both had the -588 CT/TT 
genotype and elevated homocysteine levels, had a 2.5-fold increased risk of 
RVT as compared with individuals with the –588 CC genotype and normal 
homocysteine levels. These data indicate that the GCLM -588T allele increases 
the risk of thrombosis in presence of hyperhomocysteinemia.  
Besides GCLM, mRNA expression of GTPCH1 tended to be higher in aorta of 
hyperhomocysteinemic rats. GTPCH1 is the rate-limiting step of 
tetrahydrobiopterin (BH4) synthesis, and thus might be up regulated to increase 
BH4 production. BH4 is the co-factor of eNOS, and it was previously 
demonstrated that cells treated with homocysteine had decreased levels of 
BH4, which led to uncoupling of eNOS enzyme activity resulting in decreased 
availability of NO46. Recently, we also provided evidence that 
hyperhomocysteinemia is associated with decreased NO bioavailability as we 
demonstrated that a SNP in the human eNOS gene (894 G>T) interacted with 
elevated homocysteine levels and increased the risk of thrombosis by more 
that 5-fold187. Therefore, our results of up regulation of GTPCH1 and GCLM 
suggest that the pathophysiology of hyperhomocysteinemia involves oxidative 
inactivation of eNOS. Further studies examining the role of GTPCH1 in relation 
to homocysteine-induced oxidative stress are warranted. 
 In summary, we demonstrated that GCLM mRNA expression is up regulated in 
hyperhomocysteinemic rats, which suggests that the pathophysiological 
mechanism related to hyperhomocysteinemia involves perturbations of 
glutathione homeostasis due to increased ambient oxidative stress.   
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Abstract  
 
Venous thrombosis is a multicausal disease involving both genetic as well as 
acquired risk factors. Hyperhomocysteinemia is associated with a 2-fold 
increased risk of recurrent venous thrombosis. Recently, the 894 G>T variant 
of endothelial nitric oxide synthase (eNOS) was postulated to be associated 
with hyperhomocysteinemia. We hypothesized an interrelation of 
hyperhomocysteinemia, the eNOS 894 G>T variant and recurrent venous 
thrombosis risk. The eNOS 894 G>T variant was studied in 170 cases with a 
history of recurrent venous thrombosis and 433 controls from the general 
population. The eNOS 894 TT genotype may increase recurrent venous 
thrombosis risk (OR 1.3 [0.7-2.6]), but no association of the eNOS 894 G>T 
variant with elevated homocysteine was found in controls. Interestingly, in RVT 
cases the coexistence of both the 894 TT genotype and elevated tHcy levels 
(>90th percentile) was more frequently present in cases than in controls, which 
led to a substantially increased risk of recurrent venous thrombosis (fasting 
tHcy OR 5.3 [1.1-24.1], post-load tHcy OR 6.5 [1.6-29.5]). The results of the 
present study demonstrate that the eNOS 894 G>T variation interacts with 
elevated tHcy levels leading to an increased risk of recurrent thrombotic 
events. This interaction points to the direction of S-nitrosation as a mechanism 
by which homocysteine exerts its detrimental effects on the haemostatic 
system. 
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Introduction 
 
Venous thrombosis is a multicausal disease involving both genetic and 
acquired risk factors201. Acquired risk factors include immobilization, surgery, 
pregnancy and use of oral contraceptives201. The most recognized genetic risk 
factor is the Factor V Leiden mutation, which causes resistance to activated 
protein C202.  Hyperhomocysteinemia (HHcy), a disorder of methionine 
metabolism, is a common risk factor for both atherosclerosis4,203 and venous 
thrombosis7,6. The most common genetic determinant that causes elevated 
homocysteine (tHcy) levels is the 677 C>T variant of the 
methylenetetrahydrofolate reductase (MTHFR) gene18,16. Recently, results from 
a meta-analysis showed that the MTHFR 677 TT genotype is a risk factor for 
deep-vein thrombosis6.  
In response to several stimuli the endothelium is involved in the production of 
relaxing and constricting factors to maintain accurate vasodilatation and 
constriction. Nitric oxide is produced by endothelial nitric oxide synthase 
(eNOS), and is believed to possess both vasodilatory as well as anti-thrombotic 
properties; e.g. it stimulates smooth muscle cell relaxation and inhibits platelet 
aggregation and leukocyte adhesion. Polymorphic variants of eNOS might have 
the potential to affect the synthesis of NO, and might therefore contribute to 
the pathogenesis of atherosclerotic/thrombotic diseases.  
Several polymorphisms in the eNOS gene have been described, of which only 
the 894 G>T substitution involves an amino acid substitution (Glu298Asp)204. 
This 894 G>T variant has been reported to be associated with an increased 
risk of coronary artery disease204 and increased risk of death after coronary 
stenting205. Recently, the 894 G>T variant of eNOS was postulated as a risk 
factor for HHcy in healthy non-smoking adults with low serum folate levels, 
probably through an effect on folate catabolism206.  
In the current study, we assessed whether the eNOS 894 G>T variant modifies 
the association between elevated plasma homocysteine levels and the risk of 
recurrent venous thrombosis (RVT). 
 
 
Material and Methods 
 
Patient material and biochemical analysis  
Patients (N=185) with two or more episodes of venous thrombosis were 
selected from an anticoagulant clinic of the Hague as previously described7,207. 
Controls (N=500) were selected from the general population in The Hague207. 
Plasma folate and total homocysteine (fasting and post-load) levels were 
measured according to standard methods as described before207.  The local 
ethics committee approved this study. 
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eNOS 894 G>T analysis  
Genomic DNA was isolated from peripheral blood lymphocytes according to 
standard procedures121. Presently, DNA was available from 173 RVT cases and 
438 controls. The eNOS 894 G>T genotypes were determined by PCR followed 
by restriction-enzyme analysis according to Hingorani et al 204. Briefly, exon 7 
of eNOS was amplified using two intronic primers at an annealing temperature 
of 58°C in presence of 1.5 mM MgCl2. The obtained fragment of 206 bp was 
cut by Mbo I, which cuts the 894 T allele in fragments of 119 bp and 87 bp.  
 
Statistics 
To estimate the relative risk of different genotypes on recurrent thrombosis, 
odds ratios (OR) and 95% confidence intervals (95% CI) were calculated. 
Differences in allele frequencies were tested using Pearson chi square. To 
determine whether the eNOS polymorphism alters tHcy levels we calculated 
geometric means, confidence intervals, and performed one-way analysis of 
variance (ANOVA). To estimate an interaction of the eNOS 894 TT genotype 
with hyperhomocysteinemia in the risk of recurrent venous thrombosis, OR and 
95% CI were calculated. Hyperhomocysteinemia (fasting and post-load) was 
defined as tHcy levels above the 90th percentile of the respective distribution of 
the controls.  OR and P values were corrected for age and sex differences by 
multivariate analysis.  P < 0.05 was considered statistically different; all P 
values were two tailed. 
 
 
Results 
 
Baseline characteristics 
Out of the 170 RVT cases 86 were men (50.6 %), and mean age was 61.1 
[59.0-63.2] years. Fasting and post-load tHcy levels were 12.5 [11.8-13.2] 
µmol/L and 44.2 [42.2-46.4] µmol/l respectively.  The control group (N=433) 
consisted of 177 men (40.9 %), and mean age was 50.6 [49.4-51.8] years. 
Fasting and post-load tHcy levels were 10.5 [10.1-10.8] µmol/L and 37.8 
[36.8-38.9] µmol/L respectively. Previously, we have shown that the elevated 
homocysteine levels among cases increase the risk of recurrent venous 
thrombosis by ~2-fold7. 
 
 
Genotype distribution of eNOS 894 G>T  
We could determine eNOS 894 G>T genotypes in 170 RVT cases and 433 
controls. eNOS 894 G>T allele frequencies in controls did not differ from that 
expected under Hardy-Weinberg equilibrium (P = 0.8). The allele frequency of 
the 894T allele was similar between RVT cases and controls (0.32 and 0.30 
respectively, P = 0.47). 
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Table 9.1: Genotype distribution of eNOS 894 G>T variant among recurrent venous thrombosis cases and controls 
eNOS 
894 G>T 
Cases 
N (%) 
Controls 
N (%) 
Crude OR 
[95%CI] 
Adjusted OR2 
[95% CI] 
GG 
 
GT 
 
TT 
78 (45.9%) 
 
75 (44.1%) 
 
17 (10.0%) 
214 (49.4%) 
 
179 (41.1%) 
 
40 (9.2%) 
1.01 
 
1.1 [0.8-1.7] 
 
1.2 [0.6-2.2] 
1.01 
 
1.0 [0.7-1.5] 
 
1.3 [0.7-2.6] 
1Reference category; 2Adjusted for age and sex differences 
 
The homozygous 894 TT genotype was slightly more present among RVT cases 
than controls; however a firm conclusion could not be drawn due to the broad 
confidence interval (table 9.1, OR 1.3 [0.7-2.6]. 
 
Table 9.2: eNOS 894 G>T genotypes and tHcy levels among RVT cases and controls 
 
 
894 GG 
mean1 [95%CI] 
894 GT 
mean1 [95%CI] 
894 TT 
mean1 [95%CI] 
Crude P 2 Adjusted P 3 
Fasting Homocysteine (µmol/L)1 
    Cases  
    Controls 
All  
Non-smokers 
Folate < 20th percentile  
 
Post-load Homocysteine (µmol/L)1 
    Cases  
    Controls  
All  
Non-smokers  
Folate < 20th percentile 
 
12.1 [11.2-13.0] 
 
10.6 [10.0-11.1] 
10.2 [9.4-11.1] 
12.2 [10.6-14.0] 
 
 
43.9 [41.1-47.0] 
 
39.1 [37.4-40.9] 
38.2 [35.6-41.0] 
45.3 [40.1–51.0] 
 
13.2 [12.0-14.4] 
 
10.2 [9.7-10.8] 
10.4 [9.6-11.4] 
11.9 [10.6-13.4] 
 
 
45.3 [42.2-48.6] 
 
37.4 [35.7-39.2] 
36.3 [33.4-39.3] 
41.0 [36.8-45.6] 
 
13.7 [11.1-16.9] 
 
10.5 [9.4-11.8] 
10.7 [8.7-13.2] 
11.8 [7.8 – 17.7] 
 
 
52.3 [43.5-63.0] 
 
37.4 [34.1-41.0] 
38.1 [29.1-49.8] 
37.2 [30.1-45.9] 
 
0.26 
 
0.67 
0.91 
0.93 
 
 
0.11 
 
0.36 
0.63 
0.22 
 
0.18 
 
0.31 
0.86 
0.95 
 
 
0.094 
 
0.26 
0.48 
0.19 
1Geometric mean; 2ANOVA; 3Adjusted for age and sex differences; 4 P for trend = 0.05 
 
Effect of eNOS 894 G>T variant on biochemical parameters 
The effect of the 894 G>T variant on fasting and post-load tHcy levels (table 
9.2) was tested in cases as well as controls. In controls the eNOS 894 G>T 
variant was not associated with elevated fasting or post-load tHcy (table 9.2).  
However, RVT cases with the 894 TT genotype show a trend towards increased 
post-load tHcy levels (table 9.2). Plasma folate levels were similar among the 
three eNOS 894 G>T genotypes (data not shown). 
A recent report showed an effect of the eNOS 894 G>T variant on tHcy in 
relation with smoking and folate status206. We therefore stratified according to 
smoking and folate status, but no differences in tHcy between eNOS 894 G>T 
genotypes were present among controls (table 9.2).   
 
Interaction of eNOS 894 G>T with hyperhomocysteinemia  
We investigated whether among the RVT cases the combination of 894 TT and 
HHcy was more abundant. Interestingly, the coexistence of both the 894 TT 
genotype and elevated fasting tHcy levels lead to a substantially increased risk 
of recurrent venous thrombotic events (table 9.3, OR 5.3 [1.1-24.1]). This 
increased risk was also observed for post-load tHcy levels (table 9.3, OR 6.5 
[1.4-29.5]).  
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Table 9.3: Interaction analysis of eNOS 894 G>T with tHcy levels and the risk of recurrent venous thrombosis 
 eNOS tHcy 
>90th percentile 
Cases 
N (%) 
Controls 
N (%) 
Crude OR 
[95% CI] 
Adjusted OR2 
[95% CI] 
Fasting tHcy  
(> 15.5 µmol/L) 
 
 
 
 
Post-load tHcy  
(> 57.2 µmol/L) 
894 GG 
894 GG 
 
894 TT 
894 TT 
 
894 GG 
894 GG 
 
894 TT 
894 TT 
No 
Yes 
 
No 
Yes 
 
No 
Yes 
 
No 
Yes 
65 (68.4%) 
13 (13.7%) 
 
10 (10.5%) 
7 (7.4%) 
 
71 (74.7%) 
7 (7.4%) 
 
10 (10.5%) 
7 (7.4%) 
195 (76.8%) 
19 (7.5%) 
 
37 (14.6%) 
3 (1.2%) 
 
190 (74.8%) 
24 (9.4%) 
 
37 (14.6%) 
3 (1.2%) 
1.01 
2.1 [1.0 – 4.4] 
 
0.8 [0.4 – 1.7] 
7.0 [1.8 – 27.9] 
 
1.01 
0.8 [0.3 – 1.9] 
 
0.7 [0.3 – 1.5] 
6.2 [1.6 – 24.8] 
1.01 
1.6 [0.7 – 3.7] 
 
1.0 [0.4 – 2.2] 
5.3 [1.1 – 24.1] 
 
1.01 
0.8 [0.3 – 2.2] 
 
0.8 [0.4 – 1.8] 
6.5 [1.4 – 29.5] 
1Reference category; 2Adjusted for age and sex differences 
 
 
Discussion 
 
In this study we investigated whether an interrelation of the eNOS 894 G>T 
variant with elevated homocysteine levels increases the risk of recurrent 
venous thrombosis (RVT). The eNOS 894 G>T variant has been shown to 
increase the risk of coronary artery disease204, but a possible association of the 
eNOS 894 G>T variant in relation to venous thrombosis has not been 
described before. The results of the present study show that the eNOS 894 
G>T variant itself slightly increases the risk of recurrent venous thrombosis 
but due to the broad confidence interval a firm conclusion could not be drawn. 
Interestingly, in combination with elevated homocysteine levels the 894 TT 
genotype increases the recurrence risk of thrombosis by more than 5-fold.   
Recently, Brown et al postulated that the eNOS 894 G>T variant influences 
plasma tHcy levels via folate catabolism. This association was limited to the 
group of non-smokers with low serum folate levels206. However, we did not 
find any association of eNOS 894 TT with elevated tHcy levels; also after 
stratification according to smoking or folate status, we could not confirm the 
finding of Brown et al206. 
The results of the present study point to the direction of S-nitrosation as a 
mechanism by which homocysteine can exert its detrimental effects on 
thrombosis risk. Studies have shown that nitric oxide can react with thiols like 
homocysteine to form S-nitrosothiols41.  S-nitrosothiols are compounds with 
vasodilatory and anti-platelet effects, and are more stable than nitric oxide41.  
Stamler et al hypothesized that under physiological conditions, endothelial 
cells may modulate the deleterious effects of homocysteine by releasing nitric 
oxide, which facilitates the formation of S-nitroso-Hcy (S-NO-Hcy)41. When 
less nitric oxide is available, decreased amounts of S-NO-Hcy will be formed, 
resulting in exposure of the haemostatic system to the detrimental effects of 
Hcy41.  
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The eNOS 894 G>T variation leads to an amino acid substitution of glutamate 
to aspartate at position 298 of the protein. Recently, it has been shown by an 
in vitro study that the eNOS protein with aspartate at position 298 is cleaved, 
suggesting that the eNOS 894 G>T variant has a functional effect on the eNOS 
protein208. Therefore, we speculate that the eNOS 894 TT genotype results in 
altered nitric oxide production. In combination with the presence of elevated 
homocysteine levels this might lead to less capturing of homocysteine in S-
NO-Hcy, with subsequent exposure of the haemostatic system to the toxic 
effects of homocysteine. 
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Discussion 
 
The studies described in this thesis concern about the molecular genetics and 
pathophysiology of hyperhomocysteinemia. 
 
 
PART I: GENETIC DETERMINANTS OF HYPERHOMOCYSTEINEMIA 
 
BHMT 
In chapter 2 of this thesis we performed genomic sequencing of the coding 
region of the BHMT gene in 16 vascular disease patients with 
hyperhomocysteinemia, and identified three variants in the coding region of 
this gene (e.g. 595 G>A, 716 G>A, 1218 G>T), which all involved an amino 
acid substitution (G199S, R239Q, and Q406H, respectively). None of the three 
polymorphisms led to significant changes in homocysteine levels, indicating 
that genetic variation in the coding region of the BHMT gene is not involved in 
hyperhomocysteinemia. Recently, the 716 G>A SNP was investigated in two 
other populations, in which it was demonstrated that although this SNP was 
not associated with elevated homocysteine levels, it was associated with a 
decreased risk of coronary artery disease and neural tube defects209,210. We 
also observed an odds ratio of 0.6 as an estimate of risk for vascular disease 
for the 716 AA genotype relative to the 716 GG genotype, suggesting a 
protective effect. However, a firm conclusion could not be drawn due to the 
wide 95% confidence interval (0.3-1.3) (chapter 2).  
 
SHMT 
In chapter 3 we performed single-stranded conformation polymorphism (SSCP) 
analysis of the coding regions of both the cytosolic and mitochondrial SHMT 
genes in 80 sporadic NTD patients and identified several missense mutations, 
silent mutations and a deletion. The relevance of two common variants, i.e. the 
1420 C>T substitution in the coding region of the cytosolic SHMT (cSHMT) 
gene, and a 4-bp deletion in the 3’UTR of the mitochondrial SHMT (mSHMT) 
gene, was investigated in relation to neural tube defect risk, folate and 
homocysteine levels. The 1420 CC genotype is associated with higher 
homocysteine levels in NTD mothers, and with decreased plasma folate levels 
in the control population. We therefore hypothesized (chapter 3) that this 1420 
C>T SNP might cause a shift in distribution of the different folates. The 1420 
C>T variant was recently investigated in relation to cardiovascular disease, and 
was shown to be associated with higher homocysteine levels and increased risk 
of CVD when also the MTHFR TT genotype was present (Dr. P. Cassano, 
personal communication). In another study, the cSHMT 1420 T allele was 
associated with a protective effect in mothers of an NTD child, and showed a 
trend towards increased erythrocyte folate levels211; plasma total homocysteine 
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was not measured in that study. In conclusion, the cSHMT 1420 CC genotype 
tends to be associated with elevated homocysteine, decreased folate, and 
increased NTD or cardiovascular disease risk, although some discrepancies 
exist which warrants further research.  
 
 
Genetic determinants of hyperhomocysteinemia 
Before and during the course of this project described in this thesis, several 
SNPs in genes involved in the folate dependent homocysteine metabolism were 
described by our group and others16,17,20,21,24,212-218 of which only a few might 
have an effect on total homocysteine levels (table 10.1).  
 
Table 10.1: Genetic determinants of hyperhomocysteinemia 
Gene Chromosome            SNP Amino acid change Allele frequency 
MTHFR 
MTR 
MTRR 
cSHMT 
CBS 
CTH 
1p36.3 
1q43 
5p15.3-15.2 
1p33-32.3 
21q22.3 
1p31.1 
677 C>T 
2756 A>G 
66 A>G 
1420 C>T 
31bp VNTR1 
1364 G>T 
A222V 
D919G 
I22M 
L474F 
- 
S403I 
0.26 
0.17 
0.43 
0.32 
- 
0.30 
1alternative splicing24 
 
The heritability of hyperhomocysteinemia is about 50%, of which about 10% 
can be explained by the variants identified so far, indicating that a significant 
proportion of the heritability of hyperhomocysteinemia still needs to be 
explored25. Genetic variants in other genes of the homocysteine/folate 
metabolism are therefore good candidates to examine in relation to 
hyperhomocysteinemia.  
 
 
PART II: PATHOPHYSIOLOGY OF HYPERHOMOCYSTEINEMIA 
 
EDHF-mediated vasodilatation 
In chapters 4-6 of part II of this thesis we investigated the role of EDHF in 
relation to hyperhomocysteinemia. Endothelial cells contribute to the vascular 
tone by releasing NO or prostacyclins upon different stimuli. Such stimuli also 
evoke an endothelium-dependent hyperpolarization of smooth muscle cells 
that is independent of NO and prostacyclins, and therefore this third not yet 
identified vasodilator is called endothelium-derived hyperpolarizing factor 
(EDHF).  
Hyperhomocysteinemia was induced in rats by a diet enriched in methionine in 
combination with low levels of B6, B11, and B12 (chapter 4). This diet has 
previously been shown to induce hyperhomocysteinemia, leading to 
acceleration of atherosclerosis in mice219. We showed that the EDHF-mediated 
vasodilatation was impaired in the renal vasculature of hyperhomocysteinemic 
rats (chapter 4). Supplementary experiments with periodate-oxidized 
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homocysteine (ADOX) indicated that not homocysteine but a metabolite prior 
to homocysteine, presumable AdoHcy, is involved (chapter 4). The identity of 
EDHF has still not been resolved, but several candidates have been proposed 
ranging from EETs and K+ ions to hydrogenperoxide (H2O2)66,220,221. However, 
despite extensive research none of these factors has emerged as an “universal” 
EDHF.  
 
 
Gap–junctions / Connexins 
The involvement of gap-junctions in the transmission of EDHF was 
demonstrated by the use of connexin-mimetic peptides61,59,60,137,57. Therefore, 
we hypothesized that the impaired EDHF-mediated vasodilatation observed in 
kidney of hyperhomocysteinemic rats (chapter 4), might be due to decreased 
expression of connexin 40 (Cx40) and connexin 43 (Cx43) in endothelial cells 
of renal arterioles. Endothelial cells were dissected from renal interlobular 
arterioles by lasermicrodissection and the mRNA of Cx40 and Cx43 was 
quantified by real-time quantitative PCR using molecular beacons (chapter 5). 
Endothelial Cx40 mRNA expression was 1.7-fold decreased in renal arterioles 
of hyperhomocysteinemic rats, although not significantly (chapter 5). No 
differences could be observed in Cx43 mRNA expression. Immunofluorescence 
studies were applied to determine Cx40 and Cx43 protein expression in kidney 
of hyperhomocysteinemic rats. Notably, no differences could be observed at 
the protein levels of Cx40 or Cx43 (data not shown). This finding might be 
explained in two different ways; i) the 1.7-fold decreased expression of Cx40 
mRNA is leading to a minor effect on the Cx40 protein, which might have been 
missed in our immunofluoresence studies. Application of more quantitative or 
sensitive techniques, like confocal microscopy or the Avidine Biotin Peroxidase 
Complex (ABC) might be more appropriate, ii) structural remodeling of the 
Cx40 protein might be involved in hyperhomocysteinemia. Previously, it has 
been shown that elevated levels of homocysteine lead to redistribution of Cx43 
from the cell membrane to the mitochondria, leading to defective signaling of 
EDHF by myoendothelial gap junctions148.  
We showed by experiments with ADOX that not homocysteine but presumably 
a metabolite prior to homocysteine is involved in the impaired EDHF-mediated 
vasodilatation (chapter 4). We therefore measured AdoMet and AdoHcy levels 
in kidney of hyperhomocysteinemic and controls rats and showed that both 
levels were increased due to hyperhomocysteinemia; this might indicate that 
altered DNA methylation may also be a factor. We subsequently demonstrated 
that the decreased mRNA expression of Cx40 correlates with increased AdoHcy 
levels, which might indicate that the DNA methylation of the Cx40 gene is be 
disturbed (chapter 5). Obviously, this correlation needs to be confirmed as it 
might also be that this correlation is confounded by a third mediator like 
increased oxidative stress. The involvement of oxidative stress in relation to 
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connexin was pronounced by the finding that glutathione levels correlated with 
Cx43 mRNA expression, indicating that Cx43 mRNA expression might vary in 
response to oxidative stress (data not shown) (figure 10.1). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cytochrome P450 
Cytochrome P450 metabolites have been demonstrated to be involved in the 
EDHF-mediated vasodilatation. In particular, the human CYP2C8/9 fits the 
criteria of an EDHF-synthase because i) the induction of CYP2C8 by beta-
naphthoflavone enhances the EDHF-mediated hyperpolarization and relaxation 
and ii) its mRNA could be detected in human cultured endothelial cells by RT-
PCR65,222.  Because CYP2C11 has the highest homology with the human CYP2C8 
isoform, we questioned whether this isoform could be involved in the EDHF-
mediated responses in rat kidney, and we therefore examined CYP2C11 mRNA 
expression in endothelial cells of renal arterioles (chapter 6). Notably, we could 
not detect the CYP2C11 isoform in endothelial cells dissected from renal 
arterioles, indicating that this isoform is not involved in the EDHF-mediated 
cascade, as it is not expressed in endothelial cells. The role of the two other rat 
isoforms of the CYP2C family (CYP2C23 and CYP2C24) remains to be 
established. 
 
Role for S-nitrosothiols as EDHF? 
Besides an impairment of the EDHF-mediated vasodilatation, we also observed 
a decrease in global renal response to acetylcholine (unpublished findings), 
indicating that also the NO-mediated vasodilatation might be disturbed in 
renal arterioles of hyperhomocysteinemic rats. Interestingly, it was suggested 
that S-nitrosothiols act as EDHFs in porcine coronary micro-arteries223. S-
nitrosothiols are compounds with vasodilatory and anti-platelet effects, and 
are more stable than nitric oxide41. It was hypothesized that L-NAME does not 
completely block NO synthase activity, resulting in residual NO223. This residual 
Figure 10.1: Are DNA methylation and/or oxidative stress
involved in the impaired EDHF-mediated vasodilatation of
hyperhomocysteinemic rats? Renal EDHF-mediated
vasodilatation is impaired in hyperhomocysteinemic rats.
Cx40 mRNA expression is 1.7-fold decreased in endothelial
cells of renal arterioles of hyperhomocysteinemic rats, and
correlates with increased AdoHcy levels, an inhibitor of
methylation reactions. We hypothesize that the decreased
Cx40 mRNA expression is caused by either decreased DNA
methylation (CH3) or by increased production of reactive
oxygen species (ROS). 
Homocysteine
EDHF 
Cx40
CH3
ROS
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NO can form S-nitrosothiols with for instance homocysteine, which then 
contributes to the EDHF-mediated vasodilatation. However, it still needs to be 
examined whether these S-nitrosothiols need gap-junctions, as it previously 
was demonstrated that gap junctions are a prerequisite for EDHF-mediated 
signal transmission in rats61.  
  
 
Pathophysiology of hyperhomocysteinemia in large arteries 
In chapter 8 of this thesis we have applied microarray analysis to explore the 
pathophysiological mechanism involved in hyperhomocysteinemia. We induced 
hyperhomocysteinemia in rats by a diet enriched in methionine with low levels 
of vitamin B6, B11 and B12. Before microarray analysis could be applied, the RNA 
isolated from aorta was amplified (>100-fold) in a linear manner to obtain 
enough RNA. We evaluated the T7-based RNA amplification method (i.e. 
Eberwine protocol)179, and we found by the application of real-time 
quantitative PCR that T7-based RNA amplification is reproducible and can be 
used on relatively small amounts of total RNA (~1 µg) (chapter 7).  
 
GCLM 
In chapter 5 we showed that the modifying subunit of glutamate-cysteine 
ligase (GCLM) is up-regulated in aorta of hyperhomocysteinemic rats.  GCLM is 
the rate-limiting enzyme in glutathione biosynthesis, and has been shown to 
be up-regulated in conditions of increased ambient oxidative stress196,198. 
Besides up-regulation of GCLM mRNA expression in aorta of 
hyperhomocysteinemic rats, we also found higher glutathione and decreased 
cysteine levels in plasma of these rats (chapter 8). Hyperhomocysteinemia has 
been associated with increased production of reactive oxygen species (ROS), 
and we therefore speculated that GCLM is up-regulated in 
hyperhomocysteinemia to increase glutathione production for the 
detoxification of ROS (chapter 8). Additionally, we were able to confirm the 
relevance of GCLM in relation to hyperhomocysteinemia in humans, as we 
demonstrated that a single-nucleotide polymorphism (SNP) in the human 
GCLM gene was associated with an increased risk of thrombosis in presence of 
hyperhomocysteinemia (chapter 8). This –588 C>T SNP in the promoter region 
of GCLM had previously been associated with increased risk of myocardial 
infarction and decreased promoter activity under oxidative stress conditions195. 
Therefore, we hypothesized that in hyperhomocysteinemia less glutathione is 
produced due to the presence of the –588 C>T SNP. This results in less 
detoxification of ROS, which leads to increased risk of recurrent venous 
thrombosis (chapter 8). Interestingly, this –588 C>T SNP was also associated 
with a decreased bioavailability of nitric oxide, leading to an impaired coronary 
endothelium-dependent dilatation in large but also in resistance arteries224, 
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providing evidence for a link between oxidative stress and NO-mediated 
vasodilatation in hyperhomocysteinemia. 
 
GTPCH1  
Besides the involvement of GCLM, we also found an increased expression of 
GTP cyclohydrolase I (GTPCH1) in aorta of hyperhomocysteinemic rats (chapter 
8). GTPCH1 is the rate-limiting step in tetrahydrobiopterin (BH4) synthesis225, 
and BH4 is an essential co-factor of eNOS226. The eNOS enzyme is a dimer that 
consists of two identical monomers, i.e. a C-terminal reductase domain, and a 
N-terminal oxygenase domain226.  The active enzyme is a homodimer, which is 
assembled by the association of haem and BH4 to the N-terminal oxygenase 
domain226. In presence of saturated levels of BH4, eNOS will solely produce NO. 
Notably, low levels of the co-factor BH4 will lead to the uncoupling of eNOS 
resulting in the production of superoxide anions226. Recently, a role of 
hyperhomocysteinemia in uncoupling of eNOS activity was described46. It was 
demonstrated that HUVECs treated with homocysteine had impaired NO release 
and increased production of reactive nitrogen and ROS, due to a reduced 
intracellular BH4 availability46. In addition to its role as a NOS cofactor, BH4 is 
also a potent scavenger of ROS, and oxidation of BH4 into 7,8-BH2 is the main 
pathway of BH4 degradation227. BH4 availability is thus controlled by its de novo 
synthesis by GTPCH1 and by its degradation by oxidative stress228. Both the 
degradation of BH4 and also the synthesis of BH4 are mediated by 
homocysteine46. We therefore suggest that GTPCH1 is up-regulated in aorta of 
hyperhomocysteinemic rats to increase BH4 production, and postulate that the 
pathophysiological mechanism involved in hyperhomocysteinemia involves 
oxidative stress leading to decreased NO-mediated vasodilatation. 
Some other studies have shown that the pathophysiology of homocysteine in 
aorta involves detoxification of ROS. More specifically, in bovine aortic 
endothelial cells it was shown that homocysteine treatment increased the 
activity of the antioxidant enzyme glutathione peroxidase (GPx)38.  
Interestingly, in another study it was demonstrated that homocysteine 
treatment leads to decreased nitric oxide (NO) release in bovine aortic 
endothelial cells, indicating that the adverse vascular effects of homocysteine 
are partly mediated by oxidative inactivation of NO74,73.  Our data of interaction 
between a single-nucleotide polymorphism (SNP) in the eNOS gene with 
elevated homocysteine levels are in line with this finding (chapter 5), and will 
be discussed in the next paragraph. 
 
eNOS 894 G>T SNP   
In chapter 9, we showed that the 894 G>T SNP in the eNOS gene increased the 
risk of recurrent venous thrombosis by more than 5-fold in combination with 
elevated homocysteine levels. These data suggest that NO synthesis is 
decreased in presence of hyperhomocysteinemia, and provides a mechanism 
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for homocysteine-induced vascular diseases. Notably, differential expression 
of eNOS was not observed by our micro array experiments on aorta of 
hyperhomocysteinemic rats (chapter 9), suggesting that not the synthesis of 
NO but rather the bioavailability of NO is impaired125.  
 
Folate 
Folate lowers homocysteine levels and results from recent studies also showed 
that 5-MeTHF, the active form of folate, restored the impaired endothelium-
dependent vasodilatation in familial hypercholesterolemia48,47, diabetes53,229,230, 
ischemia/reperfusion231, and hypertension232. Folates have been suggested to 
increase the endogenous production of BH4 via the regeneration of qBH2233,234. 
Our results of up-regulation of GTPCH1 in hyperhomocysteinemic rats (chapter 
8) and the interaction between hyperhomocysteinemia and the 894 G>T SNP in 
the eNOS gene (chapter 9), suggest that folate is, besides homocysteine- 
lowering, also involved in the restoration of NO-dependent vasodilatation 
through increased bioavailability of BH4 . 
 
Orphan nuclear receptors 
Besides the up-regulation of GCLM and GTPCH1, also a down-regulation was 
observed for two members of the orphan nuclear receptor family, i.e. RevErbA 
and HZF-2 (chapter 8) were identified by microarray analysis of aorta of 
hyperhomocysteinemic and control rats.  The nuclear receptor subfamily 
consists of receptors for steroid hormones, eicosanoids, and retinoic acid235. 
Included in this family are the orphan nuclear receptors for which no ligands 
have been identified yet235. The orphan nuclear receptors are widely expressed 
and might be involved in the negative transcription of several genes236. A role 
for RevErbA was described in relation to inflammation237 and differentiation of 
adipocytes238. The down-regulation of the two orphan nuclear receptors in 
aorta of hyperhomocysteinemic rats might be explained by the fact that those 
genes are involved in the negative transcription of genes236. Therefore, we 
hypothesize that these two orphan nuclear receptors are involved in the up-
regulation of GCLM and/or GTPCH1 in aorta of hyperhomocysteinemic rats. 
However, further studies examining the exact role of both receptors in relation 
to GCLM and GTPCH1 expression and hyperhomocysteinemia are warranted. 
 
Conclusion 
We suggest that hyperhomocysteinemia is associated with increased 
production of reactive oxygen species (ROS) resulting in decreased 
bioavailability of BH4 and NO, leading to impaired endothelium-dependent 
vasodilatation (figure 10.2). 
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Figure 10.2: Impaired endothelium-dependent
vasodilatation in hyperhomocysteinemia involves
oxidative stress. Increased reactive oxygen species
(ROS) are produced due to elevated homocysteine
levels, which cause oxidative stress. Under oxidative
conditions, BH4 will become oxidized leading to
reduced nitric oxide (NO) production due to
uncoupling of eNOS. The modifying subunit of
glutamate-cysteine ligase (GCLM) is up-regulated to
compensate for the adverse oxidative effects of
elevated homocysteine. GTP cyclohydrolase (GTPCH1)
is in turn up-regulated to increase NO bioavailability
by increasing BH4 synthesis. The role of orphan
nuclear receptors (NR) is not clear but they might be
involved in the transcription of GCLM or GTPCH1. 
 
GCLM
Homocysteine
Oxidative stress
Impaired vasodilatation
eNOS
BH4
NO
ROS
GTPCH1
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Future perspectives 
 
 
PART I: GENETIC DETERMINANTS OF HYPERHOMOCYSTEINEMIA 
 
Genetic variants in genes of the homocysteine metabolism 
In chapters 2 and 3 we described the role of genetic variation in the BHMT and 
SHMT genes in relation to hyperhomocysteinemia. We found that the 1420 CC 
genotype was associated with elevated homocysteine levels in mothers and 
decreased folate levels. Because SHMT is involved in the conversion of 
tetrahydrofolate to 5,10-MeTHF, the 1420 C>T variant might lead to a 
redistribution of the different folates. It was recently demonstrated that the 
1420 TT genotype is associated with elevated levels of homocysteine and 
increased risk of coronary artery disease when also the 677 TT genotype was 
present. Further research should therefore examine gene-gene interaction of 
SHMT and MTHFR in relation to hyperhomocysteinemia. Further research 
should also focus on the distribution of folates in relation to SHMT genotypes, 
as it was previously shown that the MTHFR 677 TT genotype was associated 
with decreased red blood cell levels of methyl-THF polyglutamates and 
increased levels of formyl-THF polyglutamates239.  
 
 
Identification of novel genetic determinants of hyperhomocysteinemia 
Recently, it was demonstrated by the use of segregation analysis that the 
heritability of hyperhomocysteinemia is approximately 40-50%, of which about 
10% can be explained by other polymorphisms than the MTHFR 677 C>T 
variant240,25. Recently, we demonstrated that especially post-load 
homocysteine levels are genetically controlled241. Therefore further 
investigation into the genetic control of homocysteine levels is warranted. Two 
approaches can be chosen: i) candidate gene approach and ii) a whole genome 
approach. In the first approach known genes involved in the 
homocysteine/methionine metabolism can be examined for genetic variants. A 
relatively large number of genetic variants have already been discovered and 
examined by our group and others but none of these SNPs seem to be major 
determinants of hyperhomocysteinemia. Further research should include 
dihydrofolatereductase (DHFR), thymidylate synthase (TS), methionine 
adenosyltransferase (MAT) and cystathionine γ-lyase (CTH). Polymorphisms 
within the TS and DHFR genes may affect folate levels and, indirectly, plasma 
homocysteine concentrations. Polymorphisms in MAT may result in higher 
methionine, decreased AdoMet levels and increased homocysteine levels. So 
far, no variations have been reported in the DHFR, and MAT genes. Future 
research should involve identification of genetic variants in these genes and 
investigation of their relation to hyperhomocysteinemia. In the TS gene a 28-
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bp tandem repeat has been reported, which is associated with low folate and 
increased homocysteine levels242. The role of this 28-bp tandem repeat needs 
to be confirmed in another population. In the CTH gene a 1364 G>T variant 
was recently described, which was associated with higher plasma homocysteine 
levels214. However, besides genes of the homocysteine/methionine metabolism 
also other genes of which we are unaware of to play a role in 
hyperhomocysteinemia should be investigated. A genome-wide linkage search 
could detect such previously unknown genes causing hyperhomocysteinemia. 
 
Techniques used for SNP detection 
Most SNPs are screened in our laboratory by conventional restriction-enzyme 
analysis, which is time-consuming. Future research should focus on the 
application of more rapid techniques in which several SNPs can be detected 
simultaneously. For this purpose, a SNP-microarray can be developed, on 
which SNPs of interest can be examined243. The application of SNP-arrays 
facilitates the analysis of gene-gene interactions in relation to 
hyperhomocysteinemia, although large sample sizes and sophisticated 
statistical analysis methods are acquired for this approach. As demonstrated in 
chapter 2 of this thesis, also real-time quantitative PCR can be applied for SNP 
analysis; probes (e.g. TaqMan probes or molecular beacons) can discriminate 
between the wild type and mutated allele (chapter 2), which allows rapid 
detection of the genotypes in a closed-tube format by either allele-specific 
fluorescence244,245 or by melt-curve analysis246,247. 
 
 
PART II: PATHOPHYSIOLOGY OF HYPERHOMOCYSTEINEMIA 
 
EDHF-mediated vasodilatation  
 
Cx40 
The studies described in chapters 4 and 5 of this thesis show that EDHF-
mediated vasodilatation is impaired in hyperhomocysteinemia, which might be 
explained by decreased expression of Cx40 mRNA. Future research should 
elucidate whether inhibition of Cx40 mRNA actually involves decreased signal 
transmission. For this purpose RNA interference (RNAi) might be applied to 
inhibit Cx40 mRNA expression, after which dye transfer studies using 
luciferase can be applied to investigate whether inhibition of Cx40 mRNA 
results in decreased intercellular diffusion of luciferase.  
Cx40 mRNA expression correlated with AdoHcy levels, and we speculated that 
decreased DNA methylation might be involved (chapter 5). Future studies 
should therefore focus on DNA methylation. First, DNA methylation can be 
measured by HPLC or tandem MS to verify whether genome-wide changes in 
methylation patterns are observed in kidney of hyperhomocysteinemic rats. 
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Furthermore, gene-specific DNA methylation of, for example, the Cx40 gene 
can be examined by application of bisulfite sequencing, in which unmethylated 
cytosines are converted into uracil by bisulfite treatments. The differences 
between methylated and unmethylated cytosines can then be assessed by the 
application of manual sequencing after which the differences in methylation 
patterns can be quantified using an imager248. Because folate has been shown 
to improve EDHF-mediated vasodilatation in hyperhomocysteinemia (chapter 
4), we expect that it may also lead to improvement of Cx40 mRNA expression 
and DNA methylation. It is therefore interesting to examine the effect of folate 
treatment on different outcomes (e.g. Cx40 mRNA expression, genome-wide 
DNA methylation and gene-specific methylation).  
 
Human studies 
To assess whether the findings in hyperhomocysteinemic rats are also 
functionally relevant in human, future research should focus on measurement 
of Cx40 mRNA levels in relation to AdoHcy in cultured human umbilican vein 
endothelial cells (HUVEC). Endothelial cells can be treated with ADOX, an 
inhibitor of AHCY, and Cx40 mRNA expression can then be quantified in RNA 
isolated from HUVECs by the application of real-time quantitative PCR. In 
addition, the effect of decreased methylation in relation to protein expression 
is also of potential interest; these studies are currently initiated at the 
Laboratory of Pediatrics and Neurology in collaboration with the Department of 
Endocrinology. 
 
Epidemiological approach 
Epidemiological studies can also be applied to further explore the relationship 
between Cx40 and disease outcome. The effects of SNPs in the human Cx40 
genes involved in altered expression of Cx40 could be examined in relation to 
homocysteine, AdoHcy, and markers of oxidative stress in a population with 
peripheral artery disease or myocardial infarction. If Cx40 is involved in the 
homocysteine-induced risk of impaired EDHF-mediated vasodilatation, we 
would exprect an interaction between a SNP in the Cx40 gene and 
hyperhomocysteinemia in relation to disease risk.  
Although, Connexin 43 (Cx43) mRNA expression was not altered in renal 
arterioles of hyperhomocysteinemic rats, the protein might be redistributed148 
(see discussion). Therefore, investigation of SNPs in the Cx43 gene is also of 
potential interest. 
 
 
Pathophysiology of hyperhomocysteinemia in large arteries 
 
The results described in chapters 8 and 9 of this thesis point to the 
involvement of oxidative stress in the pathophysiology of hyper-
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homocysteinemia.  Suggestions for further studies on GCLM, GTPCH1 and 
eNOS in relation to hyperhomocysteinemia are discussed below. 
 
GCLM 
The up-regulation of GCLM mRNA in aorta should be confirmed in other 
tissues (e.g. liver, heart, kidney and brain) of hyperhomocysteinemic rats to 
assess whether increased GCLM mRNA expression is a common feature in 
other tissues than aorta. Besides the quantification of GCLM mRNA expression, 
GCL enzyme activity can be measured in different tissue extracts of 
hyperhomocysteinemic rats to show that increased expression of GCLM mRNA 
is associated with an increase in enzyme activity249. In addition, to show that 
oxidative stress is increased in hyperhomocysteinemia, future studies should 
focus on the measurement of markers of oxidative stress. For example 
malondialdehyde (MDA) and F2-isoprostanes are markers of lipid peroxidation 
and can be used as potential in vivo indicators of oxidant stress250. These 
markers should be measured in serum and tissue extracts of 
hyperhomocysteinemic rats.  
 
GTPCH1 
Increased mRNA expression of GTPCH1 was found in aorta of 
hyperhomocysteinemic rats. GTPCH1 is the rate-limiting step in 
tetrahydrobiopterin (BH4) synthesis. Therefore in the future total BH4 levels 
should be measured in hyperhomocysteinemic rats251. Especially, the 
measurement of the oxidized form of BH4 (BH2) would be of great interest, 
because due to increased ambient oxidative stress, BH2 is expected to be 
increased leading to impaired NO bioavailability251. In addition, mRNA 
expression of GTPCH1 should be quantified in the different tissues of 
hyperhomocysteinemic rats. 
Because folate has been shown to improve endothelial-dependent 
vasodilatation in several diseases, which may in part be due to the restoration 
of BH4 levels, it would be interesting to evaluate GCLM and GTPCH1 mRNA 
expression in a group of rats fed a high methionine diet with increased 
amounts of folate.  In this group, we would expect that the expression of 
GCLM and GTPCH1 is restored, leading to improved vasodilatation. 
Additionally, the effect of folate treatment on global/NO-mediated 
vasodilatation, markers of oxidative stress as well as BH4 levels should be 
assessed in rats. 
 
Human studies 
In recurrent venous thrombosis patients we have shown that the 894 G>T SNP 
of the eNOS gene as well as the –588 C>T SNP of the GCLM gene interact with 
hyperhomocysteinemia and increased the risk of recurrent venous thrombosis. 
These results show that epidemiological studies can also be applied to 
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investigate the pathophysiological mechanism of hyperhomocysteinemia in 
relation to diseases like thrombosis. Future work should therefore focus on the 
role of other SNPs in genes of the oxidative stress pathways in relation to an 
increased risk of thrombotic and arterial damage. The finding of increased risk 
of thrombosis due to the interaction of the 894 G>T SNP eNOS with elevated 
homocysteine levels, should be confirmed in other population like patients 
with myocardial infarction. We speculate that the eNOS 894 G>T SNP is more 
frequently present in patients with classical homocystinuria as these patients 
show premature vascular disease. Furthermore, it would be interesting to 
examine whether patients with the eNOS 894 TT genotype would clinically 
benefit more from folate therapy than patients with the eNOS 894 GG 
genotype. Therefore, the effect of B vitamin supplementation on vascular 
disease outcome in relation to the 894 G>T genotype, should be assessed in a 
group of patients, which have received B vitamin supplementation. The same 
approach can be performed in relation to the –588 C>T SNP of the GCLM gene.  
Besides SNPs in eNOS and GCLM also other genes might be of potential interest 
to investigate in relation to the pathophysiology of hyperhomocysteinemia. 
Therefore, in collaboration with Dr. M. den Heijer (Department of 
Endocrinology and Department of Epidemiology and Biostatistics) and Dr. B. 
Franke (Department of Human Genetics), we intent to develop an “oxidative 
stress SNP array” to search for interacting genes. This approach allows the 
rapid screen for genes involved in the homocysteine-mediated increased 
oxidative stress. Furthermore, this SNP-array enables combining different 
genotypes in relation to hyperhomocysteinemia and risk of vascular diseases 
(e.g. myocardial infarction, thrombosis, stroke). Besides this epidemiological 
approach, future work should also focus on the measurement of markers of 
oxidative stress (e.g. glutathione, malondialdehyde, isoprostanes) and BH4 in 
plasma of patients with arterial disease and thrombosis to confirm the 
presence of oxidative stress in hyperhomocysteinemia patients. 
            136 
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Summary 
 
 
Hyperhomocysteinemia is an independent risk factor for cardiovascular 
diseases, neural tube defects and obstetric complications, and has been 
associated with endothelial dysfunction. Despite extensive research the 
mechanism involved remains conjectural. This thesis deals with the 
identification of genetic determinants of hyperhomocysteinemia and the 
exploration of the mechanism by which homocysteine exerts its detrimental 
effects to the endothelium. An introduction on homocysteine metabolism in 
relation to genetic variants and pathophysiology with special emphasis on 
EDHF-mediated vasodilatation is given in chapter 1 of this thesis. After the 
introduction this thesis is divided into two parts. In PART I (chapters 2-3) 
studies are described in which genes of the homocysteine metabolism are 
searched for genetic determinants involved in hyperhomocysteinemia. In PART 
II (chapters 4-9) the pathophysiology of hyperhomocysteinemia in relation to 
endothelium-dependent vasodilatation is explored. In chapters 4-6 the 
involvement of EDHF-mediated vasodilatation in relation to 
hyperhomocysteinemia, gap-junctions and cytochrome P450-metabolites in 
small renal arterioles is described, whereas chapters 7-9 concern about the 
global endothelium-dependent vasodilatation of large arteries. 
 
 
PART I 
 
In chapter 2 of this thesis we described the sequencing analysis of the coding 
region of the BHMT gene, by which three SNPs were identified (i.e. G199S, 
R239Q, Q406H). The G199S and R239Q amino acid substitutions were 
investigated in a case-control group, and were not associated with elevated 
homocysteine levels or with increased risk of vascular disease. The Q406H 
variant was found in heterozygous state in one patient only. Thus, we did not 
find any indication that genetic variation in the BHMT gene is involved in 
hyperhomocysteinemia. 
Chapter 3 describes the role of the cytosolic and the mitochondrial SHMT 
genes in relation to hyperhomocysteinemia. By application of SSCP-analysis we 
identified several SNPs in the cSHMT as well as in the mSHMT gene. One of 
these SNPs, the 1420 C>T variant (L474F) in the cSHMT gene was associated 
with lower homocysteine levels in NTD mothers and higher red blood cell 
folate levels, indicating that this variant might be protective against the 
development of hyperhomocysteinemia. As SHMT is involved in the reduction 
of THF to 5,10-MeTHF, we speculated that this 1420 C>T variant might cause 
a shift in the distribution of the different folate derivatives. 
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PART II 
 
Chronic hyperhomocysteinemia was induced in rats by a diet enriched in 
methionine with low levels of B vitamins (B6, B11 and B12) for 8 weeks. Serum, 
liver, heart, kidney, aorta and brain were collected from these rats and stored 
for laboratory measurements.  
In chapter 4 we demonstrate that the EDHF-mediated vasodilatation of renal 
arterioles is impaired in hyperhomocysteinemic rats. Administration of the S-
adenosylhomocysteine hydrolase (AHCY) inhibitor, periodate-oxidized 
adenosine (ADOX), prevented the methionine-induced rise in homocysteine 
levels, but not the inhibition of the EDHF-pathway. We, therefore, hypothesized 
that not homocysteine itself but a component prior to homocysteine, 
presumably S-adenosylhomocysteine (AdoHcy), is responsible for the 
disturbed EDHF-mediated vasodilatation. The role of AdoHcy in relation to 
hyperhomocysteinemia was further explored in chapter 5.  
In this chapter we measured endothelial Connexin 40 (Cx40) mRNA levels in 
renal arterioles of hyperhomocysteinenemic rats. Gap junctions are composed 
of connexins and are shown to be involved in the EDHF-mediated 
vasodilatation. By application of lasermicrodissection and Q-PCR we 
demonstrated that we successfully isolated endothelial cells from interlobular 
arterioles of rat kidney. In addition, we were able to quantify Cx40 mRNA 
expression in RNA isolated from the dissected endothelial cells and 
demonstrated that the expression of Cx40 mRNA was 1.7-fold down-
regulated. We also measured S-adenosylmethionine (AdoMet) and AdoHcy 
levels in kidney of hyperhomocysteinemic rats, and showed that both levels 
were elevated resulting in a decreased AdoMet:AdoHcy ratio. Interestingly, 
these increased levels of AdoHcy correlated with the decreased expression of 
Cx40 mRNA, indicating that decreased DNA methylation of the Cx40 gene 
might be involved in the impaired EDHF-mediated vasodilatation of 
hyperhomocysteinemic rats. 
In chapter 6 we investigated the expression of the rat-specific cytochrome 
P450-2C11 isoform (CYP2C11) in endothelial cells dissected from renal 
arterioles. CYP2C is proposed as an EDHF-synthase, and we therefore 
quantified the mRNA expression of the CYP2C11 isoform in endothelial cells by 
application of real-time quantitative PCR. We showed that endothelial cells do 
not express the CYP2C11 isoform, and we, therefore, hypothesized that 
CYP2C11 is not involved in the renal EDHF-mediated vasodilatation, as it is not 
expressed in endothelial cells of renal arterioles.  
Chapter 7 of this thesis describes the validation of T7-based RNA amplification 
by real-time quantitative PCR using molecular beacons. Generally, large 
amounts of total RNA are necessary to perform microarray analysis. We 
obtained ~1 µg total RNA from the abdominal part of the aorta of 
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hyperhomocysteinemic rats, which was not enough to use in microarray 
experiments. Therefore, we had to amplify the RNA by a method called T7-
based RNA amplification. Before we applied this technique we first evaluated 
whether this technique was reproducible and whether it was appropriate to use 
prior to microarray analysis. We developed specific molecular beacons against 
three housekeeping genes and applied real-time quantitative PCR (Q-PCR) for 
the quantification of the amount of anti-sense RNA obtained by T7-based RNA 
amplification. We demonstrated that T7-based RNA amplification was 
reproducible, and could therefore be applied prior to microarray analysis. 
In chapter 8 of this thesis the results of the microarray experiments on RNA 
isolated from aorta of hyperhomocysteinemic and control rats are described. 
We were the first to show that the modifying subunit of glutamate-cysteine 
ligase (GCLM), the rate-limiting enzyme in glutathione synthesis, is up-
regulated in aorta of hyperhomocysteinemic rats. As also glutathione levels 
were elevated in serum of these rats, we speculated that GCLM is up-regulated 
to compensate for the adverse oxidative effects of homocysteine on the 
vascular wall. Notably, we demonstrated that a single-nucleotide 
polymorphism (SNP) in the promoter of the human GCLM gene increased the 
risk of recurrent venous thrombosis in presence of elevated levels of 
hyperhomocysteinemia, confirming the involvement of the GCLM gene in the 
human pathophysiology of hyperhomocysteinemia.  
In chapter 9 we describe the interaction between a SNP in the human eNOS 
gene (894 G>T) and hyperhomocysteinemia that leads to a more than 5-fold 
increased risk of recurrent venous thrombosis. This finding might have 
important consequences for the pathophysiology of hyperhomocysteinemia. 
Under physiological conditions, endothelial cells may modulate the deleterious 
effects of homocysteine by releasing nitric oxide, which facilitates the 
formation of S-nitroso-Hcy.  We speculated that due to this 894 G>T SNP, less 
S-nitrosothiols will be formed, which will result in exposure of the vasculature 
to the detrimental effects of homocysteine. 
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Samenvatting 
 
 
Verhoogde concentraties van homocysteïne in het bloedplasma (= 
hyperhomocysteïnemie) zijn geassocieerd met een verhoogde kans op hart- en 
vaatziekten, neurale buis defecten en andere zwangerschapscomplicaties.  
Genetische variaties in genen die coderen voor enzymen in het homocysteïne 
metabolisme kunnen leiden tot een ophoping van homocysteïne in het 
bloedplasma. Ondanks het feit dat er veel onderzoek verricht wordt naar de 
vraag waarom een verhoogd homocysteïne geassocieerd is met een verhoogd 
risico op hart- en vaatziekten, is deze vraag nog steeds niet beantwoord. Men 
veronderstelt dat homocysteïne schade aanricht aan de binnenste laag van het 
bloedvat (= endotheelcellaag). In de hoofdstukken van dit proefschrift worden 
zowel studies waarin onderzoek gedaan is naar de moleculaire genetica van 
hyperhomocysteïnemia als ook naar de gevolgen van hyperhomocysteïnemie in 
relatie tot endotheel-afhankelijke vaatverwijding beschreven. In hoofdstuk 1 
wordt een inleiding gegeven waarin zowel de rol van genetische determinanten 
van hyperhomocysteïnemie als de rol van hyperhomocysteïnemie in relatie tot 
endotheel-afhankelijke vaatverwijding belicht worden. Na deze introductie is 
het proefschrift onderverdeeld in 2 delen; deel I bevat studies waarin 
onderzoek gedaan is naar genetische variaties in genen die coderen voor 
enzymen uit het homocysteïne metabolisme in relatie tot 
hyperhomocysteïnemie. In deel II worden de mogelijke gevolgen van verhoogd 
homocysteïne op de endotheel-afhankelijke vaatverwijding onderzocht in 
zowel de kleine bloedvaten van de nier, als ook in de grote bloedvaten (aorta). 
 
 
DEEL I 
 
In dit deel zijn twee genen, die betrokken zijn bij de remethylering van 
homocysteïne naar methionine bestudeerd. In hoofdstuk 2 beschrijven we het 
onderzoek naar genetische varianten in het gen dat codeert voor betaine-
homocysteïne methyltransferase (BHMT). Dit enzym is voornamelijk actief in de 
lever, waarbij een methylgroep afgesplitst wordt voor de omzetting van 
homocysteïne naar methionine. Drie genetische varianten werden in de 
coderende regio ontdekt door middel van DNA sequentie analyse. Twee van 
deze varianten (G199S en R239Q) zijn onderzocht in een grotere groep 
patienten en controles. Geen van de varianten lieten een effect zien op 
homocysteïne concentraties in het bloed. Mogelijk geeft de R239Q variant een 
lichte bescherming tegen het ontstaan van hart- en vaatziekten, maar omdat 
deze relatie niet significant is kunnen we dit niet hard maken. 
In hoofdstuk 3 beschrijven we de moleculair genetische analyse van de SHMT 
genen. Twee isovormen zijn bekend waarvan er één in het cytosol tot expressie 
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komt en één in het mitochondrion. Beide genen zijn onderzocht op genetische 
varianten en zowel in de cytosolaire als de mitochondriële isovorm werden 
diverse DNA veranderingen gevonden. Met name de 1420 C>T substitutie in 
de cytosolaire isovorm werd geassocieerd met verlaagde homocysteïne 
concentraties en verhoogde rode bloedcel folaat concentraties, hetgeen 
betekent dat deze variant mogelijk beschermend werkt. Aangezien SHMT 
betrokken is bij de reductie van verschillende vormen van folaat zou de 1420 
C>T variant kunnen leiden tot een verschuiving van de folaat-vormen in 
plasma. Dit is een hypothese die nog verder onderzocht dient te worden.  
 
 
DEEL II 
 
Om het mechanisme achter hyperhomocysteïnemie te kunnen bestuderen 
hebben we ratten een dieet toegediend dat een hoog gehalte aan methionine 
en tevens verlaagde concentraties aan B vitamines bevatte. De ratten kregen dit 
dieet 8 weken toegediend, waarna we het bloed en diverse organen (lever, hart, 
nieren, aorta en hersenen) verwijderd hebben voor verder laboratorium 
onderzoek. 
In hoofdstuk 4-6 beschrijven we de relatie van de endothelium-derived 
hyperpolarizing factor (EDHF) in relatie tot hyperhomocysteïnemie. Wanneer de 
twee bekendste vaatverwijdende stoffen, NO en prostacyclines, geremd worden 
is er nog steeds vaatverwijding meetbaar. Deze vaatverwijding wordt EDHF-
gemedieerde vaatverwijding genoemd omdat deze vaatverwijding afkomstig is 
uit de endotheelcel en leidt tot hyperpolarizatie van de gladde spiercellen. De 
identiteit van EDHF is tot op heden nog niet bekend. 
In hoofdstuk 4 hebben we de EDHF-gemedieerde vaatverwijding gemeten in 
arteriolen van de nier van zowel hyperhomocysteïnemische als controle ratten 
en laten we zien dat deze verminderd is onder invloed van hoge homocysteïne 
concentraties. Aanvullende experimenten met een remmer van S-
adenosylhomocysteïne hydrolase laten zien dat niet homocysteïne maar een 
andere metaboliet, mogelijk S-adenosylhomocysteïne (AdoHcy), 
verantwoordelijk is voor de verminderde EDHF-gemedieerde vaatverwijding. 
In hoofdstuk 5 hebben we AdoHcy en S-adenosylmethionine (AdoMet) 
concentraties gemeten in nierextract van hyperhomocysteïnemische en 
controle ratten en laten we zien dat beide metabolieten verhoogd zijn wat leidt 
tot een verlaging van de AdoMet:AdoHcy ratio (=methyleringsratio). Naast deze 
bevinding hebben we ook de expressie van connexine 40 (Cx40) en connexine 
43 (Cx43) mRNA, bouwstenen van gap-junctions, bestudeerd. Gap-junctions 
worden in verband gebracht met het overbrengen van de EDHF-gemedieerde 
vaatverwijding van de endotheelcel naar de gladde spiercel. Met behulp van 
lasermicrodissectie hebben we endotheelcellen kunnen isoleren uit de kleinste 
nierarteriolen van de rat. Achtereenvolgens hebben we RNA geïsoleerd uit deze 
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endotheelcellen en de expressie van het Cx40 en Cx43 mRNA bestudeerd met 
behulp van Q-PCR. De expressie van Cx40 mRNA was verlaagd in 
hyperhomocysteïnemische ratten terwijl we geen verschil zagen in de 
expressie van Cx43. Verder zagen we dat de verlaagde expressie van Cx40 
correleerde met de verhoogde AdoHcy concentraties, wat mogelijk aangeeft 
dat een verstoorde DNA methylering van Cx40 leidt tot de verminderde EDHF-
gemedieerde vaatverwijding in de hyperhomocysteïnemische ratten. 
In hoofdstuk 6 hebben we de expressie van cytochroom P450-2C11 (CYP2C11) 
bestudeerd in endotheelcellen van ratten. De CYP2C familie wordt 
verondersteld betrokken te zijn bij de EDHF-gemedieerde vaatverwijding. We 
hebben met behulp van lasermicrodissectie en Q-PCR laten zien dat de het 
mRNA van de rat-specifieke CYP2C11 isovorm niet tot expressie komt in 
endotheelcellen van nierarteriolen en dus niet betrokken kan zijn bij de EDHF-
gemedieerde vaatverwijding. 
Om verder onderzoek te kunnen doen naar genen die betrokken zijn bij de 
gevolgen van verhoogde homocysteïne concentraties hebben we gebruik 
gemaakt van genexpressie arrays. Aangezien we geïnteresseerd waren in het 
effect van homocysteïne op de endotheelcellaag, hebben we het 
expressieprofiel van de genen in de aorta van hyperhomocysteïnemische ratten 
bekeken en vergeleken met dit van controle ratten. Voor het gebruik van 
genexpressie arrays is veel RNA nodig en dit hadden we niet tot onze 
beschikking. Daarom  hebben we het RNA vermenigvuldigd met een techniek 
die lineaire RNA amplificatie heet. Alvorens deze techniek toe te passen, 
hebben we eerst gevalideerd of deze techniek leidt tot reproduceerbare 
resultaten. We hebben hiervoor een methode ontwikkeld waarmee we, 
gebruikmakend van real-time quantitatieve PCR (Q-PCR) met molecular 
beacons, de eigenschappen van lineaire RNA amplificatie konden bestuderen 
(hoofdstuk 7). Met behulp van Q-PCR hebben we aangetoond dat lineaire RNA 
amplificatie zeer reproduceerbaar is dus toegepast kan worden om RNA te 
vermenigvuldigen. 
In hoofdstuk 8 worden de resultaten van de genexpressie arrays besproken. 
Met behulp van deze techniek hebben we aangetoond dat het gen dat codeert 
voor de modulerende subunit van glutamate-cysteine ligase (GCLM) verhoogd 
tot expressie komt in aorta van hyperhomocysteïnemische ratten. GCLM is 
betrokken bij de synthese van glutathione. Naast de verhoogde genexpressie 
van GCLM vonden we tevens verhoogde glutathione concentraties in het 
plasma van de hyperhomocysteïnemische ratten. Daarnaast hebben we een 
polymorfisme in de promoter regio van het humane gen dat codeert voor 
GCLM (-588 C>T) onderzocht en hebben we aangetoond dat de aanwezigheid 
van het –588 T allel, in aanwezigheid van verhoogd homocysteïne in het 
bloedplasma, leidt tot een verhoogd risico op veneuze trombose. Deze 
resultaten duiden er op dat de expressie van GCLM verhoogd is om de 
schadelijke oxidatieve effecten van homocysteïne teniet te doen. 
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In hoofdstuk 9 hebben we een polymorfisme (894 G>T) in het gen dat 
verantwoordelijk is voor de productie van stikstofmonooxide (NO) in de 
endotheelcel (eNOS) onderzocht. Dit eNOS 894 TT genotype verhoogt in 
aanwezigheid van verhoogde homocysteïne concentraties de kans op het risico 
van veneuze trombose meer dan 5-voudig.  Hieruit concludeerden wij dat, in 
aanwezigheid van verhoogde homocysteïne concentraties, de beschikbaarheid 
van NO zal afnemen wat een verminderde vaatverwijding tot gevolg zal 
hebben. 
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